Atai Life Sciences (ATAI) 10-K 28 Mar 24 2023 FY Annual report Financial data

Cover Page

Cover Page - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2023	Mar. 01, 2024	Jun. 30, 2023
Cover [Abstract]
Document Type	10-K
Amendment Flag	false
Entity Central Index Key	0001840904
Entity Registrant Name	ATAI Life Sciences N.V.
Document Annual Report	true
Document Transition Report	false
Document Period End Date	Dec. 31, 2023
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	FY
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Trading Symbol	ATAI
Title of 12(b) Security	Common shares, par value €0.10 per share
Security Exchange Name	NASDAQ
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Shell Company	false
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity File Number	001-40493
Entity Incorporation, State or Country Code	P7
Entity Address, Address Line One	ATAI Life Sciences N.V.
Entity Address, Address Line Two	Wallstraße 16, 10179
Entity Address, City or Town	Berlin
City Area Code	49 89
Local Phone Number	2153 9035
Entity Address, Country	DE
Entity Address, Postal Zip Code	00000
Entity Tax Identification Number	00-0000000
Entity Public Float			$ 203.3
Auditor Attestation Flag	false
Document Financial Statement Error Correction [Flag]	false
Entity Common Stock, Shares Outstanding		166,026,396
Auditor Firm ID	34
Auditor Name	DELOITTE & TOUCHE LLP
Auditor Location	New Jersey
Documents Incorporated By Reference TextBlock	DOCUMENTS INCORPORATED BY REFERENCE Portions of the Registrant’s definitive proxy statement relating to its 2024 Annual Meeting of Shareholders to be filed with the Securities and Exchange Commission (the "SEC") within 120 days after the end of the fiscal year ended December 31, 2023, are incorporated herein by reference in Part III where indicated.

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 45,034	$ 190,613
Securities carried at fair value	109,223	82,496
Committed Investment Funds	25,000	0
Prepaid expenses and other current assets	5,830	14,036
Short term notes receivable - related party, net	505	0
Total current assets	185,592	287,145
Property and equipment, net	981	928
Operating lease right-of-use asset, net	1,223	226
Other investments held at fair value	89,825	0
Other investments	1,838	6,755
Long term notes receivable - related parties, net	97	7,262
Convertible notes receivable - related party	11,202	0
Other assets	2,720	3,125
Total assets	293,478	305,441
Current liabilities:
Accounts payable	4,589	2,399
Accrued liabilities	15,256	17,306
Current portion of lease liability	275	180
Other current liabilities	0	12
Total current liabilities	20,120	19,897
Contingent consideration liability - related parties	620	953
Contingent consideration liability	1,637	0
Noncurrent portion of lease liability	990	44
Convertible promissory notes - related parties	164	415
Convertible promissory notes and derivative liability	2,666	0
Long-term debt, net	15,047	14,702
Other liabilities	7,918	3,664
Total liabilities	49,162	39,675
Commitments and contingencies (Note 16)
Stockholders' equity:
Common stock, 0.10 par value ($0.12 par value at December 31, 2023 and December 31, 2022); 750,000,000 shares authorized at December 31, 2023 and December 31, 2022, respectively; 166,026,396 and 165,935,914 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively	18,573	18,562
Additional paid-in capital	794,787	774,092
Share subscription receivable	0	(24)
Accumulated other comprehensive loss	(19,460)	(21,702)
Accumulated deficit	(550,938)	(510,188)
Total stockholders' equity attributable to ATAI Life Sciences N.V. stockholders	242,962	260,740
Noncontrolling interests	1,354	5,026
Total stockholders' equity	244,316	265,766
Total liabilities and stockholders' equity	$ 293,478	$ 305,441

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical)	Dec. 31, 2023 € / shares shares	Dec. 31, 2023 $ / shares shares	Dec. 31, 2022 € / shares shares	Dec. 31, 2022 $ / shares shares
Common Stock, Par or Stated Value Per Share | (per share)	€ 0.10	$ 0.12	€ 0.10	$ 0.12
Common stock, shares authorized	750,000,000	750,000,000	750,000,000	750,000,000
Common stock, shares, issued	166,026,396	166,026,396	165,935,914	165,935,914
Common stock, shares, outstanding	166,026,396	166,026,396	165,935,914	165,935,914

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Income Statement [Abstract]
License revenue	$ 314	$ 233
Operating expenses:
Research and development	62,203	74,313
Acquisition of in-process research and development	0	357
General and administrative	63,582	70,350
Total operating expenses	125,785	145,020
Loss from operations	(125,471)	(144,787)
Other income, net:
Interest income	1,847	548
Interest expense	(2,656)	(923)
Benefit from research and development tax credit	2,445	0
Change in fair value of assets and liabilities, net	86,583	2,083
Impairment of other investments	(1,011)	0
Gain on deconsolidation of a variable interest entity, net	60	1,484
Foreign exchange gain (loss), net	(894)	6,902
Other expense, net	(189)	(489)
Total other income, net	86,185	9,605
Loss before income taxes	(39,286)	(135,182)
Provision for income taxes	(1,016)	(6,229)
Losses from investments in equity method investees, net of tax	(3,593)	(16,006)
Net loss	(43,895)	(157,417)
Net loss attributable to noncontrolling interests	(3,671)	(5,032)
Net loss attributable to ATAI Life Sciences N.V. stockholders	$ (40,224)	$ (152,385)
Basic Earnings Per Share	$ (0.25)	$ (0.98)
Diluted Earnings Per Share	$ (0.25)	$ (0.98)
Basic Weighted Average Number Of Shares Outstanding	158,833,785	155,719,585
Diluted Weighted Average Number Of Shares Outstanding	158,833,785	155,719,585

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Statement of Comprehensive Income [Abstract]
Net loss	$ (43,895)	$ (157,417)
Other comprehensive loss:
Foreign currency translation adjustments, net of tax	2,242	(13,366)
Comprehensive income (loss)	(41,653)	(170,783)
Net loss attributable to noncontrolling interests	(3,671)	(5,032)
Foreign currency translation adjustments, net of tax attributable to noncontrolling interests	(1)	50
Comprehensive loss attributable to noncontrolling interests	(3,672)	(4,982)
Comprehensive income (loss) attributable to ATAI Life Sciences N.V. stockholders	$ (37,981)	$ (165,801)

Condensed Consolidated Statemen

Condensed Consolidated Statements of Redeemable Noncontrolling Interests and Stockholders' Equity (Deficit) - USD ($) $ in Thousands	Total	Common Stock [Member]	Additional Paid-In Capital [Member]	Share Subscriptions Receivable [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Accumulated Deficit [Member]	Total Stockholders' Equity Attributable to ATAI Life Sciences N.V. Stockholders [Member]	Noncontrolling Interests [Member]
Beginning Balance at Dec. 31, 2021	$ 385,959	$ 18,002	$ 725,045	$ 0	$ (8,336)	$ (357,803)	$ 376,908	$ 9,051
Beginning Balance, Shares at Dec. 31, 2021		160,677,001
Issuance of shares upon exercise of stock options	2,295	$ 113	2,206	(24)	0	0	2,295	0
Issuance of shares upon exercise of stock options, Share		938,913
Issuance of subsidiary preferred shares	600	$ 0	0	0	0	0	0	600
Issuance of subsidiary preferred shares, shares		0
Issuance of subsidiary common shares	357	$ 0	0	0	0	0	0	357
Issuance of subsidiary common shares, Shares		0
Issuance of subsidiary shares in connection with the Columbia stock purchase agreement (Note17)	(957)
Conversion of convertible notes to common stock	4,913	$ 447	4,466	0	0	0	4,913	0
Conversion of convertible notes to common stock, Shares		4,320,000
Stock-based compensation expense	42,375	$ 0	42,375	0	0	0	42,375	0
Foreign currency translation adjustment, net of tax	(13,316)	0	0	0	(13,366)	0	13,366	50
Net income (loss)	(157,417)	$ 0	0	0	0	(152,385)	(152,385)	(5,032)
Ending Balance, Shares at Dec. 31, 2022		165,935,914
Ending Balance at Dec. 31, 2022	265,766	$ 18,562	774,092	(24)	(21,702)	(510,188)	260,740	5,026
Issuance of shares upon note conversion, Share		15,920
Issuance of shares upon note conversion	20	$ 2	18	0	0	0	20	0
Issuance of shares upon exercise of stock options	181	$ 9	172	0	0	0	181	0
Issuance of shares upon exercise of stock options, Share		74,562
Settlement of issuance of shares upon exercise of stock options	24	$ 0	0	24	0	0	24	0
Settlement of issuance of shares upon exercise of stock options, Shares		0
Adjustment to additional paid in capital upon consolidation of variable interest entity, net	(10,809)	$ 0	(10,809)	0	0	0	(10,809)	0
Issuance of subsidiary shares in connection with the Columbia stock purchase agreement (Note17)	0
Adjustment to additional paid in capital upon debt modification	(1,668)	0	(1,668)	0	0	0	(1,668)	0
Adjustment to accumulated deficit (pursuant to adoption of ASU 2016-13)	(526)				0	(526)	(526)	0
Stock-based compensation expense	32,982	0	32,982	0	0	0	32,982	0
Foreign currency translation adjustment, net of tax	2,241	0	0	0	2,242	0	2,242	(1)
Net income (loss)	(43,895)	$ 0	0	0	0	(40,224)	(40,224)	(3,671)
Ending Balance, Shares at Dec. 31, 2023		166,026,396
Ending Balance at Dec. 31, 2023	$ 244,316	$ 18,573	$ 794,787	$ 0	$ (19,460)	$ (550,938)	$ 242,962	$ 1,354

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Cash flows from operating activities
Net loss	$ (43,895)	$ (157,417)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization of long term assets	319	168
Noncash lease expense	383	0
Amortization of debt discount	371	131
In-process research and development expense	0	357
Stock-based compensation expense	32,982	42,375
Change in fair value of assets and liabilities, net	(86,583)	(2,083)
Impairment of other investments	1,011	0
Gain on deconsolidation of a variable interest entity, net	(60)	(1,484)
Impairment of short term note receivable	0	852
Provision for deferred income taxes	0	5,074
Unrealized foreign exchange (gains) losses	799	(4,950)
Losses from investments in equity method investees, net of tax	3,593	16,006
Other	(507)	(161)
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	8,663	(1,522)
Accounts payable	2,138	(3,034)
Accrued liabilities	(3,332)	1,221
Net cash used in operating activities	(84,118)	(104,467)
Cash flows from investing activities
Cash paid for securities carried at fair value	(160,262)	(309,058)
Proceeds from sale and maturities of securities carried at fair value	138,983	226,834
Funds committed for investments	(25,000)	0
Purchases of property and equipment	(259)	(773)
Capitalized internal-use software development costs	(331)	(251)
Cash Paid for Other Investments Held at Fair Value	(956)	0
Cash paid for other investments	0	(600)
Proceeds from sale of other investments	486	0
Cash paid for long term notes receivable - related parties	(3,500)	(3,000)
Cash paid for convertible notes receivable - related party	(2,014)	0
Cash paid out in variable interest entity deconsolidation	(443)	0
Net cash used in investing activities	(53,295)	(86,848)
Cash flows from financing activities
Proceeds from issuance of subsidiary preferred shares	0	600
Cash paid for acquisition of noncontrolling interest	(8,480)	0
Proceeds from conversion of convertible notes to common stock	20	4,636
Proceeds from issuance of shares upon exercise of stock options	205	2,294
Proceeds from debt financings	0	15,000
Cash paid for debt financing	(100)	(1,745)
Net cash provided by financing activities	(8,355)	20,785
Effect of foreign exchange rate changes on cash	189	(1,123)
Net increase (decrease) in cash and cash equivalents	(145,578)	(171,653)
Cash and cash equivalents – beginning of the period	190,613	362,266
Cash and cash equivalents – end of the period	45,034	190,613
Supplemental disclosures:
Cash paid for interest	1,923	508
Cash paid for taxes	1,475	652
Supplemental disclosures of non-cash investing and financing information:
Noncash consideration for acquisition of noncontrolling interest, net	2,315	0
Noncash exchange of convertible promissory note modification	1,668	0
Noncash receipt of call option	(5,062)	0
Noncash deferred credit	5,062	0
Right-of-use assets obtained in exchange for new operating lease liabilities	1,377	487
Issuance of subsidiary shares in connection with a stock purchase agreement	0	357
Share subscription receivable	$ 0	$ 24

Nature of Business

Nature of Business	12 Months Ended
	Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of Business	1. N ature of Business ATAI Life Sciences N.V. (“atai”, "Company"), headquartered in Berlin, Germany is the parent company of ATAI Life Sciences AG and, along with its subsidiaries, is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. atai was founded in 2018 as a response to the significant unmet need and lack of innovation in the mental health treatment landscape and is dedicated to efficiently developing innovative therapeutics to treat depression, anxiety, addiction, and other mental health disorders. By pooling resources and best practices, atai aims to responsibly accelerate the development of new medicines to achieve clinically meaningful and sustained behavioral change in mental health patients. The Company is subject to risks and uncertainties common to clinical stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, dependence on key personnel, third-party clinical research organizations and manufacturers, protection of proprietary intellectual property and technology, compliance with government regulations and the ability to secure additional capital to fund operations. Therapeutic candidates currently under development will require significant additional research and development efforts, including preclinical and clinical testing and regulatory approval, prior to commercialization. These efforts require significant amounts of capital, adequate personnel and infrastructure and extensive compliance-reporting capabilities. Even if the Company’s therapeutic development efforts are successful, it is uncertain when, if ever, the Company will realize revenue from sales. The Company has incurred significant losses and negative cash flows from operations since its inception. As of December 31, 2023, the Company had cash and cash equivalents of $ 45.0 million, short-term securities of $ 109.2 million and its accumulated deficit was $ 550.9 million. The Company has historically financed its operations through the sale of equity securities, sale of convertible notes, debt financings, and revenue generated from licensing and collaboration arrangements. The Company has not generated any revenues to date from the sale of its product candidates and does not anticipate generating any revenues from the sale of its product candidates unless and until it successfully completes development and obtains regulatory approval to market its product candidates. The Company operates and manages the business as one reporting and one operating segment, which is the business of identifying and advancing mental health innovations. The Company has determined that its chief executive officer is the chief operating decision maker (“CODM”). The CODM reviews consolidated operating results to make decisions about allocating resources or capital to specific compounds or projects in line with overall Company’s strategies and goals. The Company operates in two geographic regions primarily in the United States and Germany.

Basis of Presentation, Consolid

Basis of Presentation, Consolidation and Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2023
Accounting Policies [Abstract]
Basis of Presentation, Consolidation and Summary of Significant Accounting Policies	2. Basis of Presentation, Consolidation and Summary of Significant Accounting Policies Basis of Presentation The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) and follow the requirements of the United States Securities and Exchange Commission ("SEC"), and in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for a fair statement of the Company's financial position, results of operations and comprehensive loss, and cash flows for the periods presented. Any reference in these notes to applicable accounting guidance is meant to refer to the authoritative U.S. GAAP included in the Accounting Standards Codification (“ASC”), and Accounting Standards Update (“ASU”) issued by the Financial Accounting Standards Board (“FASB”). Reclassifications Certain reclassifications were made to prior period amounts in the consolidated financial statements and accompanying notes to conform with current year presentation due to the increase in the balances of the Company's operating right-of-use asset, related lease liability, and debt facility related interest during the period. Consolidation The Company's consolidated financial statements include the accounts of atai and its subsidiaries. All intercompany balances and transactions have been eliminated in the consolidation. Since its inception, the Company has created wholly owned subsidiaries or made investments in certain controlled entities, including partially-owned subsidiaries for which it has majority voting interest under the VOE model or for which it is the primary beneficiary under the VIE model, which it refers to collectively as its consolidated entities. For consolidated entities that are less than wholly-owned, the third-party’s holding of equity interest is presented as noncontrolling interests in the Company's consolidated balance sheets and consolidated statements of stockholders' equity. The portion of net income (loss) attributable to the noncontrolling interests is presented as net income (loss) attributable to noncontrolling interests in the Company's consolidated statements of operations. Ownership interests in entities over which the Company has significant influence, but not a controlling financial interest, are accounted for as cost and equity method investments. If the company has not elected the fair value option, the Company then records gains (losses) from investments in equity method investees, net of tax, for its proportionate share of the underlying company’s net results until the investment balance is adjusted to zero. If the Company makes subsequent additional investments in that same company, it may record additional gains (losses) based on changes to its investment basis and also may record additional income (loss) in equity method investments. If the Company has elected the fair value option, the fair value of the investments will be recorded upon acquisition and any changes in fair value will be recorded as a component of other income (expense), net. Significant Accounting Policies Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Significant estimates and assumptions made in the accompanying consolidated financial statements include, but are not limited to the fair value of securities carried at fair value, the fair value of other investments held at fair value, the fair value of convertible notes receivable, accruals for research and development costs, the fair value of contingent consideration liabilities, in-process research and development assets (“IPRD”), noncontrolling interests recognized in acquisitions, and the valuation of stock-based awards. The Company bases its estimates and assumptions on historical experience and on various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates. Concentrations of Credit Risk Financial instruments which potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents, short-term investments, and all no tes receivables. The Company’s cash is mainly held in financial institutions in the United States. Amounts on deposit may at times exceed federally insured limits. The credit risk associated with the Company’s investment in all notes receivables is monitored and assessed periodically. The Company does not believe that it is exposed to any significant credit risk related to these instruments. Cash and Cash Equivalents The Company considers all highly liquid investments purchased with original maturities of three months or less from the purchase date to be cash equivalents. As of December 31, 2023 and 2022, cash and cash equivalents consisted of cash on deposit and cash held in high-yield savings accounts and money market funds, and at times in excess of federally insured limits. Investment Securities Portfolio The Company maintains an investment portfolio, which is comprised of money market funds, U.S. treasury securities, commercial paper, corporate notes/bonds, and U.S. government agencies securities. The Company classified securities in the investment portfolio as available-for-sale securities. Furthermore, the Company elected the fair value option for the available-for-sale securities in the investment portfolio. The decision to elect the fair value option, which is irrevocable once elected, is determined on an instrument-by-instrument basis and applied to an entire instrument. The net gains or losses, if any, on an investment for which the fair value option has been elected are recognized as a Change in fair value of assets and liabilities, net o n the consolidated statements of operations and the amortized cost of investments approximates their fair value. The Company's securities in the investment portfolio will mature within one year. Property and Equipment Property and equipment, consisting primarily of furniture and fixtures and leasehold improvements, is r ecorded at cost, less accumulated depreciation. Maintenance and repairs that do not improve or extend the lives of the respective assets are expensed to operations as incurred. Upon disposal, retirement or sale, the related cost and accumulated depreciation is removed from the accounts and any resulting gain or loss is included in the results of operations. Depreciation of property and equipment is recorded using the straight-line method over the estimated useful lives of the related assets once the asset has been placed in service. The company estimates the useful life of furniture and fixtures to be 7 years. Leasehold improvements are amortized using the straight-line method over the estimated useful life or remaining lease term, whichever is shorter . Operating lease right-of-use asset At the inception of an arrangement, the Company determines if an arrangement is, or contains, a lease based on the unique facts and circumstances present in that arrangement. Lease classification, recognition, and measurement are then determined at the lease commencement date. For arrangements that contain a lease the Company (i) identifies lease and non-lease components, (ii) determines the consideration in the contract, (iii) determines whether the lease is an operating or financing lease; and (iv) recognizes lease right-of-use (ROU) assets and liabilities. Lease liabilities and their corresponding ROU assets are recorded based on the present value of lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable and as such, the Company uses its incremental borrowing rate based on the information available at the lease commencement date, which represents an internally developed rate that would be incurred to borrow, on a collateralized basis, over a similar term, an amount equal to the lease payments in a similar economic environment. Most leases include options to renew and, or, terminate the lease, which can impact the lease term. The exercise of these options is at the Company's discretion. The Company does not include any of these options within the expected lease term, as it is not reasonably certain it will exercise these options. Variable Interest Entities and Voting Interest Entities The Company consolidates those entities in which it has a direct or indirect controlling financial interest based on either the variable interest model (the “VIE model”) or the voting interest model (the “VOE model”). VIEs are entities that, by design, either (i) lack sufficient equity to permit the entity to finance its activities without additional subordinated financial support from other parties; or (ii) have equity investors that do not have the ability to make significant decisions relating to the entity’s operations through voting rights, or do not have the obligation to absorb the expected losses, or do not have the right to receive the residual returns of the entity. The primary beneficiary of a VIE is required to consolidate the assets and liabilities of the VIE. The primary beneficiary is the party that has both (i) the power to direct the activities of the VIE that most significantly impact the VIE’s economic performance; and (ii) the obligation to absorb losses or the right to receive benefits from the VIE that could potentially be significant to the VIE through its interest in the VIE. To assess whether the Company has the power to direct the activities of a VIE that most significantly impact the VIE’s economic performance, the Company considers all the facts and circumstances, including its role in establishing the VIE and its ongoing rights and responsibilities. This assessment includes identifying the activities that most significantly impact the VIE’s economic performance and identifying which party, if any, has power over those activities. In general, the parties that make the most significant decisions affecting the VIE (management and representation on the board of directors) and have the right to unilaterally remove those decision-makers are deemed to have the power to direct the activities of a VIE. To assess whether the Company has the obligation to absorb losses of the VIE or the right to receive benefits from the VIE that could potentially be significant to the VIE, the Company considers all of its economic interests, which primarily include equity investments in preferred and common stock and notes receivable that are convertible into preferred stock, that are deemed to be variable interests in the VIE. This assessment requires the Company to apply judgment in determining whether these interests, in the aggregate, are considered potentially significant to the VIE. Factors considered in assessing the significance include: the design of the VIE, including its capitalization structure; subordination of interests; payment priority; relative share of interests held across various classes within the VIE’s capital structure; and the reasons why the interests are held by the Company. At the VIE’s inception, the Company determines whether it is the primary beneficiary and if the VIE should be consolidated based on the facts and circumstances. The Company then performs on-going reassessments of the VIE based on reconsideration events and reevaluates whether a change to the consolidation conclusion is required each reporting period. If the Company is not deemed to be the primary beneficiary in a VIE, the Company accounts for the investment or other variable interests in a VIE in accordance with the applicable GAAP. Upon the occurrence of certain events and on a regular basis, the Company evaluates whether it no longer has a controlling interest in its consolidated VIEs. If the Company determines it no longer has a controlling interest, the subsidiary is deconsolidated. The Company records a gain or loss on deconsolidation based on the difference on the deconsolidation date between (i) the aggregate of (a) the fair value of any consideration received, (b) the fair value of any retained noncontrolling investment in the former subsidiary and (c) the carrying amount of any noncontrolling interest in the subsidiary being deconsolidated, less (ii) the carrying amount of the former subsidiary’s assets and liabilities. Entities that do not qualify as a VIE are assessed for consolidation under the VOE model. Under the VOE model, the Company consolidates the entity if it determines that it, directly or indirectly, has greater than 50 % of the voting shares and that other equity holders do not have substantive voting, participating or liquidation rights. Acquisitions The Company evaluates each of its acquisitions under the accounting framework in Accounting Standards Codification (“ASC”) Topic 805, Business Combinations , to determine whether the transaction is a business combination or an asset acquisition. In determining whether an acquisition should be accounted for as a business combination or an asset acquisition, the Company first performs a screen test to determine whether substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or a group of similar identifiable assets. If this is the case, the acquired set is not deemed to be a business and is instead accounted for as an asset acquisition. If this is not the case, the Company then further evaluates whether the acquired set includes, at a minimum, an input and a substantive process that together significantly contribute to the ability to create outputs. If so, the Company concludes that the acquired set is a business. During the years ended December 31, 2023 and 2022, the Company did not have any acquisitions that were accounted for as business combinations. For asset acquisitions that involve the initial consolidation of a VIE that is not a business for which the Company is the primary beneficiary, the transactions are accounted for under ASC 810, Consolidation , and no goodwill is recognized. Rather, the Company recognizes the identifiable assets acquired (excluding goodwill), the liabilities assumed, and any noncontrolling interests as though the VIE was a business and subject to the guidance on recognition and measurement in a business combination under ASC 805, and recognizes a gain or loss for the difference between (a) the sum of the fair values of consideration paid (including any contingent consideration) and noncontrolling interests, (b) the fair value of the VIE’s identifiable assets and liabilities, and (c) the reported amounts of any previously held interests. Acquisition-related expenses incurred by the Company in asset acquisitions that involve the initial consolidation of a VIE that is not a business, are not included as a component of consideration transferred, but are accounted for as an expense in the period in which the costs are incurred. In an asset acquisition, including the initial consolidation of a VIE that is not a business, acquired in-process research and development (“IPR&D”) with no alternative future use is charged to operating expenses at the acquisition date. Other Investments Held at Fair Value As permitted under Accounting Standards Codification 825, Financial Instruments, or ASC 825, the Company has elected the fair value option to account for its investment in IntelGenx, which otherwise would be subject to ASC 323. In accordance with ASC 825, the Company records this investment at fair value under the Other investments held at fair value in the Company's consolidated balance sheets and changes in fair value are recognized asChange in fair value of assets and liabilities, net, a component of other income (expense), net in the consolidated statements of operations. At the most recent remeasurement date, the Company evaluated its ability to continue to exercise significant influence over its investment and determined that it no longer had significant influence. The Company's COMPASS investment is accounted for at fair value under ASC 321 and recorded in Other investments held at fair value on the consolidated balance sheets and changes in fair value are recognized as Change in fair value of assets and liabilities, net, a component of other income (expense), net in the consolidated statements of operations. Equity Method Investments The Company utilizes the equity method to account for investments when it possesses the ability to exercise significant influence, but not control, over the operating and financial decisions of the investee. Generally, the ability to exercise significant influence is presumed when the investor possesses more than 20% of the voting interests of the investee. This presumption may be overcome based on specific facts and circumstances that demonstrate that the ability to exercise significant influence is not present. The Company applies the equity method to investments in common stock and to other investments in nonconsolidated entities that have risk and reward characteristics that are substantially similar to an investment in the investee’s common stock. In applying the equity method, the Company’s investments are initially recorded at cost in Other investments on the consolidated balance sheets. Upon recording an equity method investment, the Company evaluates whether there are basis differences between the carrying value and fair value of the Company’s proportionate share of the investee’s underlying net assets. Typically, the Company amortizes basis differences identified on a straight-line basis over the underlying assets’ estimated useful lives when calculating the attributable earnings or losses, excluding the basis differences attributable to IPR&D that had no alternative future use. To the extent a basis difference relates to IPR&D and the investee is not a business as defined in ASC 805, the Company immediately expenses such basis difference related to IPR&D. If the Company is unable to attribute all the basis difference to specific assets or liabilities of the investee, the residual excess of the cost of the investment over the proportional fair value of the investee’s assets and liabilities is recognized within the equity investment balance. The Company subsequently adjusts the carrying amount of the investment by the Company’s proportionate share of the net earnings or losses and other comprehensive income or loss of the investee based on the Company’s percentage of common stock or in-substance common stock ownership during the respective reporting period. The Company records its share of the results of equity method investees and any impairment related to equity method investments as earnings or losses from investments in equity method investees, net of tax in the consolidated statements of operations. In the event that net losses of the investee reduce the carrying amount to zero, additional net losses may be recorded if the Company has other investment or other outstanding loans and advances to the investee and would be determined based on the Company’s proportionate share of the respective class of securities. Currently the Company is not obligated to make additional capital contributions for its equity method investments, and therefore only records losses up to the amount of its total investment, inclusive of other investments in and loans to the investee, which are not accounted for as equity method investments. To the extent that the Company’s share of losses of the equity method investee on a cumulative basis exceeds its total investment amount, inclusive of its equity method investment, other investments, and loans, the Company will discontinue equity method loss recognition as the Company does not have guaranteed obligations of the investee nor has the Company otherwise committed to provide further financial support for the investee. The Company will resume recording its share of losses in future periods only after its share of the earnings of the equity method investee equals the Company’s share of losses not recognized during the suspended period. The Company evaluates additional equity method investments made after the suspension of loss recognition to determine whether such investments represent the funding of prior suspended losses of the equity method investee. Equity method investments are reviewed for indicators of other-than-temporary impairment at each reporting period. Equity method investments are written down to fair value if there is evidence of a loss in value that is other-than-temporary. Methodologies that the Company may use to estimate the fair value of its equity method investments include, but are not limited to, considering recent investee equity transactions, discounted cash flow analysis, recent operating results, comparable public company operating cash flow multiples and in certain situations, balance sheet liquidation values. If the fair value of the investment has declined below the carrying amount, management considers several factors when determining whether an other-than-temporary decline has occurred, such as the length of the time and the extent to which the estimated fair value or market value has been below the carrying value, the financial condition and the near-term prospects of the investee, the intent and ability of the Company to retain its investment in the investee for a period of time sufficient to allow for any anticipated recovery in market value and general market conditions. The estimation of fair value and whether an other-than-temporary impairment has occurred requires the application of significant judgment and future results may vary from current assumptions. If declines in the value of the equity method investments are determined to be other-than-temporary, a loss is recorded in earnings in the current period as a component of losses from investments in equity method investees, net of tax on the consolidated statements of operations. Evidence of a loss in value might include, but would not necessarily be limited to, absence of an ability to recover the carrying amount of the investment or inability of the investee to sustain an earnings capacity that would justify the carrying amount of the investment. This evaluation consists of several qualitative and quantitative factors including recent financial results and operating trends of the investee, implied values in recent transactions of investee securities, or other publicly available information that may affect the value of the Company’s investments. The Company presents income/losses from equity investments and any impairment related to equity method investments as Income(Losses) from investments in equity method investees, net of tax on the consolidated statement of operations. Other Investments Other investments include ownership rights that either (i) do not provide the Company with control or significant influence, or (ii) do not have risk and reward characteristics that are substantially similar to an investment in the investee’s common stock. The Company records such investments under the measurement alternative method pursuant to ASC 321 as these investments do not have readily determinable fair values. Under the measurement alternative method, the Company records the investment at cost less impairment losses, if any, unless it identifies observable price changes in orderly transactions for the identical or a similar investment of the same issuer, in which case the Company will measure its investments at fair value as of the date that the observable transaction occurred. Such investments are presented as Other Investments on the consolidated balance sheets and any impairment recognized related to these investments are presented as Impairment of other investments, a component of other income(expense), net in the consolidated statements of operations. The Company performs a qualitative assessment at each reporting period considering impairment indicators to evaluate whether the investment is impaired. Impairment indicators that the Company considers include but are not limited to; i) a significant deterioration in the earnings performance, credit rating, asset quality, or business prospects of the investee, ii) a significant adverse change in the regulatory, economic, or technological environment of the investee, iii) a significant adverse change in the general market condition of either the geographical area or the industry in which the investee operates, iv) a bona fide offer to purchase, an offer by the investee to sell, or a completed auction process for the same or similar investment for an amount less than the carrying amount of that investment; v) factors that raise significant concerns about the investee’s ability to continue as a going concern, such as negative cash flows from operations, working capital deficiencies, or noncompliance with statutory capital requirements or debt covenants. If the qualitative assessment indicates that an investment is impaired, a loss is recorded equal to the difference between the fair value and carrying value of the investment. Convertible Notes Receivable As permitted under ASC 825, Financial Instruments , or ASC 825, the Company has elected the fair value option to account for its IntelGenx convertible notes, which otherwise would be subject to ASC 320. In accordance with ASC 825, the Company records this investment at fair value under Convertible notes receivable - related party in the Company's consolidated balance sheets and changes in fair value are recognized as Change in fair value of assets and liabilities, net, a component of other income(expense), net in the consolidated statements of operations. Notes Receivable The Company has certain notes receivable that are carried at cost, which includes the principal value of the note receivable, accrued interest and net of any payments received and expected credit losses. Management utilizes an undiscounted probability-of-default (“PD”) and loss-given-default (“LGD”) method for estimating credit losses on its assets pool, which is comprised of loans to other companies. Under the PD and LGD method, the expected credit loss percentage (or “loss rate”) is calculated as the probability of default (i.e., the probability the asset will default within the given time frame) multiplied by the loss given default (i.e., the percentage of the asset not expected to be collected because of default). Based on the terms of the notes receivable, certain notes receivable are classified as long term as their payments are due after twelve months from the balance sheet date. Contingent Consideration Liability The Company may record contingent consideration as part of the cost of acquisitions. Contingent consideration is recognized at fair value as of the date of acquisition and accounted under Contingent consideration liability on the consolidated balance sheet. Contingent considerations are remeasured on a quarterly basis, as appropriate, using a discounted cash-flow valuation technique until fulfillment of the contingency. Changes in the fair value of the contingent consideration are recognized as Change in fair value of assets and liabilities, net , a component of other income (expense), net in the consolidated statements of operations. Debt Issuance Costs and Debt Discount Debt issuance costs include incremental and direct costs incurred in relation to debt, such as legal fees, accounting fees, and other direct costs of the financing. Amounts paid to the lender are a reduction in the proceeds received by the Company and are generally considered a component of issuance discount, unless it is paid to compensate the lender for the services rendered or as a reimbursement of direct costs incurred by them in relation to the debt, in which case it would be akin to a debt issuance cost. Debt issuance costs related to a recognized debt liability are presented in the consolidated balance sheet as a direct deduction from the carrying amount of the debt liability rather than as an asset, consistent with the presentation of debt discounts, and are amortized to interest expense over the term of the related debt using the effective interest method. Research and Development Costs Research and development costs are expensed as incurred. Research and development consist of salaries, benefits and other personnel related costs including equity-based compensation expense, laboratory supplies, preclinical studies, clinical trials and related clinical manufacturing costs, costs related to manufacturing preparations, fees paid to other entities to conduct certain research and development activities on the Company’s behalf and allocated facility and other related costs. Nonrefundable advance payments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized as prepaid expenses until the related goods are delivered or services are performed. Preclinical and clinical study costs a re accrued over the service periods specified in the contracts and adjusted as necessary based upon an ongoing review of the level of effort and costs actually incurred. Payments for a product license prior to regulatory approval of the product and payments for milestones achieved prior to regulatory approval of the product are expensed in the period incurred as research and development expense. Contingencies The Company may be, from time to time, a party to various disputes and claims arising from normal business activities. The Company continually assesses any litigation or other claims it may confront to determine if an unfavorable outcome would lead to a probable loss or reasonably possible loss which could be estimated. The Company will accrue for all contingencies at the earliest date at which the Company deems it probable that a liability has been incurred and the amount of such liability can be reasonably estimated. If the estimate of a probable loss is a range and no amount within the range is more likely than another, the Company will accrue the minimum of the range. In the cases where the Company believes that a reasonably possible loss exists, the Company will disclose the facts and circumstances of the litigation, including an estimable range, if possible. Licenses of Intellectual Property The Company may enter into collaboration and out-licensing arrangements for research and development, manufacturing, and commercialization activities with counterparties for the development and commercialization of its product candidates. The agreements may have units of account within the scope of ASC 606 where the counterparties meet the definition of a customer as well as units of account within the scope of ASC 808 where both parties are determined to be active participants exposed to significant risk and rewards. The arrangements may contain multiple components, which may include (i) licenses, or options to obtain licenses to the Company’s intellectual property or sale of the Company’s license, (ii) research and development activities, (iii) participation on joint steering committees, and (iv) the manufacturing of commercial, clinical or preclinical material. Payments pursuant to these arrangements may include non-refundable, upfront payments, milestone payments upon the achievement of significant development events, research and development reimbursements, sales milestones, and royalties on product sales. The amount of variable consideration is constrained until it is probable that the revenue is not at a significant risk of reversal in a future period. The contracts into which the Company enters generally do not include significant financing components. In determining the appropriate amount of revenue to be recognized as it fulfills its obligations under each of its collaboration and license agreements, the Company performs the following steps: (i) identification of the promised goods or services in the contract within the scope of ASC 606; (ii) determination of whether the promised goods or services are performance obligations including whether they are capable of being distinct and distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; a

Dispositions

Dispositions	12 Months Ended
	Dec. 31, 2023
Business Combinations [Abstract]
Acquisitions	3. Dispositions 2023 Dispositions Psyber, Inc. In October 2023, the Company entered into a Framework Agreement with the founders of Psyber, Inc. ("Founders") through which the Company transferred its equity interest in Psyber, Inc. ("Psyber") to the Founders in exchange for certain intellectual property. As a result of the disposition, the Company ceased having controlling financial interest in Psyber. The Company determined that it was no longer the primary beneficiary, no longer had the power to direct the significant activities of Psyber, and accordingly, deconsolidated Psyber. T he Company derecognized all of Psyber's assets and liabilities, with the exception of the retained intellectual property, from its consolidated balance sheet and recognized a loss of $ 0.3 million, which was reported as Loss on deconsolidation of a variable interest entity, a component of other income, net in the consolidated statement of operations for the year ended December 31, 2023. The Company concluded that the decision to deconsolidate Psyber, which was based on resource capital allocation decisions, did not represent a significant strategic shift that would have a material effect on the Company's operations and financial results. Therefore, the Company did not present the results of Psyber prior to deconsolidation as discontinued operations in its consolidated statements of operations for the year ended December 31, 2023. TryptageniX, Inc. In December 2023, the Company finalized and entered into a Framework Agreement with CB Therapeutics, Inc. ("CBT") through which the Company transferred its equity interest in TryptageniX Inc. ("TryptageniX") to CBT in exchange for certain intellectual property and an Amended and Restated Development Services and Exclusive License Agreement. As a result of the disposition, the Company ceased having controlling financial interest in TryptageniX. The Company determined that it was no longer the primary beneficiary, no longer had the power to direct the significant activities of TryptageniX, and accordingly, deconsolidated TryptageniX. The Company derecognized all of TryptageniX 's assets and liabilities from its consolidated balance sheet, and recognized a gain of $ 0.4 million, which was reported as Gain on deconsolidation of a variable interest entity, a component of other income, net in the consolidated statement of operations for the year ended December 31, 2023. The Company concluded that the decision to deconsolidate TryptageniX, which was based on resource capital allocation decisions, did not represent a significant strategic shift that would have a material effect on the Company's operations and financial results. Therefore, the Company did not present the results of TryptageniX prior to deconsolidation as discontinued operations in its consolidated statements of operations for the year ended December 31, 2023. 2022 Dispositions Neuronasal, Inc. In November 2022, the Company finalized and entered into a Redemption, Termination and Release Agreement ("Termination Agreement") with Neuronasal through which atai disposed of its equity interests and residual SPA funding obligations. Pursuant to the Neuronasal Termination Agreement, the Company transferred all of its approximately equity interest in Neuronasal in exchange for the redemption consideration in the form of certain warrants. The Neuronasal Termination Agreement entitles the Company to purchase certain common stock in Neuronasal upon the occurrence of certain contingencies, such as an initial public offering, qualified financing event, or certain clinical studies. The Company has no further obligations to fund Neuronasal. As a result of the disposition, the Company ceased having controlling financial interest in Neuronasal. The Company determined that it was no longer the primary beneficiary, as it no longer had the power to direct the significant activities of Neuronasal, and accordingly deconsolidated Neuronasal. Upon the effective termination date, the Company derecognized all of Neuronasal's assets and liabilities from its balance sheet, and recognized a gain of $ 1.5 million, which was reported as Gain on deconsolidation of a variable interest entity, a component of other income, net in the consolidated statement of operations for the year ended December 31, 2022. The Company determined that the value of the warrants received in connection with the Termination Agreement were de minimis as of the termination date and continue to be de minimis as of the year ended December 31, 2023 . In connection with the deconsolidation of Neuronasal, the Company concluded that the loan assets were impaired and recognized an impairment of $ 0.9 million, which was reported in Other income(expense), net in the consolidated statements of operations for the year ended December 31, 2022 The Company concluded that the decision to deconsolidate Neuronasal, which was based on clinical data that did not meet expectations, did not represent a significant strategic shift. Therefore, the Company did not present the results of Neuronasal prior to deconsolidation as discontinued operations in its consolidated statements of operations for the year ended December 31, 2022.

Variable Interest Entities and

Variable Interest Entities and a Voting Interest Entity	12 Months Ended
	Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Variable Interest Entities and a Voting Interest Entity	4. Variable Interest Entities and a Voting Interest Entity Consolidated VIEs At each reporting period, the Company reassesses whether it remains the primary beneficiary for Variable Interest Entities (“VIEs”) consolidated under the VIE model. The entities consolidated by the Company are comprised of wholly and partially owned entities for which the Company is the primary beneficiary under the VIE model as the Company has (i) the power to direct the activities that most significantly impact the VIE’s economic performance and (ii) the obligation to absorb losses that could potentially be significant to the VIE, or the right to receive benefits from the VIE that could potentially be significant to the VIE. The results of operations of the consolidated entities are included within the Company’s consolidated financial statements from the date of acquisition to December 31, 2023. As of December 31, 2023 and 2022, the Company has accounted for the following consolidated investments as VIEs, excluding the wholly owned subsidiaries: Consolidated Entities Relationship as of Relationship as of Date Ownership % Ownership % Perception Neuroscience Holdings, Inc. Controlled VIE Controlled VIE November 2018 59.2 % 58.9 % Kures, Inc. Controlled VIE Controlled VIE August 2019 64.5 % 64.5 % EntheogeniX Biosciences, Inc. Wholly Owned Subsidiary Controlled VIE November 2019 100.0 % 80.0 % DemeRx IB, Inc. Wholly Owned Subsidiary Controlled VIE December 2019 100.0 % 59.5 % Recognify Life Sciences, Inc. Controlled VIE Controlled VIE November 2020 51.9 % 51.9 % PsyProtix, Inc. Controlled VIE Controlled VIE February 2021 75.0 % 75.0 % Psyber, Inc. (1) - Controlled VIE February 2021 — 75.0 % InnarisBio, Inc. Wholly Owned Subsidiary Controlled VIE March 2021 100.0 % 82.0 % TryptageniX Inc. (1) — Controlled VIE December 2021 — 65.0 % (1) As discussed in Note 3, the Company deconsolidated Psyber, Inc. and TryptageniX, Inc. in October and December 2023, respectfully. As of December 31, 2023 and 2022, the assets of the consolidated VIEs can only be used to settle the obligations of the respective VIEs. The liabilities of the consolidated VIEs are obligations of the respective VIEs and their creditors have no recourse to the general credit or assets of atai. EntheogeniX Biosciences, Inc. In November 2019, the Company entered into a series of agreements with Cyclica Inc. ("Cyclica") to form EntheogeniX Biosciences, Inc. ("EntheogeniX"), a company dedicated to developing the next generation of innovative mental health drugs employing an AI-enabled computational biophysics platform designed to optimize and accelerate drug discovery. Based on the Company's assessment of the transaction at the time of acquisition, the Company concluded that EntheogeniX was not a business and accounted for the Company's investment as an initial consolidation of a VIE that is not a business under ASC 810. In February 2022 and September 2022, the Company purchased additional shares of Class A common stock for an aggregate purchase price of $ 2.2 million. As a result of anti-dilution protection available to Cyclica, the Company's ownership percentage in EntheogeniX did not change due to its purchase. In March 2023, the Company purchased additional shares of Class A common stock for an aggregate purchase price of $ 1.0 million. As a result of anti-dilution protection available to Cyclica, the Company's ownership percentage in EntheogeniX did not change due to its purchase. In September 2023, the Company and Cyclica entered into a Stock Transfer Agreement which resulted in the Company's acquisition of Cyclica’s equity ownership of EntheogeniX for an aggregate purchase price of $ 0.5 million (the “Stock Transfer”). As a result of the Stock Transfer, the Company owned 100 % of the outstanding common stock of EntheogeniX. The Stock Transfer was accounted for as an equity transaction with no gain or loss recognized. The difference between the carrying amount of EntheogeniX's noncontrolling interest and the consideration for the acquisition of the additional equity interest was recorded as a reduction in Additional paid-in capital in the consolidated balance sheets and consolidated statements of stockholders' equity. DemeRx IB, Inc. In December 2019, DemeRx IB, Inc. (“DemeRx IB”) was incorporated as a wholly-owned subsidiary of DemeRx, Inc., formed for the purpose of facilitating a joint venture transaction between DemeRx, Inc. and ATAI AG. DemeRx, Inc. and ATAI AG jointly created DemeRx IB, which was designed to use DemeRx Inc.'s intellectual property to develop Ibogaine as a treatment for opioid dependence. Based on the Company's assessment of the transaction at the time of acquisition, the Company concluded that DemeRx IB was not a business and accounted for the Company's investment as an initial consolidation of a VIE that is not a business under ASC 810. In October 2023, the Company and DemeRx, Inc. entered into a Stock Purchase and Framework Agreement which resulted in the Company's acquisition of DemeRx, Inc.’s equity ownership of DemeRx IB (the “Stock Purchase”). As a result of the Stock Purchase, the Company owned 100 % of the outstanding common stock of DemeRx IB. The Stock Purchase consideration included an $ 8.0 million upfront cash payment, transfer of the Company's ownership in DemeRx, NB, Inc., settlement of a related term loan, and earn-out consideration contingent upon the achievement of certain development milestones directly related to DemeRx’s oral capsule formulation of ibogaine (“DMX-1002”) program. At the execution of the Stock Transfer, the earn-out consideration was recorded as a liability at an estimated fair value of $ 1.3 million and reflected in Contingent consideration - related parties in the consolidated balance sheet. The Stock Purchase was accounted for as an equity transaction with no gain or loss recognized. The difference between the carrying amount of DemeRx IB's noncontrolling interest and the consideration given for the acquisition of the additional equity interest was recorded as a reduction in Additional paid-in capital in the consolidated balance sheets and consolidated statements of stockholders' equity. InnarisBio, Inc. In February 2021, the Company jointly formed InnarisBio, Inc. ("InnarisBio") with UniQuest Pty Ltd (“UniQuest”) for the purpose of adding a solgel-based direct-to-brain intranasal drug delivery technology to the Company’s platform. Based on the Company's assessment of the transaction at the time of acquisition, the Company concluded that InnarisBio was not a business and accounted for the Company's investment as an initial consolidation of a VIE that is not a business under ASC 810. In October 2023, InnarisBio and UniQuest entered into an Assignment, Termination and Release Agreement ("ATRA") which resulted in InnarisBio reacquiring UniQuest’s equity interest in exchange for the assignment of intellectual property and the termination of certain license and research agreements . The assigned intellectual property has an approximate fair value of $ 0.1 million, and the termination of agreements resulted in the extinguishment of a $ 0.1 million contingent commitment liability. As a result of the ATRA, the Company owned 100 % of the outstanding common stock of InnarisBio, and InnarisBio became a wholly owned subsidiary of the Company. The ATRA was accounted for as an equity transaction with no gain or loss recognized.The difference between the carrying amount of InnarisBio's noncontrolling interest and the consideration given for the acquisition of the additional equity interest was recorded as a reduction in Additional paid-in capital in the consolidated balance sheets and consolidated statements of stockholders' equity. The following table presents the assets and liabilities (excluding intercompany balances that were eliminated in consolidation) for all VIEs as of December 31, 2023 (in thousands): Perception Kures EntheogeniX DemeRx IB Recognify PsyProtix InnarisBio Assets: Current assets: Cash $ 97 $ 257 $ 675 $ 528 $ 4,356 $ 35 $ 326 Accounts receivable 84 — — — — — — Prepaid expenses and other current assets 257 — 124 — 450 — 878 Total current assets 438 257 799 528 4,806 35 1,204 Long term notes receivable — — — — — 97 — Other assets — — — — — — 16 Total assets $ 438 $ 257 $ 799 $ 528 $ 4,806 $ 132 $ 1,220 Liabilities: Current liabilities: Accounts payable $ 31 $ 329 $ 59 $ 51 $ 1,926 $ — $ — Accrued liabilities 718 84 247 434 609 26 10 Other current liabilities 12 — — 2 1 — 1 Total current liabilities 761 413 306 487 2,536 26 11 Total liabilities $ 761 $ 413 $ 306 $ 487 $ 2,536 $ 26 $ 11 The following table presents the assets and liabilities (excluding intercompany balances that were eliminated in consolidation) for all consolidated VIEs as of December 31, 2022 (in thousands): Perception Kures EntheogeniX DemeRx IB Recognify PsyProtix Psyber InnarisBio TryptageniX Assets: Current assets: Cash $ 8,703 $ 220 $ 467 $ 12,251 $ 7,526 $ 1 $ 683 $ 719 $ 513 Accounts receivable 197 — — — — — — — — Prepaid expenses and other current assets 466 174 91 21 1,742 66 — 13 2,850 Total current assets 9,366 394 558 12,272 9,268 67 683 732 3,363 Long term notes receivable — — — 1,075 — 109 — — — Other assets — — — — — — 353 — — Total assets $ 9,366 $ 394 $ 558 $ 13,347 $ 9,268 $ 176 $ 1,036 $ 732 $ 3,363 Liabilities: Current liabilities: Accounts payable $ 661 $ 25 $ 124 $ 332 $ 381 $ 33 $ 10 $ 3 $ — Accrued liabilities 1,738 266 121 671 596 46 37 158 154 Other current liabilities 121 2 — 133 2 1 1 1 — Total current liabilities 2,520 293 245 1,136 979 80 48 162 154 Total liabilities $ 2,520 $ 293 $ 245 $ 1,136 $ 979 $ 80 $ 48 $ 162 $ 154 Noncontrolling Interests The Company recognizes noncontrolling interests related to its consolidated VIEs and provides a rollforward of the noncontrolling interests balance, as follows (in thousands): Perception Kures Recognify Total Balance as of December 31, 2022 $ 1,731 $ 451 $ 2,844 $ 5,026 Issuance of noncontrolling interests — — — — Net loss attributable to noncontrolling interests - preferred ( 1,302 ) ( 84 ) ( 2,287 ) ( 3,673 ) Comprehensive income attributable to noncontrolling interests ( 1 ) 2 — 1 Balance as of December 31, 2023 $ 428 $ 369 $ 557 $ 1,354 Perception Kures Recognify Total Balance as of December 31, 2021 $ 5,232 $ — $ 3,819 $ 9,051 Issuance of noncontrolling interests — 957 — 957 Net income (loss) attributable to noncontrolling ( 3,551 ) ( 149 ) ( 975 ) ( 4,675 ) Net income (loss) attributable to noncontrolling — ( 357 ) — ( 357 ) Comprehensive loss attributable to noncontrolling 50 — — 50 Balance as of December 31, 2022 $ 1,731 $ 451 $ 2,844 $ 5,026 Nonconsolidated VIEs The Company evaluated the nature of its investments in Innoplexus AG (“Innoplexus”) and IntelGenx and determined that the investments are VIEs as of the date of the Company’s initial investment through the earlier of the date of disposal or December 31, 2023. The Company is not the primary beneficiary as it did not have the power to direct the activities that most significantly impact the investments’ economic performance and therefore concluded that it did not have a controlling financial interest that would require consolidation as of December 31, 2023 and 2022. The Company will reevaluate if the investments meet the definition of a VIE upon the occurrence of specific reconsideration events. The Company accounted for these investments under either the equity method, fair value option, or the measurement alternative included within ASC 321. As of December 31, 2023, the Company’s maximum exposure for its nonconsolidated VIEs was $ 6.1 million relating to the carrying values in Other investments held at fair value, $ 0.1 million relating to the carrying value in Long term notes receivable – related party, and $ 11.2 relating to Convertible notes receivable - related party. As of December 31, 2022 , the Company’s maximum exposure for its nonconsolidated VIEs was $ 6.8 million relating to the carrying values in its Other investments and $ 7.2 million relating to the carrying value in Long term notes receivable - related party.

Equity Method Investments and O

Equity Method Investments and Other Investments	12 Months Ended
	Dec. 31, 2023
Cash and Cash Equivalents [Abstract]
Equity Method Investments and Other Investments	5. Equity Method Investments and Other Investments Equity Method Investments As o f December 31, 2023 and 2022, the Company accounted for the following investments in the investee’s common stock under the equity method (in thousands): As of December 31, 2023 As of December 31, 2022 Date First Common Stock Carrying Common Stock Carrying Investee Acquired Ownership % Value Ownership % Value Innoplexus A.G. August 2018 35.0 % $ — 35.0 % $ — COMPASS Pathways plc December 2018 15.4 % (1) — 22.4 % — GABA Therapeutics, Inc November 2020 3.6 % (2) — 7.5 % (2) — Total $ — $ — (1) The Company accounted for its investment in COMPASS Pathways plc ("COMPASS") under the equity method until August 18, 2023, the closing date of COMPASS's dilutive financing round described below in Other investments held at fair value. (2) The Company is deemed to have significant influence over GABA Therapeutics, Inc ("GABA") through its total ownership interest in GABA, including the Company’s investment in GABA’s preferred stock, described below in Other investments. The Company’s total ownership interest, considering both preferred and common stock is 54.1% . Other investments held at fair value COMPASS Pathways plc COMPASS is a mental health care company dedicated to pioneering the development of a new model of psilocybin therapy with its product COMP360. The Company first acquired investments in COMPASS in December 2018 with additional investments through 2021.The Company’s ownership interest in COMPASS as of December 31, 2022 , was 22.4 %. In August 2023, COMPASS closed its most recent financing round, in which the Company did not participate, and the Company's ownership interest in COMPASS was reduced to 15.4 %. For the year ended December 31, 2022 and the period through August 18, 2023, the Company maintained significant influence through its ownership interest and accounted for its COMPASS investment under the equity method. The carrying value of the Company's COMPASS investment was reduced to zero as of December 31, 2022 due to IPR&D charges with no alternative future use and recognition of its proportionate share of COMPASS net losses. During the year ended December 31, 2022 , the Company recognized its proportionate share of COMPASS’s net loss of $ 10.1 million as Losses from investments in equity method investees, net of tax on the consolidated statements of operations. Following COMPASS's August 2023 financing, the Company evaluated its ability to continue to exercise significant influence over its investment and determined that it no longer had significant influence. Subsequent to this remeasurement date, the Company's COMPASS investment is accounted for at fair value under ASC 321 and recorded in Other investments held at fair value on the consolidated balance sheets. Any changes in fair value of the Company's COMPASS investment are recorded as a Change in fair value of assets and liabilities, net in its consolidated statements of operations. Based on quoted market prices, the fair value of the Company’s COMPASS investment was $ 83.7 million as of December 31, 2023. For the year ended December 31, 2023 , the Company recorded $ 81.9 million of Change in fair value of assets and liabilities, net. IntelGenx Technologies Corp. IntelGenx is a novel drug delivery company focused on the development and manufacturing of novel oral thin film products for the pharmaceutical market. In March 2021, IntelGenx and the Company entered into the Strategic Development Agreement and Purchaser Rights Agreement (“PPA”). Securities Purchase Agreement In May 2021, IntelGenx and the Company executed a Securities Purchase Agreement (the “IntelGenx SPA”) after obtaining IntelGenx shareholder approval, whereby IntelGenx issued shares of its common stock and warrants to the Company at a price of approximately $ 12.3 million. Each warrant (the “Initial Warrants”) entitles the Company to purchase one share at a price of $ 0.35 per share for a period of three years from the closing of the initial investment in March 2021. Pursuant to the IntelGenx SPA, the Company has the right to purchase (in cash, or in certain circumstances, the Company’s equity) additional units for a period of three years from the closing of the initial investment (the “Additional Unit Warrants”). Each Additional Unit Warrant will be comprised of (i) one share of common stock and (ii) one half of one warrant (the “Additional Warrants”). The price for the Additional Unit Warrants will be (i) until the date which is 12 months following the closing and the purchase does not result in the Company owning more than 74,600,000 common shares of IntelGenx, $ 0.331 (subject to certain exceptions), and (ii) until the date which is 12 months following the closing and the purchase results in the Company owning more than 74,600,000 common shares of IntelGenx or following the date which is 12 months following the closing regardless of the number of shares held by the Company, the lower of (A) a 20 % premium to the volume weighted average price of the common share for the thirty trading days immediately preceding the news release of the additional closing, and (B) $ 0.50 if purchased in the second year following closing or $ 0.75 , if purchased in the third year following closing. Each Additional Warrant will entitle the Company, for a period of three years from the date of issuance, to purchase one share at the lesser of either (i) a 20 % premium to the price of the corresponding additional share, or (ii) the price per share under which shares of IntelGenx are issued under convertible instruments that were outstanding on February 16, 2021, provided that the Company may not exercise Additional Warrants to purchase more than the lesser of (x) 44,000,000 common shares of IntelGenx, and (y) the number of common shares issued by IntelGenx under outstanding convertibles held by other investors as of February 16, 2021. Following the initial closing, the Company held a 25 % voting interest in IntelGenx. Pursuant to the PPA, the Company is entitled to designate a number of directors to the IntelGenx’s board of directors in the same proportion as the shares of common stock held by the Company to the outstanding of IntelGenx common shares. The Company has significant influence over IntelGenx through the Company's ownership interest in IntelGenx’s equity and its noncontrolling representation on IntelGenx’s board of directors. The Company qualified for and elected to account for its investment in the IntelGenx common stock under the fair value option. The Company believes that the fair value option better reflects the underlying economics of the IntelGenx common stock investment. The Initial Warrants and the Additional Units Warrant are accounted for at fair value under ASC 321 and recorded in Other investments held at fair value on the consolidated balance sheets. The Company applied a calibrated model and determined that the initial aggregate fair value of its $ 12.3 million investment was equal to the transaction price and recorded the common shares at $ 3.0 million, the Initial Warrants at $ 1.2 million and the Additional Unit Warrants at $ 8.2 million on a relative fair value basis resulting in no initial gain or loss recognized in the consolidated statements of operations. The Company recognizes subsequent changes in fair value of the common shares, the Initial Warrants and the Additional Unit Warrants as Change in fair value of assets and liabilities, net, a component of other income (expense), net in the consolidated statements of operations. The carrying amount of the investment was reduced to zero as of December 31, 2021. During the years ended December 31, 2023 and 2022 , the Company did no t recognize a change in fair value in the consolidated statements of operations. The carrying value of the investment remained at zero as of December 31, 2023 and 2022. Subscription Agreement, as amended In August 2023, IntelGenx and the Company entered into a subscription agreement (the “Subscription Agreement”), under which the Company paid IntelGenx $ 2.2 million for 2,220 convertible debenture units (the "2023 Initial Units"), with each convertible debenture unit consisting of: (i) $ 1,000 principal amount convertible promissory notes (the “2023 Initial Notes”) bearing interest at a rate of 12.0 % per annum, payable quarterly in arrears beginning September 30, 2023, with all principal and accrued interest convertible into common shares of IntelGenx, at any time from the date that is six months following their issuance up to and including August 31, 2026 at a conversion price equal to $ 0.185 per common share; and (ii) 5,405 common share purchase warrants of IntelGenx (the “2023 Initial Warrants”), each exercisable at an exercise price of $ 0.26 per common share for a period of three years following their issuance. Pursuant to the Subscription Agreement, the Company agreed to subscribe for an additional 750 convertible debenture units (the "2023 Subsequent Units") at a price of $ 750,000 subject to obtaining certain shareholder approvals. The Subsequent Units contain the same terms as the Initial Units, with each Subsequent Unit consisting of (i) $ 1,000 principal amount convertible promissory notes ("2023 Subsequent Notes") and (ii) 5,405 common share purchase warrants of IntelGenx ("2023 Subsequent Warrants"). Effective September 30, 2023 , IntelGenx and the Company amended the Subscription Agreement (the “Amended Subscription Agreement”), allowing the Company, subject to obtaining certain shareholder approvals, the "Call Option" to purchase up to an additional 7,401 convertible debenture units (the “Call Option Units”). The Call Option Units contain the same terms as the Initial Units, with each Call Option Unit consisting of (i) $ 1,000 principal amount convertible promissory notes, and (ii) 5,405 common share purchase warrants of IntelGenx. The issuance of any Call Option Unit shall result in a corresponding reduction in the Company's remaining purchase right pursuant to the IntelGenx SPA executed in May 2021 (the “2021 Purchase Right”), with such right to be reduced by the maximum number of shares of common stock issuable in connection with such Call Option Units, and (ii) in the event that the 2021 Purchase Right has been fully or partially exercised such that the aggregate number of shares of common stock issued thereunder together with the number of shares of common stock issuable in accordance with the Call Option Units would exceed 100,000,000 , the number of shares of common stock that may be issued in connection with the Call Option Units shall be reduced such that the aggregate number of shares of common stock issued thereunder together with the number of shares of common stock issuable in accordance with the Call Option Units does not exceed 100,000,000 . The maximum number of shares of common stock available under the 2021 Purchase Right was reduced from 130,000,000 shares of common stock to 100,000,000 shares of common stock, such that in no event shall the aggregate number of shares of common stock issuable in accordance with the Call Option Units and the 2021 Purchase Right exceed 100,000,000 . There are limits over the conversion of the Initial Units, Subsequent Units, Call Options Units and the IntelGenx Term Loan into common shares. The Company qualified for and elected to account for its investment in the convertible debenture units and call option under the fair value option. The Company believes that the fair value option better reflects the underlying economics of the convertible debenture units and call option. The convertible promissory notes are accounted for at fair value under ASC 320 and recorded in Convertible notes receivable - related party in the consolidated balance sheet, as described further in Note 6. The warrants and call option are accounted for pursuant to the fair value option election and recorded in Other investments held at fair value in the consolidated balance sheet. For the Initial Units, the Company applied a calibrated model and determined that the initial aggregate fair value of its $ 2.2 million investment was equal to the transaction price and recorded the 2023 Initial Notes at $1 .5 million and the 2023 Initial Warrants at $ 0.7 million on a relative fair value basis resulting in no initial gain or loss recognized in the consolidated statements of operations. The Company will recognize subsequent changes in fair value of the Initial Units as Change in fair value of assets and liabilities, net, a component of other income (expense), net in the consolidated statements of operations. As of December 31, 2023 , the fair value of the 2023 Initial Warrants was $ 0.7 million. For the year ended December 31, 2023, the Company recognized an immaterial amount in Change in fair value of assets and liabilities, net relating to the 2023 Initial Warrants in its consolidated statements of operations. In November 2023, upon shareholder approval, the Company paid $ 750,000 for the 2023 Subsequent Units. The Company applied a calibrated model and determined that the initial aggregate fair value of its $ 0.8 million investment was equal to the transaction price and recorded the 2023 Subsequent Notes at $ 0.6 million and the 2023 Subsequent Warrants at $ 0.2 million on a relative fair value basis resulting in no initial gain or loss recognized in the consolidated statements of operations. The Company will recognize subsequent changes in fair value of the Subsequent Units as Change in fair value of assets and liabilities, net, a component of other income (expense), net in the consolidated statements of operations. As of December 31, 2023 , the fair value of the 2023 Subsequent Warrants was $ 0.2 million. For the year ended December 31, 2023, the Company recognized an immaterial amount in Change in fair value of assets and liabilities, net relating to the 2023 Subsequent Warrants in its consolidated statements of operations. In November 2023, upon shareholder approval, the Call Option had an estimated fair value of $ 5.1 million and is recorded in Other investments held at fair value in the consolidated balance sheet. The Call Option is additional value conveyed to the Company relating to its investment in and Strategic Development Agreement with IntelGenx. Accordingly, the Company has also recorded a $ 5.1 million deferred credit, included in Other liablities in the consolidated balance sheet. As appropriate, the Company will account for the deferred credit as a reduction of research and development expense in its consolidated statements of operation until the credit is exhausted or the Company is no longer receiving goods or services from IntelGenx. As of December 31, 2023 , the fair value of the Call Option was $ 5.2 million. For the year ended December 31, 2023 , the Company recognized $ 0.1 million in Change in fair value of assets and liabilities, net relating to the Call Option in its consolidated statements of operations. Strategic Development Agreement Pursuant to the Strategic Development Agreement, the Company engages IntelGenx to conduct research and development projects (“Development Project”) using IntelGenx’s proprietary oral thin film technology. Under the terms of the Strategic Development Agreement, the Company can select four (4) program products. As of the effective date of the Strategic Development Agreement, the Company nominated two (2) program products - DMT and Salvinorin A. 20 % of any funds that IntelGenx received or will receive through the Company’s equity investment under the IntelGenx SPA will be available to be credited towards research and development services that IntelGenx conducts for the Company under the Development Projects. The Company is eligible to receive a total credit of $ 2.5 million. For the years ended December 31, 2023 and 2022 , research and development expense relating to the Strategic Development Agreement were $ 0.7 million and $ 0.5 million, respectively, which was applied as a reduction in research and development expenses in accordance with the Strategic Development Agreement. Other investments The Company has accounted for its other investments that do not have a readily determinable fair value under the measurement alternative. As of December 31, 2023 and 2022, the carrying values of Other investments, which consisted of investments in the investee’s preferred stock and common stock not in the scope of ASC 323 were as follows (in thousands): December 31, December 31, 2023 2022 GABA Therapeutics, Inc. $ 1,838 $ 5,387 DemeRx NB, Inc. — 1,024 Juvenescence Limited — 344 Total $ 1,838 $ 6,755 The Company’s investments in the preferred stock of Innoplexus, GABA, and DemeRx NB are not considered as in-substance common stock due to the existence of substantial liquidation preferences and therefore did not have subordination characteristics that were substantially similar to the common stock. During the years ended December 31, 2023 and 2022 there were no observable changes in price recorded related to the Company’s Other Investments. During the years ended December 31, 2023 and 2022, the Company evaluated all of its other investments to determine if certain events or changes in circumstance during these time periods in 2023 and 2022 had a significant adverse effect on the fair value of any of its investments in nonconsolidated entities. Based on this analysis, the Company did not note any impairment indicators associated with the Company’s Other Investments. Innoplexus AG Innoplexus AG is a technology company that provides “Data as a Service” and “Continuous Analytics as a Service” solutions that aims to help healthcare organizations leverage their technologies and expedite the drug development process across all stages—preclinical, clinical, regulatory and commercial. The Company first acquired investments in Innoplexus in August 2018. As of December 31, 2020, the Company owned 35.0 % of the common stock issued by Innoplexus. The Company has significant influence over Innoplexus through its noncontrolling representation on the investee’s supervisory board. Accordingly, the Company’s investment in Innoplexus’ common stock was accounted for in accordance with the equity method. The Company’s investment in Innoplexus’ preferred stock did not meet the criteria for in-substance common stock. As such, the investment in Innoplexus’ preferred stock was accounted for under the measurement alternative as discussed below. In February 2 021, the Company entered into a Share Purchase and Assignment Agreement (the “Innoplexus SPA”) to sell its shares of common and preferred stock held in Innoplexus to a current investor of Innoplexus (the “Purchaser”) in exchange for an initial purchase price of approximately $ 2.4 million. In addition, the Company is entitled to receive contingent payments based on the occurrence of subsequent equity transactions or liquidity events at Innoplexus as determined under the Innoplexus SPA. Pursuant to the Innoplexus SPA, the Purchaser is required to hold a minimum number of shares equivalent to the number of shares purchased from the Company through December 31, 2026 . In the event that the Purchaser is in breach of this requirement, the purchaser is required to pay the Company an additional purchase price of approximately $ 9.6 million. The transaction was accounted for as a secured financing as it did not qualify for sale accounting under ASC Topic 860, Transfers and Servicing (ASC 860), due to the provision under the Innoplexus SPA which constrained the Purchaser from its right to pledge or exchange the underlying shares and provided more than a trivial benefit to the Company. The initial proceeds from the transaction are reflected as a secured borrowing liability of $ 2.4 million as of December 31, 2023 and 2022, which is included in Other liabilities in the Company’s consolidated balance sheets. The Company will continue to account for its investment in Innoplexus’ common stock under the equity method of accounting and its investment in Innoplexus’ preferred shares under the measurement alternative. In addition, the Innoplexus SPA also provides the rights for the Company to receive additional consideration with a maximum payment outcome of $ 22.3 million should the equity value of Innoplexus exceed certain thresholds upon the occurrence of certain events. The Company concluded that this feature met the definition of a derivative which required bifurcation. As the probability of the occurrence of certain events defined in the Innoplexus SPA was less than remote, the Company concluded that the fair value of the embedded derivative ascribed to this feature was de minimis as of December 31, 2023 and 2022. The carrying value of the Company’s investment in Innoplexus was zero as of December 31, 2023 and December 31, 2022. GABA Therapeutics, Inc. GABA is a California based biotechnology company focused on developing GRX-917 for anxiety, depression and a broad range of neurological disorders. The Company is deemed to have significant influence over GABA through its total ownership interest in GABA’s equity, including the Company’s investment in GABA’s preferred stock, and the Company’s noncontrolling representation on GABA’s board of directors. Common Stock Investment The Company’s investment in GABA’s common stock was accounted for in accordance with the equity method. In November 2020 the Company exercised its option to purchase additional shares of common stock of GABA at a price of approximately $ 1.8 million pursuant to an Omnibus Amendment Agreement under which the Right of First Refusal and Co-Sale Agreement was amended. Pursuant to the amended Right of First Refusal and Co-Sale Agreement, the Company also has the option but not the obligation to purchase additional shares of common stock for up to $ 2.0 million from the existing common shareholders. The carrying value of the investment in GABA common stock was reduced to zero as of December 31, 2020 due to IPR&D charges with no alternative future use and remained zero as of December 31, 2023. Preferred Stock Investment The Company’s investment in GABA’s preferred stock did not meet the criteria for in-substance common stock. As such, the investment in GABA’s preferred stock is accounted for under the measurement alternative. In August 2019, GABA and the Company entered into the Preferred Stock Purchase Agreement (the “GABA PSPA”), whereby GABA issued shares of its Series A preferred stock to the Company at a price of approximately $ 5.5 million. At closing, the Company had an overall ownership interest of over 20 % in GABA and a noncontrolling representation on the board. Pursuant to the GABA PSPA, the Company was obligated to purchase additional shares of Series A preferred stock for up to $ 10.0 million with the same price per share as its initial investment, upon the achievement of specified contingent clinical development milestones. In April 2021, pursuant to the GABA PSPA, the Company purchased additional shares of Series A preferred stock of GABA, for an aggregate cost of $ 5.0 million based on the achievement of certain development milestones. In May 2021, the Company exercised its option to purchase additional shares of Series A preferred stock prior to the achievement of certain development milestone for an aggregate cost of $ 5.0 million completing its obligation to purchase additional shares. The completion of the Series A Preferred stock purchase in May 2021 was deemed to be a reconsideration event at which point GABA was no longer deemed a VIE as GABA now had sufficient equity at risk to finance its activities through the initial development period without additional subordinated financial support. Entities that do not qualify as a VIE are assessed for consolidation under the voting interest model (“VOE model”). Under the VOE model, the Company consolidates the entity if it determines that it, directly or indirectly, has greater than 50 % of the voting shares and that other equity holders do not have substantive voting, participating or liquidation rights. While the Company holds greater than 50% of the outstanding equity interest of GABA, the Company does not have the power to control the entity. Concurrent with the exercise of the option, the Company executed a side letter with the other equity holders of GABA agreeing to forego the rights to additional seats on the board of directors, resulting in the Company lacking the ability to control the investee. The Company concluded that it does not have a controlling financial interest that would require consolidation under the VOE model and accounted for the investments in GABA preferred stock under the measurement alternative per ASC 323. As of December 31, 2023 and2022, the investment in GABA’s preferred stock was recorded in Other investments in the consolidated balance sheets. In May 2021, GABA and the Company entered into an Amendment to Preferred Stock Purchase Agreement (the "Amended GABA PSPA”) under which the GABA PSPA was amended and shares of its Series A preferred stock were issued to the Company at a price of approximately $ 0.6 million. Pursuant to the Amended GABA PSPA, the Company is obligated to purchase additional shares of Series A preferred stock from GABA for up to $ 1.5 million with the same price per share as its initial investment upon the achievement of specified contingent clinical development milestones. In September 2022, pursuant to the Amended PSPA, GABA issued additional shares of its Series A preferred stock to the Company at a price of approximately $ 0.6 million based on the achievement of certain development milestones. As of December 31, 2023 , the Company's remaining obligation to purchase additional shares of Series A preferred stock from GABA is for up to $ 0.9 million at the same price per share as its initial investment upon the achievement of specified contingent milestones. In accordance with the Amended GABA PSPA, the Company also has the option but not the obligation to purchase the aforementioned additional shares of Series A preferred stock at any time prior to the achievement of any milestone at the same price per share as its initial investment. GABA’s net losses attributable to the Company were determined based on the Company’s ownership percentage of preferred stock in GABA and recorded to the Company’s investments in GABA preferred stock. During the year ended December 31, 2023 and 2022 , the Company recognized its proportionate share of GABA’s net loss of $ 3.6 million and $ 5.9 million, respectively as Losses from investments in equity method investees, net of tax on the consolidated statements of operations. DemeRx NB, Inc. In December 2019, the Company jointly formed DemeRx NB, Inc. ("DemeRx NB") with DemeRx Inc. DemeRx Inc. and DemeRx NB entered into a Contribution Agreement whereby DemeRx inc. assigned all of its rights, title, and interests in and to all of its assets relating to DMX-1002, Noribogaine, in exchange for shares of common stock of DemeRx NB. DemeRx NB will use the contributed intellectual property to develop Noribogaine. Noribogaine is an active metabolite of ibogaine designed to have a longer plasma half-life and potentially reduced hallucinogenic effects compared to ibogaine. In connection with the Contribution Agreement, the parties entered into a Series A Preferred Stock Purchase Agreement (the “DemeRx NB PSPA”) pursuant to which the Company purchased shares of Series A preferred stock of DemeRx NB at a purchase price of $ 1.0 million. At closing, the Company had less than 20 % of ownership interest in DemeRx NB and a noncontrolling representation on DemeRx NB's board of directors. The investment in DemeRx NB was recorded in Other investments on the consolidated balance sheets under the measurement alternative under ASC 321. In October 2023, the Company and DemeRx, Inc. entered into a Stock Purchase and Framework Agreement which resulted in the Company's acquisition of DemeRx, Inc.’s equity ownership of DemeRx IB (the “Stock Purchase”), in exchange for consideration that included, among other items, the transfer of the Company's ownership in DemeRx, NB, Inc. to DemeRx, Inc. In connection with the Stock Purchase, the Company assessed the fair market value of its DemeRx NB investment and determined that it had been impaired. As a result, the Company recognized a $ 1.0 million impairment loss in Impairment of other investments, a component of other income, net in the consolidated statements of operations for the year ended December 31, 2023. Juvenescence Limited As of December 31, 2022 the Company’s investment in Juvenescence Limited (“Juvenescence”) was in common stock, however, it was not able to exercise significant influence over the operating and financial decisions of Juvenescence. During the year ended December 31, 2023 , the Company divested its investment in Juvenescence Limited ("Juvenescence") and recognized a $ 0.1 million gain on the transaction reflected in Other income (expense), net on the consolidated statements of operations. Summarized Financial Information The following is a summary of financial data for investments accounted for under the equity method of accounting (in thousands): Balance Sheets December 31, 2023 GABA Current assets $ 1,720 Non-current assets — Total assets $ 1,720 Current liabilities $ 1,546 Non-current liabilities — Total liabilities $ 1,546 December 31, 2022 COMPASS (1) GABA Current assets $ 191,651 $ 3,933 Non-current assets 5,643 — Total assets $ 197,294 $ 3,933 Current liabilities $ 15,596 $ 1,542 Non-current liabilities 418 — Total liabilities $ 16,014 $ 1,542 Statements of operations Nine Months Ended September 30, 2023 Year Ended December 31, 2023 COMPASS (1) GABA Revenue $ — $ — Loss from continuing operations $ ( 98,514 ) $ ( 3,593 ) Net loss $ 85,932 $ ( 3,593 ) Year Ended December 31, 2022 COMPASS (1) GABA Revenue $ — $ — Loss from continuing operations $ ( 110,403 ) $ ( 5,867 ) Net loss $ ( 91,505 ) $ ( 5,867 ) (1) As of August 18, 2023, the Company determined that it no longer had significant influence. At this remeasurement date, the Company qualified for and elected to account for its investment in COMPASS under the fair value option. Summarized financial information is as of and for the nine month period ending September 30, 2023 as this information is not readily available as of August 18, 2023 and the Company has no practical way to estimate otherwise.

Notes Receivable

Notes Receivable	12 Months Ended
	Dec. 31, 2023
Receivables [Abstract]
Notes Receivable	6. Notes Receivable DemeRx Promissory Note In January 2020, DemeRx IB loaned to DemeRx Inc. $ 1.0 million pursuant to the terms of a Promissory Note (the "DemeRx Note"). Pursuant to the terms of the DemeRx Note, the aggregate principal amount of $ 1.0 million together with all accrued and unpaid interest and any other amounts payable are due to be paid on the date that is the earlier of (i) 5 years from the initial closing and (ii) the closing of an initial public offering or a deemed liquidation event of DemeRx IB (the “DemeRx Maturity Date”). Pursuant to the terms of the DemeRx Note, DemeRx Inc. may, in its sole discretion pay any amount due under the DemeRx Note, in cash or through cancellation shares of common stock of DemeRx IB, par value $ 0.0001 per share, of the fair market value of such shares. In October 2023, the Company and DemeRx, Inc. entered into a Stock Purchase and Framework Agreement which resulted in the Company's acquisition of DemeRx, Inc.’s equity ownership of DemeRx IB (the “Stock Purchase”). The Stock Purchase, a liquidation event, required a repayment of the DemeRx Note. Pursuant to the terms of the DemeRx Note, DemeRx, Inc opted to repay the outstanding balance through the cancellation of its shares of common stock of DemeRx IB. As of December 31, 2023, and 2022 , the DemeRx Note outstanding balance of $ 0 and $ 1.1 million, respectively, was recorded in Long term notes receivable - related parties, net on the consolidated balance sheets. For the years ended December 31, 2023, and 2022, the Company did not earn any interest income associated with the DemeRx Note. IntelGenx Term Loan, as amended In March 2021, the Company and IntelGenx entered into a loan agreement (the "Original Loan Agreement") under which the Company provided a loan to IntelGenx for an aggregate principal amount of $ 2.0 million. In May 2021, the Company paid an additional advance of $ 0.5 million as an additional term loan. In September 2021, the Company entered into an amended and restated loan agreement which, among other things, increased the principal amount of loans available to IntelGenx by $ 6.0 million, for a total of up to $ 8.5 million. The additional $ 6.0 million loan amount was funded via two separate $ 3.0 million tranches. The first $3.0 million tranche was funded in January 2022 and the second $3.0 million tranche was funded in January 2023. The loan bears an annualized interest rate of 8 % and such interest is accrued daily. The Company recorded this loan at cost in Long term notes receivable - related parties, net on the consolidated balance sheets. On January 1, 2023, the Company adopted ASU 2016-13, Financial Instruments - Credit Losses, as further discussed in Note 2, which resulted in a $ 0.4 million increase to accumulated deficit and allowance for credit losses related to the IntelGenx loan. In August 2023, the Company and IntelGenx entered into the first amendment to the amended and restated loan agreement (the "First Amendment") which, among other things, extended the maturity date from January 5, 2024 to January 5, 2025 and granted the Company additional security over any non-licensed intellectual property owned or controlled by IntelGenx. The Company determined that this modification did not have a material impact on the amortized cost basis of the IntelGenx Term Loan (as defined below). Effective September 30, 2023, the Company and IntelGenx entered into a second amendment to the amended and restated loan agreement (the "Second Amendment", and together with the Original Loan Agreement and the First Amendment, the "IntelGenx Term Loan") which, subject to obtaining certain shareholder approvals, entitles the Company to convert any portion of the outstanding and unpaid principal and accrued interest into common shares of IntelGenx at a conversion price per share of $ 0.185 (the "Conversion Feature"). There are limits over the conversion of the IntelGenx Term Loan, along with Initial Units, Subsequent Units, and Call Options Units into common shares. Although IntelGenx cash flows may be insufficient to meet expenses relating to its operations, considering the underlying collateral and other settlement terms available, the Company deems it probable that it will collect the full value of the IntelGenx Term Loan. In November 2023, upon shareholder approval, the Conversion Feature was effective. The Company evaluated this modification subject to accounting guidance in ASU 2022-02, Financial Instruments - Credit Losses and determined the Conversion Feature is considered the addition of a substantive conversion option and the modification is more than minor. Therefore, the Second Amendment should be treated as an extinguishment of the existing loan and the issuance of a new convertible debt instrument. The IntelGenx Term Loan, as amended, meets the definition of a security and will be accounted for under ASC 320. Pursuant to the remeasurement event, the Company is eligible and has elected the fair value option to account for its investment in the IntelGenx Term Loan. The Company believes that the fair value option better reflects the underlying economics of the loan. The Company recorded the new convertible debt instrument at its fair value of $ 9.2 million in Convertible notes receivable - related party on the consolidated balance sheets. The existing carrying value of the extinguished loan was $ 9.3 million ($ 8.5 million of principal and $ 1.2 million of accrued interest, net of $ 0.4 million allowance for credit losses). The difference of $ 0.1 million is recorded as an extinguishment loss and included in Change in fair value of assets and liabilities, net in the consolidated statements of operations. The IntelGenx Term Loan will be subsequently remeasured at each reporting date until settled or converted. The Company will recognize subsequent changes in fair value of the IntelGenx Term Loan in Change in fair value of assets and liabilities, net, a component of other income(expense), net in its consolidated statements of operations. As of December 31, 2023 , the $ 8.6 million fair value of the amended IntelGenx Term Loan was recorded in Convertible notes receivable – related party on the consolidated balance sheet. As of December 31, 2022 , the $ 6.1 million carrying value ($ 5.5 million of principal and $ 0.6 million of accrued interest) of the IntelGenx Term Loan was recorded in Long term notes receivable - related parties on the consolidated balance sheet. For the years ended December 31, 2023 and 2022 , the Company recognized $ 0.6 million and $ 0.4 million of interest income, respectively, associated with the IntelGenx Term Loan. For the year ended December 31, 2023 , the Company recorded $ 0.3 million in Change of fair value of convertible notes receivable - related party for the reduction in fair value of IntelGenx Term Loan. IntelGenx Convertible Notes On August 30, 2023, the Company and IntelGenx entered into the Subscription Agreement (as further described in Note 5), under which the Company paid IntelGenx $ 2.2 million for 2,220 convertible debenture units (the "Initial Units"), with each convertible debenture unit consisting of (i) $ 1,000 principal amount convertible promissory notes (the “2023 Initial Notes”); and (ii) 5,405 common share purchase warrants of IntelGenx. The 2023 Initial Notes are accounted for at fair value under ASC 320 and recorded in Convertible notes receivable - related party in the consolidated balance sheet. The Company applied a calibrated model and determined that the initial aggregate fair value of its $ 2.2 million investment was equal to the transaction price and recorded the 2023 Initial Notes at $1 .5 million and the 2023 Initial Warrants at $ 0.7 million on a relative fair value basis resulting in no initial gain or loss recognized in the consolidated statements of operations. The Company will recognize unpaid interest and subsequent changes in fair value of the 2023 Initial Notes as Change in fair value of assets and liabilities, net, a component of other income (expense), net in the consolidated statements of operations. In November 2023, upon shareholder approval, the Company paid $ 750,000 for the 2023 Subsequent Units (as further described in Note 5), which included the 2023 Subsequent Notes. The 2023 Subsequent Notes are accounted for at fair value under ASC 320 and recorded in Convertible notes receivable - related party in the consolidated balance sheet. The Company applied a calibrated model and determined that the initial aggregate fair value of its $ 0.8 million investment was equal to the transaction price and recorded the 2023 Subsequent Notes at $ 0.6 million and the 2023 Subsequent Warrants at $ 0.2 million on a relative fair value basis resulting in no initial gain or loss recognized in the consolidated statements of operations. The Company will recognize unpaid interest and subsequent changes in fair value of the 2023 Subsequent Notes as Change in fair value of assets and liabilities, net, a component of other income (expense), net in the consolidated statements of operations. As of December 31, 2023 ., the fair value of the 2023 Initial Notes and 2023 Subsequent Notes was $1 .8 million and $ 0.5 million, respectively, and recorded in Convertible notes receivable - related party in the consolidated balance sheets. For the year ended December 31, 2023 , the Company recognized $ 0.3 million and an immaterial amount in Change in fair value of assets and liabilities, net relating to the 2023 Initial Notes and 2023 Subsequent Notes, respectively in its consolidated statements of operations. IntelGenx 2023 Term Loan Note In December 2023, the Company and IntelGenx entered into a new term loan agreement under which the Company provided the aggregate principal amount of $ 500,000 (the “2023 Term Loan Note”). The loan bears an annualized interest rate of 14.0 % compounding monthly. Principal and interest outstanding shall be due and payable from proceeds of future IntelGenx fundraising. The outstanding principal and interest on the 2023 Term Loan Note is due and payable on the earlier of December 31, 2024 or the bankruptcy, receivership or insolvency of IntelGenx. As of December 31, 2023 , the 2023 Term Loan Note had an outstanding balance of $ 0.5 million, and the Company recognized an immaterial amount of interest income for the year ended December 31, 2023.

Fair Value Measurement

Fair Value Measurement	12 Months Ended
	Dec. 31, 2023
Fair Value Disclosures [Abstract]
Fair Value Measurement	7. Fair Value Measurement The following table presents information about the Company’s financial assets and liabilities that are measured at fair value on a recurring basis and indicates the fair value hierarchy of the valuation (in thousands): Fair Value Measurements as of As of December 31, 2023 Level 1 Level 2 Level 3 Total Assets: Cash equivalents: Cash & Money market funds $ 56 $ — $ — $ 56 Investment in securities at fair value: U.S. Treasuries — 67,119 — 67,119 Corporate Notes/Bonds — 5,007 — 5,007 U.S. Government Agencies — 37,097 — 37,097 Other investments held at fair value 83,701 — 6,124 89,825 Convertible notes receivable - related party — — 11,202 11,202 $ 83,757 $ 109,223 $ 17,326 $ 210,306 Liabilities: Contingent consideration liability - related parties $ — $ — $ 620 $ 620 Contingent consideration liability — — 1,637 1,637 2018 convertible promissory note conversion option — — 2,385 2,385 $ — $ — $ 4,643 $ 4,643 Fair Value Measurements as of December 31, 2022 Level 1 Level 2 Level 3 Total Assets: Cash equivalents: Cash & Money market funds $ 72,334 $ — $ — $ 72,334 Investment in securities at fair value: Commercial Paper — 5,958 — 5,958 Corporate Notes/Bonds — 17,719 — 17,719 U.S. Government Agencies — 58,819 — 58,819 $ 72,334 $ 82,496 $ — $ 154,830 Liabilities: Contingent consideration liability - related parties $ — $ — $ 953 $ 953 $ — $ — $ 953 $ 953 Investment in securities at fair value The Company elected the fair value option for the securities in its investment portfolio. The fair value is based on quoted market prices, when available. When a quoted market price is not readily available, the Company uses the market price from its last sale of similar assets. The cash and cash equivalents held by the Company are categorized as Level 1 investments as quoted market prices are readily available for these investments. All other investments in the investment portfolio are categorized as Level 2 investments as inputs utilized to fair value these securities are either directly or indirectly observable, such as the market price from the last sale of similar assets. The Company purchases investment grade marketable debt securities which are rated by nationally recognized statistical credit rating organizations in accordance with its investment policy. This policy is designed to minimize the Company's exposure to credit losses and to ensure that the adequate liquidity is maintained at all times to meet anticipated cash flow needs. The unrealized gains and losses on the available-for-sale securities, represented by change in the fair value of the investment portfolio, is reported in earnings. Since the investment in the available-for-sale securities are already measured at fair value, no separate credit losses would be recorded in the financials. For the year-ended December 31, 2023 and 2022 , the Company recognized a $ 5.5 million and $ 0.3 million gain related to the change in fair value change in its available for sale securities recorded as a Change in fair value of assets and liabilities, net in its consolidated statements of operations. Other investments held at fair value COMPASS Pathways plc As described in Note 5 above, pursuant to the August 2023 financing, the Company determined that it no longer had significant influence and accounted for its COMPASS investment at fair value under ASC 321 with any changes in fair value recorded as a Change in fair value of assets and liabilities, net in its consolidated statements of operations. For the year ended December 31, 2023, the Company recorded $ 81.9 million of Change in fair value of assets and liabilities, net. IntelGenx Technologies Corp. As described in Note 5 and 6 above, the Company's investment in IntelGenx includes Initial Warrants, Additional Unit Warrants, 2023 Initial Warrants, and 2023 Subsequent Warrants, collectively referred to as the “Warrants”, Common Stock and the IntelGenx Term Loan. The Company determined that the Warrants and the Call Option do not meet the definition of a derivative instrument under ASC 815. The Company has classified the Common Stock as Level 2 assets and the Warrants and the Call Option as Level 3 assets in the fair value hierarchy. The Warrants and Call Option are measured at fair value on a quarterly basis and any changes in the fair value will be recorded as Change in fair value of assets and liabilities, net, a component of other income(expense), net in the consolidated statements of operations. The fair value of Common Shares is estimated by applying a discount for lack of marketability (DLOM) of 5.0 % as of December 31, 2023 and 2022. The Company estimated a DLOM in connection with the valuation of the Common Shares at initial recognition and as of December 31, 2023 and 2022 to reflect the restrictions associated with the Common Shares. As of December 31, 2023 and 2022, the only restriction that remains is the unregistered nature of the Common Shares. The fair value of Common Shares, which is included in Other investments held at fair value in the consolidated balance sheet, was zero as of December 31, 2023 and 2022. The Initial Warrants, 2023 Initial Warrants, 2023 Subsequent Warrants and Call Option were recorded at fair value utilizing the Black-Scholes option pricing model. The Black Scholes option pricing model is based on the estimated market value of the underlying common stock at the valuation measurement date, the remaining contractual term of the Warrants and Call Option, risk-free interest rates, expected dividends, and expected volatility of the price of the underlying common stock. The expected volatility is based on a peer group volatility which is a Level 3 input within the fair value hierarchy. The fair value of the Initial Warrants, which is included in Other investments held at fair value in the consolidated balance sheet, was zero as of December 31, 2023 and 2022. As of December 31, 2023 , the fair value of the 2023 Initial Warrants, 2023 Subsequent Warrants and Call Option was $ 0.7 million, $ 0.2 million and $ 5.2 million, respectively, and recorded in Other investments held at fair value in the consolidated balance sheets. The significant unobservable inputs that are included in the valuation of the Initial Warrants, 2023 Initial Warrants, 2023 Subsequent Warrants and Call Option as of December 31, 2023 and 2022 are (i) estimated market value of the underlying common stock of $ 0.13 , including discount for lack of marketability and (ii) volatility of 100 %. An additional significant unobservable input that is included in the valuation of the Call Option as of December 31, 2023 is discount rate of 45.9 % based on an assessment of IntelGenx credit risk and market yields of companies with similar credit risk. The fair value of the Additional Units is estimated using a Binomial Lattice in a risk-neutral framework (a special case of the Income Approach). Specifically, the future stock price of the IntelGenx is modeled assuming a Geometric Brownian Motion in a risk-neutral framework. For each modeled future price, the Additional Unit is calculated based on the contractual terms (incorporating any optimal early exercise), and then discounted at the term-matched risk-free rate. Finally, the value of the Additional Units is calculated as the probability-weighted present value over all future modeled payoffs. The fair value of the Additional Units, which is included in Other investments held at fair value in the consolidated balance sheet, was zero as of December 31, 2023 and 2022. The significant unobservable inputs that are included in the valuation of the Additional Units Warrant as of December 31, 2023 and 2022 are (i) estimated market value of the underlying common stock of $ 0.13 , including discount for lack of marketability and (ii) volatility of 100 %. Convertible notes receivable - related party The fair value of the 2023 Initial Notes, 2023 Subsequent Notes ,and the IntelGenx Term Loan (collectively "Convertible Notes") at issuance were estimated based on significant inputs not observable in the market, which represents a Level 3 measurement within the fair value hierarchy. The fair value of the 2023 Initial Notes and the 2023 Subsequent Notes is estimated using a Binomial Lattice in a risk-neutral framework (a special case of the Income Approach). Specifically, the future stock price of the IntelGenx is modeled assuming a Geometric Brownian Motion in a risk-neutral framework. For each modeled future price, the 2023 Initial Notes and the 2023 Subsequent Notes is calculated based on the contractual terms (incorporating any optimal early exercise), and then discounted at the term-matched risk-free rate. Finally, the value of the 2023 Initial Notes and the 2023 Subsequent Notes is calculated as the probability-weighted present value over all future modeled payoffs. T he fair value of the 2023 Initial Notes and 2023 Subsequent Notes was $ 1.7 million and $ .05 million, respectively, and recorded in Convertible notes receivable - related party in the consolidated balance sheets as of December 31, 2023. The significant unobservable inputs that are included in the valuation of the 2023 Initial Notes and 2023 Subsequent Notes as of December 31, 2023 are (i) discount rate of 45.9 % based on an assessment of IntelGenx credit risk and market yields of companies with similar credit risk, (ii) estimated market value of the underlying common stock of $ 0.13 , including discount for lack of marketability and (iii) volatility of 100 % . The fair value of the IntelGenx Term Loan was estimated as the present value of the debt cash-flows plus the fair value of the Conversion Feature. The Conversion Feature fair value was estimated utilizing the Black-Scholes option pricing model. The Black Scholes option pricing model is based on the estimated market value of the underlying common stock at the valuation measurement date, the remaining contractual term of the Conversion Feature, risk-free interest rates, expected dividends, and expected volatility of the price of the underlying common stock. The expected volatility is based on a peer group volatility which is a Level 3 input within the fair value hierarchy. As of December 31, 2023, the $ 8.6 million fair value of the amended IntelGenx Term Loan was recorded in Convertible notes receivable – related party on the consolidated balance sheet. The significant unobservable inputs that are included in the valuation of the IntelGenx Term Loan as of December 31, 2023 are (i) discount rate of 45.9 % based on an assessment of IntelGenx credit risk and market yields of companies with similar credit risk, (ii) volatility of 100 % and (iii) estimated market value of the underlying common stock of $ 0.13 . Contingent consideration liability - related parties The contingent consideration liability - related parties in the table above relates to milestone and royalty payments in connection with the acquisition of Perception Neuroscience Holdings, Inc. (“Perception”), and InnarisBio. The fair value of the contingent consideration liability—related parties was determined based on significant inputs not observable in the market, which represent Level 3 measurements within the fair value hierarchy. The fair value of the contingent milestone and royalty liabilities was estimated based on the discounted cash flow valuation technique. The technique considered the following unobservable inputs: • market-based discount rates, • the probability and timing of achieving the specified milestones and royalties as of each valuation date, • the probability of executing the license agreement, and • the expected first year of revenue. Perception The fair value of the Perception contingent milestone and royalty liabilities could change in future periods depending on prospects for the outcome of R-Ketamine milestone meetings with the FDA or other regulatory authorities, and whether the Company realizes a significant increase or decrease in sales upon commercialization. The most significant assumptions in the discounted cash flow valuation technique that impacts the fair value of the milestone contingent consideration are the projected milestone timing and the probability of the milestone being met. Further, significant assumptions in the discounted cash flow that impacts the fair value of the royalty contingent consideration are the projected revenue over ten years, the timing of royalties on commercial revenue, and the probability of success rate for a commercial R-Ketamine product. The valuations as of December 31, 2023 and 2022, used inputs that were unobservable inputs with the most significant being the discount rates for royalties on projected commercial revenue and clinical milestones and probability of success estimates over the following ten years, which represent Level 3 measurements within the fair value hierarchy. The fair value of the contingent milestone and royalty liabilities for Perception was estimated to be $ 0.6 million and $ 0.6 million as of December 31, 2023 and 2022, respectively. The fair value of the Perception contingent consideration liability - related parties was calculated using the following significant unobservable inputs: December 31, 2023 December 31, 2022 Valuation Technique Significant Unobservable Inputs Input Range Input Range Discounted cash flow Milestone contingent consideration: Discount rate 13.5 % 13.1 % Probability of the milestone 28.0 % 10.0 % - 21.0 % Discounted cash flow Royalty contingent consideration: Discount rate for royalties 13.0 % - 14.2 % 20.0 % - 21.1 % Discount rate for royalties on milestones 13.0 % - 14.2 % 12.3 % - 13.4 % Probability of success rate 13.4 % - 28.0 % 10.1 % - 21.0 % InnarisBio The fair value of the contingent milestone and royalty liabilities for InnarisBio was estimated to be $ 0.0 million and $ 0.1 million as of December 31, 2023 and 2022, respectively. Contingent Consideration Liability The contingent consideration liability in the table above relates to milestone payments in connection with the acquisition of DemeRx IB, Inc. ("DemeRx"), and TryptageniX. The fair value of the contingent consideration liability was determined based on significant inputs not observable in the market, which represent Level 3 measurements within the fair value hierarchy. The fair value of the contingent milestone and royalty liabilities was estimated based on the discounted cash flow valuation technique. The technique considered the following unobservable inputs: • market-based discount rates, and • the probability and timing of achieving the specified milestones as of each valuation date DemeRx In October 2023, the Company and DemeRx, Inc. entered into a Stock Purchase and Framework Agreement which resulted in the Company's acquisition of DemeRx, Inc.’s equity ownership of DemeRx IB (the “Stock Purchase”), in exchange for consideration that included, among other items, earn-out consideration of up to an additional $ 8.0 million payable to DemeRx, Inc. contingent upon the achievement of certain development milestones directly related to DemeRx’s oral capsule formulation of ibogaine (“DMX-1002”) program. The earn-out consideration was recorded at fair value in contingent consideration as a liability under AC 480 and the fair value is adjusted each quarter and reflected in other income and expense in the statement of operations. The fair value of the DemeRx contingent milestone could change in future periods depending on prospects for the outcome of ibogaine milestone meetings with the FDA or other regulatory authorities. The most significant assumptions in the discounted cash flow valuation technique that impacts the fair value of the milestone contingent consideration are the projected milestone timing and the probability of the milestone being met. The valuations as of December 31, 2023 , used inputs that were unobservable inputs with the most significant being the discount rates clinical milestones and probability of success, which represent Level 3 measurements within the fair value hierarchy. The fair value of the contingent milestone for DemeRx was estimated to be $ 1.4 million as of December 31, 2023. The fair value of the DemeRx contingent consideration liability - related parties was calculated using the following significant unobservable inputs: December 31, 2023 Valuation Technique Significant Unobservable Inputs Input Range Discounted cash flow Milestone contingent consideration: Discount rate 13.9 % Probability of the milestone 20 % - 25 % TryptageniX The fair value of the contingent liability for TryptageniX was estimated to be $ 0.2 million and $ 0.2 million as of December 31, 2023 and 2022, respectively. The contingent liability is comprised of research and development milestone success fee payments and royalties payments. The fair value of the success fee liability was estimated based on the scenario-based method within the income approach. The fair value of the contingent liability for TryptageniX was determined based on significant unobservable inputs, including the discount rate, estimated probabilities of success, and timing of achieving certain clinical milestones. The fair value of the royalties liability was determined to be de minimis as the products are in the early stages of development. The Company will continue to assess the appropriateness of the fair value of the contingent liability as the products continue through development. Convertible Promissory Note As described in Note 11, in December 2023, a nonrelated party noteholder and the Company entered into a subscription agreement ("2023 Subscription Agreement") which the noteholder exchanged its ATAI Life Sciences AG notes ("Old AG Notes") into the same principal amount of new convertible notes issued by ATAI Life Sciences N.V. ("New NV Notes"). The exchange resulted in the new NV Notes conversion option no longer meeting the equity classification criteria. Accordingly, at the time of the exchange modification, the Company bifurcated the conversion option and reclassified the conversion option fair value from equity to a liability and is included in Convertible promissory notes in the consolidated balance sheet. The conversion option is measured at fair value on a quarterly basis and any changes in the fair value will be recorded as Change in fair value of assets and liabilities, net, a component of other income (expense), net in the consolidated statements of operations. For the year ended December 31, 2023 , the Company recognized a loss of $ 0.7 million as a result of the change in fair value of the New NV notes. The Conversion Feature fair value was estimated utilizing the Black-Scholes option pricing model. The Black Scholes option pricing model is based on the estimated market value of the underlying common stock at the valuation measurement date, the remaining contractual term of the Conversion Feature, risk-free interest rates, expected dividends, and expected volatility of the price of the underlying common stock. The expected volatility is based upon the historical volatility of daily lognormal returns on atai shares, which is a Level 3 input within the fair value hierarchy. The significant unobservable input that is included in the valuation of the Conversion Feature as of December 31, 2023 is volatility of 78.6 %. The following table provides a roll forward of the aggregate fair values of the Company’s financial instruments described above, for which fair value is determined using Level 3 inputs (in thousands): IntelGenx Convertible Notes Receivable IntelGenx Investments Held at Fair Value (1) Contingent (2) Contingent (3) 2018 Convertible Notes Call Option Balance as of December 31, 2022 $ — $ — $ 743 $ 210 $ — Initial fair value of instrument 10,800 5,787 — 1,329 1,668 Change in fair value, including interest ( 116 ) 105 ( 34 ) 98 717 Additional contribution 518 232 — — — Extinguishment of liability — — ( 89 ) — — Balance as of December 31, 2023 $ 11,202 $ 6,124 $ 620 $ 1,637 $ 2,385 (1) Includes, Initial Warrants, Additional Unit Awards, 2023 Initial Warrants, 2023 Subsequent Warrants, and Call Option Units (2) Includes Perception milestone based contingent consideration liability and InnarisBio milestone and royalty based contingent consideration liability (3) Includes contingent consideration liability related to DemeRx IB Stock Purchase and contingent consideration liability related to the TryptageniX research and development milestone success fee payments and royalties payments Contingent Warrant Liability Balance as of December 31, 2021 $ 2,483 $ 336 Change in fair value ( 1,480 ) ( 336 ) Extinguishment of liability ( 50 ) — Balance as of December 31, 2022 $ 953 $ —

Prepaid Expenses and Other Curr

Prepaid Expenses and Other Current Assets	12 Months Ended
	Dec. 31, 2023
Prepaid Expense and Other Assets, Current [Abstract]
Prepaid Expenses and Other Current Assets	8. Prepaid Expenses and Other Current Assets Prepaid expenses consist of the following (in thousands): December 31, December 31, Prepaid research and development related expenses $ 1,822 $ 4,626 Tax receivables 1,752 5,631 Prepaid insurance 1,410 2,034 Other 846 1,745 Total $ 5,830 $ 14,036

Accrued Liabilities

Accrued Liabilities	12 Months Ended
	Dec. 31, 2023
Accrued Liabilities, Current [Abstract]
Accrued Liabilities	9. Accrued Liabilities Accrued liabilities consist of the following (in thousands): December 31, December 31, Accrued payroll $ 4,941 $ 5,260 Accrued accounting, legal, and other professional fees 5,468 3,566 Accrued external research and development expenses 3,031 5,550 Other liabilities 1,101 706 Taxes payable 715 2,224 Total $ 15,256 $ 17,306

Leases

Leases	12 Months Ended
	Dec. 31, 2023
Leases [Abstract]
Leases	10. Leases Effective January 1, 2022, the Company adoptions ASU 2016-02, Leases (Topic 842), as amended, using the modified transition approach as of the effective date. The adoption resulted in the recognition of a $ 0.2 million operating lease right-of-use asset , a $ 0.1 million current operating lease liability, and a $ 0.1 million long-term operating lease liability on the Company's consolidated balance sheet related to its existing facility operating lease. The new standard provided a number of optional practical expedients in transition. The Company elected the “package of practical expedients,” which permitted it to not reassess under the new standard its prior conclusions about lease identification, lease classification, and initial direct costs. As a result, the Company has continued to account for existing leases - i.e. leases for which the commencement date is before January 1, 2022 - in accordance with Topic 840 throughout the entire lease term, including periods after the effective date, with the exception that the Company applied the new balance sheet recognition guidance for operating leases and applied Topic 842 for remeasurements and modifications after the Transition Date. The Company also elected the hindsight expedient in determining the lease term and assessing impairment of right-of-use assets when transitioning to ASC 842. As a result, the Company evaluated the lease term for its existing leases as of the transition date, January 1, 2022. Operating lease Right-of-Use (“ROU”) assets and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at the commencement date. The operating lease ROU asset also includes lease payments made, lease incentives, and initial direct costs incurred, if any. The Company leases certain office space under long-term operating leases that expire at various dates through 2028. The Company generally has options to renew lease terms on its facilities, which may be exercised at the Company's sole discretion. The Company evaluates renewal and termination options at the lease commencement date to determine if it is reasonably certain to exercise the option and has concluded on all operating leases that is it not reasonably certain that any options will be exercised. The weighted-average remaining lease term for the Company’s operating leases as of December 31, 2023 was 4.2 years. The weighted-average discount rate for the Company’s operating leases as of December 31, 2023 was 12.7 %. ROU assets and lease liabilities related to the Company’s operating leases are as follows (in thousands): Balance Sheet Classification December 31, 2023 December 31, 2022 Right-of-use assets Operating lease right-of-use asset, net $ 1,223 $ 226 Current lease liabilities Current portion of lease liability 275 180 Non-current lease liabilities Non-current portion of lease liability 990 44 Expenses related to leases is recorded on a straight-line basis over the lease term. The following table summarizes lease costs by component for the year ended December 31, 2023 and 2022 (in thousands): Lease Cost Components Statement of Operations Classification December 31, 2023 December 31, 2022 Operating lease cost Operating expenses: General and administrative $ 663 $ 266 Short-term lease cost Operating expenses: General and administrative 338 434 Total lease cost $ 1,001 $ 700 Future minimum commitments under all non-cancelable operating leases are as follows (in thousands): Year Ended 2024 $ 415 2025 370 2026 370 2027 370 2028 123 Total lease payments 1,648 Less: Imputed interest ( 383 ) Present value of lease liabilities $ 1,265 Supplemental cash flow information related to the Company’s operating leases for the year ended December 31, 2023 and 2022 (in thousands): December 31, 2023 December 31, 2022 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 440 $ 267 Right-of-use assets obtained in exchange for new operating lease liabilities 1,377 487

Debt

Debt	12 Months Ended
	Dec. 31, 2023
Debt Disclosure [Abstract]
Debt	11. Debt Convertible Promissory Notes 2018 Convertible Promissory Notes—Related Parties During November 2018 and October 2020, the Company executed a terms and conditions agreement (the “Convertible Note Agreement”) under which it would issue convertible promissory notes to investors. An investor would become a party to the Convertible Note Agreement and would be issued a convertible promissory note by executing and delivering a subscription form. In November 2018 and October 2020, certain investors subscribed to the Convertible Note Agreement and the Company issued convertible promissory notes in the aggregate principal amount of € 1.0 million or $ 1.2 million (collectively, the “2018 Convertible Notes”). The 2018 Convertible Notes are non-interest-bearing, unsecured and are due and payable on September 30, 2025, unless previously redeemed, converted, purchased or cancelled (the “Maturity Date”). Each 2018 Convertible Note has a face value of € 1 and is convertible into one share of ATAI Life Sciences AG upon the payment of € 17.00 . Conversion rights may be exercised by a noteholder at any time prior to maturity, except during certain periods subsequent to the consummation of the IPO. The 2018 Convertible Notes may be declared for early redemption by the noteholders upon occurrence of specified events of default, including payment default, insolvency and a material adverse change in the Company’s business, operations or financial or other condition. Upon early redemption, the conversion right with respect to the 2018 Convertible Notes may no longer be exercised. The Company concluded that both the embedded conversion feature, which is exercisable by the investor at any time during the maturity, and the contingent put option, which would trigger upon the occurrence of an event of default of the 2018 Convertible Notes, do not meet the criteria to be bifurcated and separately accounted for as derivatives and the notes were recorded net of discount and issuance costs, or a reduction to the carrying value of the notes issued in November 2018, with a corresponding adjustment to additional paid in capital. The discount is being amortized using the effective interest method over the period from the respective date of issuance to the Maturity Date. The Company determined that the October 2020 notes were issued in exchange for services previously provided by the Company’s founders and other shareholders and were fully vested and non-forfeitable upon issuance. These instruments were therefore considered share based compensation awards to non-employees, and the instruments were initially measured and recorded at their grant date fair value based on a Black-Scholes option- pricing model. The fair value of the October 2020 notes exceeded the principal amount that will be due at maturity. Therefore, at initial recognition, the October 2020 notes were accounted for as convertible debt issued at a substantial premium, such that the face value of the note is recorded as a liability and the premium was recorded as paid-in capital. Conversion of 2018 Convertible Promissory Notes - Related Parties In April 2021, the Company undertook a corporate reorganization. Upon the corporate reorganization, ATAI Life Sciences N.V became the sole shareholder of ATAI Life Sciences AG. In connection with the corporate reorganization, all former shareholders of ATAI Life Sciences AG c ontributed their shares of ATAI Life Sciences AG to ATAI Life Sciences N.V. and received sixteen shares in ATAI Life Sciences N.V. for every one share of ATAI Life Sciences AG. In 2021, several noteholders elected to convert their convertible promissory notes into shares of ATAI Life Sciences N.V. These investors paid € 17.00 per share for an aggregate amount of € 5.8 million or $ 6.9 . million in order to convert their convertible promissory notes into ATAI Life Sciences AG common shares, which was in accordance with the original terms of the 2018 Convertible Note Agreements. In May 2022 and July 2022, certain noteholders elected to convert some of their convertible promissory notes into shares of ATAI Life Sciences N.V. The investors paid € 17.00 per share for the aggregate amount of € 4.6 million or $ 4.6 million in order to convert their convertible promissory notes into ATAI Life Sciences AG common shares, which was in accordance with the original terms of the 2018 Convertible Note Agreements. In 2023, certain noteholders elected to convert some of their convertible promissory notes into shares of ATAI Life Sciences N.V for an immaterial amount. The Company accounted for the conversion of the 2018 Convertible Notes as a conversion such that carrying values of these notes were derecognized with an offset to common stock at par of ATAI Life Sciences AG and the excess of the carrying values of these notes over the common stock at par of ATAI Life Sciences AG was recorded as additional paid-in capital. Concurrently, with the conversion of the 2018 Convertible Notes into ATAI Life Sciences AG shares, the shares of ATAI Life Sciences AG that were issued to the noteholders were exchanged for shares of ATAI Life Sciences N.V. through a transfer and sale arrangement. As ATAI Life Sciences AG continued to remain a wholly owned subsidiary of ATAI Life Sciences N.V., the transaction was accounted for as an equity transaction that resulted in no gain or loss recognition. The carrying amounts of the Company’s remaining 2018 Convertible Notes do not approximate fair value because the fair value is driven by the underlying value of the Company’s common stock into which the notes are to be converted. As of December 31, 2023 , the carrying amount and fair value amount of the notes was $ 0.2 million and $ 1.5 million, respectively. As of December 31, 2022 , the carrying amount and fair value amount of the 2018 Convertible Notes was $ 0.4 million and $ 13.1 million, respectively. 2018 Convertible Promissory Notes Exchange of 2020 Convertible Promissory Notes In November 2023, a nonrelated party noteholder of the October 2020 notes and ATAI Life Sciences AG executed an exchange agreement ("2023 Exchange Agreement") where the noteholder agreed to exchange its 2020 convertible notes issued by ATAI Life Sciences AG ("Old AG Notes") into the same principal amount of new convertible notes issued by ATAI Life Sciences N.V. ("New NV Notes"). The New NV Note are non-interest-bearing, unsecured and are due and payable on September 30, 2025, unless previously redeemed, converted, purchased or cancelled (the “Maturity Date”). Each New NV Note has a face value of € 1 and is convertible into 16 common shares of ATAI Life Sciences N.V. upon the payment of € 17.00 . Conversion rights may be exercised by a noteholder at any time prior to maturity. The New NV Notes may be declared for early redemption by the noteholders upon occurrence of specified events of default, including payment default, insolvency and a material adverse change in the Company’s business, operations or financial or other condition. Upon early redemption, the conversion right with respect to the New NV Notes may no longer be exercised. In December 2023, the Company and the same noteholder entered into a subscription agreement ("2023 Subscription Agreement") and exchanged its Old AG Notes into New NV Notes. The Company determined that the note exchange was a modification of the debt. The 2023 Exchange Agreement and 2023 Subscription Agreement resulted in the new NV Notes conversion option no longer meeting the equity classification criteria. Accordingly, at the time of the 2023 Exchange Agreement modification, the Company bifurcated the conversion option and reclassified the conversion option fair value from equity to a liability and is included in Convertible promissory notes and derivative liability in the consolidated balance sheet. The conversion option is measured at fair value on a quarterly basis and any changes in the fair value will be recorded as Change in fair value of assets and liabilities, net, a component of other income (expense), net in the consolidated statements of operations. For the year ended December 31, 2023 , the Company recognized a loss of $ 0.7 million as a result of the change in fair value of the New NV notes. As of the year ended December 31, 2023 , the carrying value of the Convertible promissory note was $ 2.7 million, which includes the principal amount and the fair value of the conversion option. Term Loan Hercules Loan and Security Agreement In August 2022, the Company and certain subsidiaries, as guarantors, and Hercules Capital, Inc. entered into a Loan and Security Agreement the “Hercules Loan Agreement”. The Hercules Loan Agreement provides for term loans in an aggregate principal amount of up to $ 175.0 million under multiple tranches (the “2022 Term Loan Facility”). On May 26, 2023, ATAI Life Sciences N.V. (the “Company”), ATAI Life Sciences AG (“ATAI AG” and together with the Company, the “Borrowers”) and certain subsidiary guarantors of the Company (collectively, the “Subsidiary Guarantors”) entered into the Second Amendment to Loan and Security Agreement (the “Amendment”), with the several banks and other financial institutions or entities from time to time parties to the Hercules Loan Agreement (collectively, the “Lenders”) and Hercules Capital, Inc., a Maryland corporation, in its capacity as administrative agent and collateral agent for itself and for the Lenders (the “Agent”) which amends that certain Loan and Security Agreement, dated August 9, 2022 (as amended by that certain First Amendment to Loan and Security Agreement dated as of March 13, 2023, the “Existing Loan Agreement,” and as amended by the Amendment, the “Agreement”) to, among other things, (i) extend the availability of Tranche 1B of $ 10.0 million, from May 1, 2023, under the Existing Loan Agreement, to November 15, 2024, (ii) extend the availability of Tranche 1C of $ 15.0 million, from December 15, 2023, under the Existing Loan Agreement, to December 15, 2024, (iii) provide Tranche 1D of $ 20.0 million, available upon the earlier of (x) the full draw of Tranche 1C and (y) the expiration of Tranche 1C availability, through February 15, 2025, (iv) extend the availability of Tranche 2 of $ 15.0 million, from June 30, 2024, under the Existing Loan Agreement, subject to certain conditions under the Agreement, to the earlier of (x) the full draw of Tranche 1D and (y) the expiration of Tranche 1D availability, through March 15, 2025, subject to the Tranche 2 Draw Test, (v) extend the timeline to achieve the second amortization extension condition, from June 30, 2024, in the Existing Loan Agreement, to December 15, 2024, (vi) amend the Tranche 2 Draw Test, satisfaction of which is a condition to draw Tranche 2 under the Agreement and (vii) extend the financial covenant commencement date, from the later of (x) July 1, 2023, and (y) the date that the outstanding debt under the facility is equal to or greater than $ 40.0 million, in the Existing Loan Agreement, to the later of (x) May 1, 2024, and (y) the date that the outstanding debt under the facility is equal to or greater than $ 30.0 million, provided, that the financial covenant is waived if the Company has a market capitalization of at least $ 550.0 million. The 2022 Term Loan Facility will mature on August 1, 2026 (the “Maturity Date”), which may be extended until February 1, 2027 if the Company achieves certain performance milestones, raises at least $ 175.0 million of unrestricted new net cash proceeds from certain permitted sources after the Closing Date and prior to June 30, 2024, and satisfies certain other specified conditions. The outstanding principal balance of the 2022 Term Loan Facility bears interest at a floating interest rate per annum equal to the greater of either (i) the prime rate as reported in the Wall Street Journal plus 4.55 % and (ii) 8.55 %. Accrued interest is payable monthly following the funding of each term loan advance. The Company may make payments of interest only, without any loan amortization payments, for a period of thirty (30) months following the Closing Date, which period may be extended to (i) thirty-six months if certain additional performance milestones have been achieved; and (ii) forty-two months if certain additional performance milestones have been achieved. At the end of the interest only period, the Company is required to begin repayment of the outstanding principal of the 2022 Term Loan Facility in equal monthly installments. The Hercules Loan Agreement contains customary closing and commitment fees, prepayment fees and provisions, events of default and representations, warranties and affirmative and negative covenants, including a financial covenant requiring the Company to maintain certain levels of cash in accounts subject to a control agreement in favor of the Agent (the “Qualified Cash”) at all times commencing from the Closing Date, which includes a cap on the amount of cash that can be held by, among others, certain of our foreign subsidiaries in Australia and the United Kingdom. In addition, the financial covenant under the Loan Agreement requires that beginning on the later of (i) July 1, 2023 and (ii) the date on which the aggregate outstanding amount borrowed under the 2022 Term Loan Facility is equal to or greater than $ 40.0 million, the Company shall maintain Qualified Cash in an amount no less than the sum of (1) 33 % of the outstanding amount under the 2022 Term Loan Facility, and (2) the amount of the Borrowers’ and Subsidiary Guarantors’ accounts payable that have not been paid within 180 days from the invoice date of the relevant account payable, subject to certain exceptions; provided, that the financial covenant shall not apply on any day that the Company's market capitalization is at least $ 550.0 million measured on a consecutive 10-business day period immediately prior to such date of measurement and tested on a daily basis. Upon the occurrence of an event of default, including a material adverse effect, subject to certain exceptions, on ATAI NV and ATAI AG’s, taken together, business, operations, properties, assets or financial condition, and subject to any specified cure periods, all amounts owed by the Company may be declared immediately due and payable by the Lenders. As of December 31, 2023, the Company was in compliance with all applicable covenants under the Hercules Loan Agreement. In addition, the Company is required to make a final payment fee (the “End of Term Charge”) upon the earlier of (i) the Maturity Date, (ii) the date that the Company prepays, in full or in part, the principal balance of the 2022 Term Loan Facility, or (iii) the date that the outstanding balance of the 2022 Term Loan Facility becomes due and payable. The End of Term Charge is 6.95 % of the aggregate original principal amount of the term loans so repaid or prepaid under the Loan Agreement. The Company may, at its option, prepay the term loans in full or in part, subject to a prepayment penalty equal to (i) 2.00 % of the principal amount prepaid if the prepayment occurs on or prior to the first anniversary of the Closing Date, (ii) 1.0 % of the principal amount prepaid if the prepayment occurs after the first anniversary and on or prior to the second anniversary of the Closing Date, and (iii) 0.5 % of the principal amount prepaid if the prepayment occurs after the second anniversary and prior to the Maturity Date. The Company incurred financing expenses related to the Hercules Loan Agreement, which are recorded as an offset to long-term debt on the Company's consolidated balance sheets. These deferred financing costs are being amortized over the term of the debt using the effective interest method, and are included in other income, net in the Company’s consolidated statements of operations. The Company incurred financing expenses related to the Hercules Loan Agreement, which are recorded as an offset to long-term debt on the Company's consolidated balance sheets. These deferred financing costs are being amortized over the term of the debt using the effective interest method, and are included in other income, net in the Company’s consolidated statements of operations. During the years ended December 31, 2023 and 2022, respectively, interest expense included $ 0.4 million and $ 0.1 million of amortized deferred financing costs related to the 2022 Term Loan Facility. Outstanding debt obligations are as follows (in thousands): December 31, 2023 December 31, 2022 Principal amount $ 15,000 $ 15,000 End of the term charge 1,042 1,042 Less: unamortized issuance discount ( 204 ) ( 274 ) Less: unamortized issuance costs ( 84 ) ( 113 ) Less: unamortized end of term charge ( 707 ) ( 952 ) Net carrying amount 15,047 14,702 Less: current maturities — — Long-term debt, net of current maturities and unamortized debt discount and issuance costs $ 15,047 $ 14,702 The fair value of the outstanding Hercules debt obligations was $ 16.2 million and $ 14.9 million as of December 31, 2023 and 2022 , respectively. The fair value of the Hercules debt obligations represent Level 3 measurements within the fair value hierarchy.

Common Stock

Common Stock	12 Months Ended
	Dec. 31, 2023
Stockholders' Equity Note [Abstract]
Common Stock	12. Common Stock In Nove mber and December 2020, the Company issued and sold 14,933,344 shares of common stock of € 0.10 par value to new and existing investors, including related parties, at a price of € 4.69 or $ 5.56 per share, for proceeds of $ 77.2 million, net of issuance costs of $ 5.2 million which includes advisory fees paid to Small & Mid Cap Investmentbank AG ("SMC"). SMC paid a portion of the advisory fees received from the Company to Apeiron (see Note 17). In November 2020, in connecti on with the Company’s issuance and sale of its common stock, all of the outstanding principal and accrued interest under the 2020 Convertible Notes, totaling $ 32.2 million, was automatically converted into 8,773,056 shares of common stock pursuant to their original terms. Once the notes were converted, the converted shares were recorded at fair value of $ 5.56 per share price equal to the price per share of common stock issued in November 2020. In January 2021, pursuant to an additional closing from the common stock issuance in November and December 2020, the Company issued and sold 2,133,328 shares of common stock to Apeiron at the same issuance price, for cash proceeds of $ 12.2 million. In March 2021, the Company issued and sold 13,419,360 shares of common stock to new and existing investors, including related parties, at a price of € 9.69 or $ 11.71 per share, for cash proceeds of $ 152.2 million, net of issuance costs of $ 4.9 million. On June 22, 2021, atai closed the IPO of its common stock on Nasdaq. As part of the IPO, the Company issued and sold 17,250,000 shares of its common stock, which included 2,250,000 shares sold pursuant to the exercise of the underwriters’ over-allotment option, at a public offering price of $ 15.00 per share. The Company received net proceeds of $ 231.6 million from the IPO, after deducting underwriters’ discounts and commissions of $ 18.1 million and offering costs of $ 9.0 million. All common shareholders have identical rights. Each share of common stock entitles the holder to one vote on all matters submitted to the stockholders for a vote. All holders of common stock are entitled to receive dividends, as may be declared by the Company’s board of directors. Upon liquidation, common stockholders will receive distribution on a pro rata basis. As of December 31, 2023 and 2022, no cash dividends have been declared or paid.

Stock-Based Compensation

Stock-Based Compensation	12 Months Ended
	Dec. 31, 2023
Share-Based Payment Arrangement [Abstract]
Stock-Based Compensation	13. Stock-Based Compensation atai Equity Incentive Plans Stock Option activity under 2020 Incentive Plan and 2021 Incentive Plan The stock options outstanding noted below consist primarily of both service and performance-based options to purchase common stock. These stock options have a five-year or ten-year contractual term. These awards are subject to the risk of forfeiture until vested by virtue of continued employment or service to the Company. Atai Life Sciences 2020 Equity Incentive Plan Effective August 21, 2020, the Company adopted an equity-based compensation plan, the 2020 Employee, Director and Consultant Equity Incentive Plan (as amended from time to time, “2020 Incentive Plan”). The 2020 Incentive Plan is administered by the Company’s Board. The plan is intended to encourage ownership of shares by employees, directors and certain consultants to the Company in order to attract and retain such individuals, to induce them to work for the benefit of the Company and to provide additional incentive for them to promote the success of the Company. The 2020 Incentive Plan enables the Company to grant incentive stock options or nonqualified stock options, restricted stock awards and other stock-based awards to executive officers, directors and employees and consultants of the Company. The Company has reserved up to 22,658,192 shares of common stock, excluding any shares issued under its Hurdle Share Option Program ("HSOP") described below, for issuance to executive officers, directors, other employees and consultants of the Company pursuant to the 2020 Incentive Plan. Shares that are expired, terminated, surrendered, or canceled without having been fully exercised will be available for future awards. As of December 31, 2023 , there were no shares available for future grants under the 2020 Incentive Plan and any shares subject to outstanding options originally granted under the 2020 Equity Incentive Plan that terminate, expire or lapse for any reason without the delivery of shares to the holder thereof shall become available for issuance pursuant to the atai Life Sciences 2021 Incentive Award Plan discussed below. Atai Life Sciences 2021 Incentive Award Plan Effective April 23, 2021, the Company adopted and the atai shareholders approved the 2021 Incentive Award Plan (“2021 Incentive Plan”). The 2021 Incentive Plan is administered by the Company’s supervisory board. The plan is intended to encourage ownership of shares by employees, directors, and certain consultants to the Company in order to attract and retain such individuals, to induce them to work for the benefit of the Company or of an affiliate and to provide additional incentive for them to promote the success of the Company. The 2021 Incentive Plan enables the Company to grant incentive stock options or nonqualified stock options, restricted stock awards and other stock-based awards to executive officers, directors and other employees and consultants of the Company. The Company has reserved up to 55,035,590 shares of common stock, for issuance to executive officers, directors and employees and consultants of the Company pursuant to the 2021 Incentive Plan. In accordance with the evergreen clause in the Company's 2021 Incentive Plan, the number of shares initially available for issuance was increased by 8,033,850 and 8,296,796 shares of common stock effective January 1, 2022 and 2023, respectfully. Shares that are expired, terminated, surrendered, or canceled without having been fully exercised will be available for future awards. Shares that are expired, terminated, surrendered, or canceled without having been fully exercised will be available for future awards. As of December 31, 2023 , 33,866,036 shares were available for future grants under the 2021 Incentive Plan. Stock Options The stock options outstanding noted below consist primarily of both service and performance-based options to purchase Common Stock. These stock options have a ten-year contractual term. These awards are subject to the risk of forfeiture until vested by virtue of continued employment or service to the Company. The following is a summary of stock option activity from December 31, 2022 to December 31, 2023: Number of Weighted- Weighted- Aggregate Outstanding as of December 31, 2022 34,880,603 $ 5.98 5.71 $ 10,647 Granted 10,425,028 (1) 1.29 — — Exercised ( 74,562 ) 2.44 — — Cancelled or forfeited ( 6,164,615 ) 5.77 — — Outstanding as of December 31, 2023 39,066,454 (2) $ 4.62 5.56 $ 6,294 Options exercisable as of December 31, 2023 22,314,503 $ 5.40 3.67 $ 4,410 (1) Includes (a) 9,835,328 stock options that will vest over a four-year service period (b) 452,700 stock options that will vest over a one-year service period and (c) 137,000 stock options that will vest over a two-year service period . (2) Includes 16,751,951 outstanding unvested stock options; (a) 15,138,297 that will continue to vest over a one to four-year service period, (b) 992,654 that will continue to vest over a three to four-year service period and upon the satisfaction of specified performance-based vesting conditions, (c) 137,000 stock options that will continue to vest over a two-year service period, (d) 100,000 stock options that will continue to vest over a two-year service period and upon the satisfaction of specified market-based conditions tied to price of the Company's publicly traded shares, and (e) 384,000 stock options that will vest on the one-year anniversary of the date of grant. The weighted-average grant-date fair value of options granted during the year months ended December 31, 2023 and 2022 was $ 1.02 and 3.17 . The Company estimates the fair values of stock options using the Black-Scholes option-pricing model on the date of grant. For the years ended December 31, 2023 and 2022, the assumptions used in the Black-Scholes option pricing model were as follows: Years Ended December 31, 2023 2022 Weighted average expected term in years 6.23 5.89 Weighted average expected stock price volatility 85.7 % 71.7 % Risk-free interest rate 3.50 % - 4.18 % 1.46 % - 4.31 % Expected dividend yield 0 % 0 % For the years ended December 31, 2023 and 2022 , the Company recorded stock-based compensation expense of $ 27.9 million and $ 37.1 million, respectively. As of December 31, 2023 , total unrecognized compensation cost related to the unvested stock-based awards was $ 34.5 million, which is expected to be recognized over a weighted average period of 1.92 years. Restricted stock units The restricted stock units noted below consist of service-based awards vesting over a two-year period, subject to the risk of forfeiture until vested by virtue of continued employment or service to the Company. The Company reflects restricted stock units as issued and outstanding common stock when vested and the shares have been delivered to the individual. The following is a summary of restricted stock unit activity from December 31, 2022 to December 31, 2023: Restricted Stock Units Weighted Average Grant Date Fair Value Unvested at January 1, 2023 — $ — Granted 3,251,815 1.18 Vested — — Forfeited 306,880 1.18 Unvested at December 31, 2023 2,944,935 $ 1.18 For the years ended December 31, 2023 , the Company recorded stock-based compensation expense of $ 1.4 million. The total fair value of restricted stock units vested during the year ended December 31, 2023 was $ 0 . As of December 31, 2023 , total unrecognized compensation cost related to the unvested stock-based awards was $ 2.0 million, which is expected to be recognized over a weighted average period of 1.19 years. Atai Life Sciences Hurdle Share Option Plan On August 21, 2020, the Partnership (as defined below) approved and implemented an employee stock option plan for selected executives, employees, and consultants of the Partnership (so-called Hurdle Share Options Program or “HSOP Plan”), which became effective on January 2, 2021, the date the first grants under the HSOP Plan were made (“HSOP Options”). This plan is primarily aimed at German-based executives, employees, and consultants of the Company (collectively as “HSOP Participants”). The purpose of the HSOP Plan is to permit these individuals to indirectly participate in the appreciation in value of the Company through a German law private partnership, ATAI Life Sciences HSOP GbR (the “Partnership”). The HSOP Plan was established under the Partnership Agreement of the Partnership. The HSOP Plan requires the exercise price to be equal to the fair value of the shares on the date of grant. The Partnership acquired 7,281,376 shares of atai common stock (“HSOP Shares”) pursuant to the HSOP Plan. HSOP Options that are canceled or forfeited without having been fully exercised will be available for future awards. As of December 31, 2023 , 257,419 HSOP Options were available for future grants under the HSOP Plan. The HSOP Plan mimics the economics of a typical stock option plan, however, with the HSOP Shares to which the HSOP Options refer already being issued to the Partnership. Each HSOP Option contains both service and performance-based vesting conditions, including a liquidity-based condition, and gives the holder the option to request the distribution of HSOP Shares under its vested HSOP Options. The grantee is required to pay a nominal value (€ 0.06 per share) for the shares upon grant (“Nominal Upfront Payment”). The nominal amount paid at the grant date is refundable if the HSOP Options do not vest or are forfeited. Otherwise, the nominal amount is refundable until the later of the occurrence of a Liquidity Event (as defined in the “HSOP Plan”) or the exercise date. The HSOP Shares issued under the HSOP Plan to the Partnership are indirectly owned by HSOP Participants (being the holders of HSOP Options) via their interest in the Partnership. However, each HSOP Participant signed a nonrevocable power of attorney ceding virtually all rights and decisions, including their rights as shareholders to the Managing Partner (as defined in the Partnership agreement) of the Partnership. HSOP Participants have a forfeitable right to distributions until the HSOP Options vest, at which time the right becomes nonforfeitable. Accordingly, the HSOP Shares issued to the Partnership and allocated to the HSOP Options holders are not considered outstanding for accounting purposes. Therefore, the Company accounted for the Nominal Upfront Payment as an in-substance early exercise provision under ASC 718 as the nominal amount is deducted from the exercise price upon exercise. As of December 31, 2023 , the $ 0.5 million Nominal Upfront Payment was recorded as an Other liability on the consolidated balance sheets. The HSOP Options include a provision that requires the HSOP Options holders pay compensation equal to 2 % per annum interest on the unpaid exercise price less the € 0.06 nominal amount paid upon grant (“Non-recourse Loan”) upon qualifying events (as defined in the Partnership agreement), which occurred on April 23, 2021 currently with the corporate reorganization discussed in Note 1. The 2 % per annum interest rate is fixed and not linked to something other than a service, performance, or market condition, therefore, the Company accounted for the fixed rate interest charge as an in-substance non-recourse loan in a stock compensation arrangement under ASC 718. In such cases, the rights and obligations embodied in a transfer of equity shares to an employee for a note that provides no recourse to other assets or the employee (other than the correlating shares) are substantially the same as those embodied in a grant of share options. The 2 % per annum interest was considered in the valuation of the HSOP Options. HSOP Options The HSOP Options outstanding noted below consist of service and performance-based options to request the distribution of HSOP Shares. These HSOP Options have a fifteen-year contractual term. These HSOP Options vest over a three to four-year service period, only if and when a “Liquidity Event” (as defined in the Partnership agreement) occurs within fifteen years of the date of grant. If a Change in Control (as defined in the Partnership agreement) or in the event the holder’s service with the Partnership is terminated due to his death or disability by June 30, 2021 or December 31, 2021, an additional 25 % or 12.5 %, respectively, HSOP Options will accelerate and vest upon the occurrence of the transaction. These awards are subject to the risk of forfeiture until vested by virtue of continued employment or service to the Company. The liquidity-based performance condition contingent upon the achievement of a Liquidity Event was satisfied in June of 2021, therefore, the Company began recognizing expense for all associated options that were previously deemed improbable of vesting. The following is a summary of stock option activity from December 31, 2022 to December 31, 2023: Number of Weighted- Weighted- Aggregate Outstanding as of December 31, 2022 6,921,829 $ 6.64 13.01 $ — Granted — — — — Exercised — — — — Cancelled or forfeited — — — — Outstanding as of December 31, 2023 6,921,829 $ 6.64 12.01 $ — Options exercisable as of December 31, 2023 6,754,232 $ 6.64 12.01 $ — The Company estimates the fair values of stock options using the Black-Scholes option-pricing model on the date of grant. As shown above, the Company did not grant any new HSOP options during the year ended December 31, 2023 and 2022. For the years ended December 31, 2023 and 2022 , the Company recorded stock-based compensation expense of $ 3.1 million and $ 4.5 million, respectively. As of December 31, 2023 , total unrecognized compensation cost related to the unvested stock-based awards was $ 0.1 million which is expected to be recognized over a weighted average period of 0.1 years. Subsidiary Equity Incentive Plans Certain controlled subsidiaries of the Company adopt their own equity incentive plan (“EIP”). Each EIP is generally structured so that the applicable subsidiary, and its affiliates’ employees, directors, officers and consultants are eligible to receive non-qualified and incentive stock options and restricted stock unit awards under their respective EIP. Standard option grants have time-based vesting requirements, generally vesting over a period of four years with a contractual term of ten years. Such time-based stock options use the Black-Scholes option pricing model to determine grant date fair value. For the years ended December 31, 2023 and 2022 , the Company recorded stock-based compensation expense of $ 0.5 million and $ 0.7 million, respectively, in relation to subsidiary EIPs. As of December 31, 2023 , there was $ 0.2 million of total unrecognized stock-based compensation expense related to unvested EIP awards to employees and non-employee directors expected to be recognized over a weighted-average period of approximately 0.6 years. Stock-Based Compensation Stock-based compensation expense is allocated to either Research and development or General and administrative expense on the consolidated statements of operations based on the cost center to which the option holder belongs. The following table summarizes the total stock-based compensation expense by function for the year ended December 31, 2023, which includes expense related to stock options and restricted stock awards (in thousands): Year Ended December 31, 2023 atai atai Other Subsidiaries Equity Plan Total Research and development $ 12,262 $ — $ 426 $ 12,688 General and administrative 17,203 3,052 39 20,294 Total share based compensation expense $ 29,465 $ 3,052 $ 465 $ 32,982 The following table summarizes the total stock-based compensation expense by function for the year ended December 31, 2022, which includes expense related to stock options and restricted stock awards (in thousands): Year Ended December 31, 2022 atai atai Other Subsidiaries Equity Plan Total Research and development $ 15,797 $ — $ 527 $ 16,324 General and administrative 21,333 4,551 167 26,051 Total share based compensation expense $ 37,130 $ 4,551 $ 694 $ 42,375

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2023
Income Tax Disclosure [Abstract]
Income Taxes	14. Income Taxes The component of German and overseas income (loss) from continuing operations before income taxes is as follows (in thousands): Years Ended 2023 2022 Germany $ 19,916 $ ( 55,845 ) International ( 59,201 ) ( 79,337 ) Total loss before income taxes and loss from equity method investments $ ( 39,286 ) $ ( 135,182 ) The tax provision (benefits) for income taxes consists of the following (in thousands): Years Ended December 31, 2023 2022 Current income tax provision: Germany $ — $ — International 1,016 1,155 Total current income tax provision: $ 1,016 $ 1,155 Deferred income tax provision: Germany $ — $ — International — 5,074 Total deferred income tax provision: — 5,074 Total income tax provision: $ 1,016 $ 6,229 The international current tax provision for December 31, 2023 and 2022 is primarily comprised of corporate income taxes incurred in the United States, United Kingdom and Australia. A reconciliation of the statutory income tax rate to the Company’s effective income tax rate for continuing operations is as follows (in thousands): Years Ended 2023 2022 Loss before income taxes: Germany $ 19,916 $ ( 55,845 ) International ( 59,201 ) ( 79,337 ) Total loss before income taxes: ( 39,286 ) ( 135,182 ) German statutory rate 30.18 % 30.18 % Expected income tax benefit ( 11,856 ) ( 40,791 ) US state income taxes, net of US federal tax benefit $ ( 3,662 ) $ ( 6,509 ) International tax rate differential 5,188 7,276 Effect of Australian R&D tax credit incentives 582 ( 338 ) Effect of taxes not provided on outside basis differences in investments regarding: fair value adjustments — ( 109 ) Effect of consolidation and deconsolidation of subsidiaries 3,250 ( 1,394 ) Effect of share-based compensation expense 975 216 Effect of non-deductible US compensation expense under IRC Section 162(m) 1,368 411 Expenses not deductible for tax purposes 600 ( 324 ) Effect of statutory to US GAAP accounting adjustments — 98 Return to Provision and deferred tax adjustments 10,188 758 Uncertain Tax Positions 96 — Change in German and international valuation allowance ( 5,713 ) 46,935 Total income tax expense $ 1,016 $ 6,229 Effective income tax rate: - 2.59 % - 4.61 % The Company is headquartered in Berlin, Germany and has subsidiaries in the United States, Australia, the United Kingdom, and Singapore as well as minority investments in Canada, Germany, and the United Kingdom. The Company incurred tax losses in most jurisdictions, however, generated taxable profits in certain United States subsidiaries, United Kingdom, and Australian subsidiaries. The weighted-average combined German corporate income tax rate for the year ended December 31, 2023 and 2022 was 30.18 % ((inclusive a corporate income tax rate of 15.00 %, solidarity surcharge of 0.83 %, and trade tax rate of 14.35 %). The weighted-average United States corporate income tax rate for year ended December 31, 2023 and 2022 was 21.00 %. The weighted-average Australia corporate income tax rate for the year ended December 31, 2023 and 2022 was 25.00 %. In 2023 it was noted that atai Therapeutics Pty Ltd would not qualify for the reduced rate under the base rate entity ("BRE") test as the amount of passive income exceed 90% of total income. This entity was therefore subject to a 30 % tax rate. The weighted-average United Kingdom corporate income tax rate for the year ended December 31, 2023 and 2022 was 25.00 % and 19.00 %, respectively. The Singapore corporate income tax rate for the year ended December 31, 2023 was 17.00 %. Deferred income taxes are provided for the effects of temporary differences between the amounts of assets and liabilities recognized for financial reporting purposes and the amounts recognized for income tax purposes. Significant components of deferred tax assets and deferred tax liabilities consisted of the following (in thousands): As of 2023 2022 Deferred tax assets: German tax loss carryforward $ 49,014 $ 45,560 International tax loss carryforward 16,270 10,585 Share compensation 35,062 31,078 Capitalized research and experimentation expenses 19,312 11,975 Operating lease right-of-use liability 13 - Other deductible timing differences 1,127 1,864 Total deferred tax assets, gross 120,798 101,062 Valuation allowance ( 89,968 ) ( 95,678 ) Total deferred tax assets, net $ 30,830 $ 5,384 Deferred tax liabilities: Fixed and intangible assets $ ( 930 ) $ ( 908 ) Unrealized foreign exchange ( 4,904 ) ( 4,472 ) Outside basis differences in equity and other investments ( 2 ) ( 4 ) Investments ( 24,982 ) — Operating lease right-of-use asset ( 12 ) — Total deferred tax liabilities ( 30,830 ) ( 5,384 ) Total deferred tax asset $ — $ — The valuation allowance provided against net deferred tax assets as of December 31, 2023 and 2022 was $ 90.0 million and $ 95.7 million, respectively. The valuation allowance recorded at both periods was primarily related to German and international tax loss carryforwards, capitalized research and experimental costs, and stock-based compensation timing differences that, in the judgment of management, are not more-likely-than-not, to be realized. In 2022, a valuation allowance was provided against net deferred tax assets recognized with regard to certain subsidiaries in the United States and United Kingdom where in the judgment of management, are not more-likely-than-not to be realized as a result of a change in tax and finance policies. As relevant to certain United States subsidiaries, the Tax Cuts and Jobs Act of 2017 requires taxpayers to capitalize and amortize certain research and experimental (“R&D”) expenditures under Internal Revenue Code ("IRC") Section 174 for tax years beginning after December 31, 2021 resulting in the capitalization of certain R&D costs within the Company's tax provision in 2023 and 2022. IRC Section 174 costs attributable to R&D performed in the United States and outside of the United States is amortizable over 5 years and 15 years, respectively. The majority of the Company's R&D costs incurred in 2023 were performed outside of the United States and are amortizable over a 15 year period. In assessing the realizability of deferred tax assets, management regularly considers whether it is more-likely-than-not that some or all of the recorded deferred tax assets will be realized. The future realization of deferred tax assets is subject to the existence of sufficient taxable income of the appropriate character (e.g., ordinary income or capital gain) as provided under the carryforward provisions of local tax law. Additionally, deferred tax assets with respect to tax losses in the United States may be subject to limitation as a result of ownership changes within the meaning of Section 382 of the IRC. Management considers the Company’s limited history and historical tax losses, future projected taxable income, including the character and jurisdiction of such income, the scheduled reversal of deferred tax liabilities (including the effect in available carryback and carryforward periods), and tax-planning strategies in making this assessment. In the event that there is a change in the ability to recover deferred tax assets, our income tax provision would increase or decrease in the period in which the assessment is changed. We note that a Section 382 analysis was undertaken in 2021, which determined that the tax loss carryforwards recorded by one United States subsidiary were able to be utilized in full, offsetting the entity's United States taxable income generated for the year ended December 31, 2021, subject to statutory limitations. The Company has limited prior earnings history and, due to the early stages of its development and research activities, is expected to generate losses for the next several years and cannot accurately estimate future profit projections beyond such time. As such, management believes that it is more likely than not that the Company will not realize the benefits of such tax loss carryforwards and deductible differences. As of December 31, 2023 and 2022 the Company did no t have any significant unremitted earnings in its foreign subsidiaries The Company’s gross tax loss carryforward for tax return purposes are as follows (in thousands): Year Ended 2023 2022 Germany tax losses $ 162,436 $ 150,991 International tax losses 56,691 41,908 Total $ 219,127 $ 192,899 The Company's tax loss carryforwards have an indefinite carryforward period, however, for tax years 2021 and beyond, in the United States, utilization of certain tax losses may not exceed 80 % of United States taxable income in any one year, computed without regard a deduction for tax losses utilized. The Company's 2020 through 2023 tax returns are currently open to audit. The 2021 tax return for Perception Neuroscience Holdings, Inc. is currently under routine audit by the Internal Revenue Service. The Company is not under examination for any other entity. Unrecognized tax benefits arise when the estimated benefit recorded in the financial statements differs from the amounts taken or expected to be taken in a tax return because of the uncertainties described above. As of December 31, 2023 and 2022, the Company the Company notes the following unrecognized tax benefits. Year Ended 2023 2022 Balance at beginning of period $ — $ — Increases—prior year tax positions — — Decreases—prior year tax positions — — Increases—current year tax positions 369 — Balance at end of period $ 369 $ — The balances of unrecognized tax benefits as of December 31, 2023 was $ 0.4 million, which represent the amounts that, if recognized, impact the effective income tax rate in future periods.

Net Loss Per Share

Net Loss Per Share	12 Months Ended
	Dec. 31, 2023
Earnings Per Share [Abstract]
Net Loss Per Share	15. Net Loss Per Share Basic and diluted net loss per share attributable to atai stockholders were calculated as follows (in thousands, except share and per share data): Years Ended December 31, 2023 2022 Numerator: Net loss $ ( 43,895 ) $ ( 157,417 ) Net loss attributable to noncontrolling ( 3,671 ) ( 5,032 ) Net loss attributable to ATAI Life Sciences $ ( 40,224 ) $ ( 152,385 ) Denominator: Weighted average common shares outstanding 158,833,785 155,719,585 Net loss per share attributable to ATAI Life $ ( 0.25 ) $ ( 0.98 ) HSOP Shares issued to the Partnership and allocated to the HSOP Participants are not considered outstanding for accounting purposes and not included in the calculation of basic weighted average common shares outstanding in the table above because the HSOP Participants have a forfeitable right to distributions until the HSOP Options vest and are exercised, at which time the right becomes nonforfeitable. The following also represents the maximum amount of outstanding shares of potentially dilutive securities that were excluded from the computation of diluted net loss per share attributable to common shareholders for the periods presented because including them would have been antidilutive: Potentially dilutive securities to the Company’s common shares: As of December 31, 2023 2022 Options to purchase common stock 39,066,454 34,880,604 HSOP options to purchase common stock 6,921,829 6,921,829 2018 convertible promissory notes - related parties 2,367,200 6,201,824 2018 convertible promissory notes 3,818,704 — Unvested restricted stock units 2,944,935 — 55,119,122 48,004,257 As of December 31, 2023 and 2022 , the remaining 2018 convertible promissory notes - related parties would be issuable upon the exercise of conversion rights of convertible note holders for 147,950 and 387,614 shares of common stock of ATAI Life Sciences AG, respectfully. Upon conversion, it is expected that the remaining 2018 convertible promissory notes - related parties would be exchanged on a one-for-sixteen basis for shares of ATAI Life Sciences N.V. which is reflected in the table above. See the Debt note to the Consolidated Financial Statements. As of December 31, 2023 , the remaining 2018 convertible promissory notes would be issuable upon the exercise of conversion rights of convertible note holders for 3,818,704 shares of common stock of ATAI Life Sciences N.V. See the Debt note to the Consolidated Financial Statements.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	16. Commitments and Contingencies Research and Development Agreements The Company may enter into contracts in the normal course of business with clinical research organizations for clinical trials, with contract manufacturing organizations for clinical supplies and with other vendors for preclinical studies, supplies and other services and products for operating purposes. Indemnification In the ordinary course of business, the Company may provide indemnifications of varying scope and terms to vendors, lessors, business partners, board members, officers and other parties with respect to certain matters, including, but not limited to, losses arising out of breach of such agreements, services to be provided by the Company, negligence or willful misconduct of the Company, violations of law by the Company, or intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with directors and certain officers and employees that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors, officers or employees. No demands have been made upon the Company to provide indemnification under such agreements, and thus, there are no claims that the Company is aware of that could have a material effect on the Company’s consolidated financial statements. The Company also maintains director and officer insurance, which may cover certain liabilities arising from its obligation to indemnify the Company’s directors. To date, the Company has not incurred any material costs and has not accrued any liabilities in the consolidated financial statements as a result of these provisions. Contingencies From time to time, the Company may become involved in legal proceedings arising in the ordinary course of business. The Company is unable to predict the outcome of these matters or the ultimate legal and financial liability, and at this time cannot reasonably estimate the possible loss or range of loss and accordingly has not accrued a related liability. At each reporting date, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under the provisions of the authoritative guidance that addresses accounting for contingencies. The Company accrues a liability when a loss is considered probable and the amount can be reasonably estimated. When a material loss contingency is reasonably possible but not probable, the Company does not record a liability, but instead discloses the nature and the amount of the claim, and an estimate of the loss or range of loss, if such an estimate can be made. Legal fees are expensed as incurred. The Company currently believes that the outcome of these legal proceedings, either individually or in the aggregate, will not have a material effect on its consolidated financial position, results of operations or cash flows.

License Agreements

License Agreements	12 Months Ended
	Dec. 31, 2023
License Agreements [Abstract]
License Agreements	17. License Agreements Otsuka License and Collaboration Agreement On March 11, 2021, Perception entered into a license and collaboration agreement (the “Otsuka Agreement”) with Otsuka under which Perception granted exclusive rights to Otsuka to develop and commercialize products containing arketamine, known as PCN-101, in Japan for the treatment of any depression, including treatment-resistant depression, or major depressive disorder or any of their related symptoms or conditions. Under the terms of the Otsuka Agreement, Otsuka received an exclusive right to develop and commercialize products containing PCN-101 in Japan at its own cost and expense. Perception retained all rights to PCN-101 outside of Japan. Otsuka owed Perception an upfront, non-refundable payment of $ 20.0 million as of the execution of the Otsuka Agreement. Perception is also entitled to receive aggregate payments of up to $ 35.0 million if certain development and regulatory milestones are achieved for the current or a new intravenous formulation of a product and up to $ 66.0 million in commercial milestones upon the achievement of certain commercial sales thresholds. Otsuka is obligated to pay Perception a tiered, double-digit royalty on net sales of products containing PCN-101 in Japan, subject to reduction in certain circumstances. The Otsuka Agreement will expire upon the fulfillment of Otsuka’s royalty obligations on a product-by-product basis. Otsuka shall have the right to terminate this agreement in its entirety for convenience at any time (a) on ninety (90) days’ prior written notice to Perception if such notice is given before the first regulatory approval of the first licensed product in the Otsuka territory, or (b) on one hundred and eighty (180) days’ prior written notice to Perception if such notice is given on or after the first regulatory approval of the first licensed product in the Otsuka territory. The Otsuka Agreement may be terminated in its entirety at any time during the term upon written notice by either party if the other party is in material breach of its obligations and has not cured such breach within thirty (30) days in the case of a payment breach, or within ninety (90) days in the case of all other breaches. The Company first assessed the Otsuka Agreement under ASC 808 to determine whether the Otsuka Agreement or units of accounts within the Otsuka Agreement represent a collaborative arrangement based on the risks and rewards and activities of the parties. The Company concluded that Otsuka is a customer in the context of the Otsuka Agreement and the units of account are within the scope of ASC 606. The Company determined that the combined promise of the exclusive license to PCN-101 and non-exclusive license to conduct clinical trials in Asia are a single performance obligation. The Company determined that the option rights for CMC study data, additional research services and development supply do not represent material rights to Otsuka as these options were issued at standalone selling prices. As such, they are not performance obligations at the outset of the arrangement. Based on this assessment, the Company concluded three performance obligations exists at the outset of the Otsuka Agreement: (i) the exclusive license to PCN-101 and exclusive license to conduct clinical trials in Japan, (ii) Global Requested Ongoing Clinical Studies and (iii) Global Ongoing Clinical Studies. The Company determined that the upfront payment of $ 20.0 million constitutes the transaction price at the outset of the Otsuka Agreement. Future potential milestone payments were fully constrained as the risk of significant revenue reversal related to these amounts has not yet been resolved. The achievement of the future potential milestones is not within the Company’s control and is subject to certain research and development success or regulatory approvals and therefore carry significant uncertainty. The Company will reevaluate the likelihood of achieving future milestones at the end of each reporting period. As all performance obligations will have been satisfied in advance of the achievement of the milestone events, if the risk of significant revenue reversal is resolved, any future milestone revenue from the arrangement will be added to the transaction price (and thereby recognized as revenue) in the period the risk is resolved. For the years ended December 31, 2023 and 2022, there were no additional milestones achieved under the Otsuka Agreement. The Company recognized revenues of $ 0.3 million and $ 0.2 million related to certain research and development services during the years ended December 31, 2023 and 2022, respectively. National University Corporation Chiba University License Agreement In August 2017, Perception entered into a license agreement (the “CHIBA License”) , with the National University Corporation Chiba University or CHIBA, relating to Perception’s drug discovery and development initiatives. Under the CHIBA License, Perception has been granted a worldwide exclusive license under certain patents and know-how of CHIBA to research, develop, manufacture, use and commercialize therapeutic products. Perception paid an upfront license fee which was recorded as research and development expense during the year ended December 31, 2017. The Company previously exercised an option and purchased licenses to additional CHIBA technologies and related know-how, and as such the Company is required to pay an annual maintenance fee until the filing of a new drug application with the Food and Drug Administration. In addition, Perception is also required to pay tiered royalties ranging in the low to mid-single-digit on future net sales of licensed products that are covered by a valid claim of a licensed patent, if any. In addition, the Company is obligated to make contingent milestone payments totaling up to $ 1.2 million upon the achievement of certain clinical or regulatory milestones for each of the first two licensed products and $ 1.0 million upon the achievement of certain clinical or regulatory milestones for each additional licensed product. The Company has the right to terminate the CHIBA License for any reason upon a 90 -day notice and if CHIBA materially breaches the agreement and fails to remedy any such default within specified cure periods. CHIBA has the right to terminate the CHIBA License if the Company declares bankruptcy, becomes insolvent or otherwise materially breaches the agreement and fails to remedy any such default within specified cure periods. Such termination does not preclude CHIBA’s rights to any milestone payments, royalties, and other payments described above. The CHIBA License will remain in effect until terminated by the parties according to their rights. During the years ended December 31, 2023 and 2022 , respectively, the Company made no material payments pursuant to the CHIBA License. Allergan License Agreement In February 2020, Recognify entered into an amended and restated license agreement (the "Allergan License Agreement"), with Allergan Sales, LLC, or Allergan, under which Allergan granted Recognify an exclusive (non-exclusive as to know-how), sublicensable and worldwide license under certain patent rights and know-how controlled by Allergan to develop, manufacture and commercialize certain products for use in all fields including the treatment of certain diseases and conditions of the central nervous system. Under the Allergan License Agreement, Recognify is subject to certain diligence obligations and is obligated to use commercially reasonable efforts, either by itself or through its affiliates or sublicensees, to develop, obtain regulatory approvals for and commercialize certain licensed products, at its sole cost. If Recognify decides to enter into negotiation of a change of control transaction with any third parties or receives a proposal from a third party for such transaction, Allergan has a right of first negotiation to negotiate the terms and conditions for acquisition of Recognify or its assets. As partial consideration for the rights granted by Allergan to Recognify under the Allergan License Agreement, Recognify paid Allergan an upfront payment of $ 0.5 million which was paid prior to the Company’s acquisition of Recognify in November 2020. Recognify is also responsible for paying Allergan a mid-single-digit royalty on the net sales of the licensed products. In addition, Recognify is obligated to pay Allergan a low teen percentage of the non-royalty sublicense payments it receives from a third party receiving a sublicense to practice the rights licensed to Recognify under the Allergan License Agreement. Upon the occurrence of certain change of control transactions involving Recognify, or sale, assignment or transfer (other than sublicense) to a third party of any rights licensed to Recognify under the Allergan License Agreement, Recognify is required to share with Allergan a low teen percentage of the proceeds it receives from such transactions. Recognify has the right to terminate the Allergan License Agreement for any reason, subject to a specified notice period, and if Allergan materially breaches the agreement and fails to remedy any such default within specified cure periods. Allergan has the right to terminate the Allergan License Agreement if Recognify declares bankruptcy, becomes insolvent or otherwise materially breaches the agreement and fails to remedy any such default within the specified cure periods. Such termination does not preclude Allergan’s rights to any milestone payments, royalties, or other payments described above. The Allergan License Agreement will remain in effect until terminated by the parties according to their rights. During the year ended December 31, 2021, the Company made no material payments pursuant to the Allergan License Agreement. During the years ended December 31, 2023 and 2022 , respectively, the Company made no material payments pursuant to the Allergan License Agreement. Columbia Stock Purchase and License Agreement In June 2020, Kures entered into a license agreement (the “License Agreement”) with Trustees of Columbia University (“Columbia”), pursuant to which, Kures obtained an exclusive license under certain patents and technical information to discover, develop, manufacture, use and commercialize such patents or other products in all uses and applications (“Columbia IP”). In addition, in consideration for the rights to the Columbia IP, Kures entered into a Stock Purchase Agreement (the “SPA”) with Columbia in contemplation of the License Agreement. Pursuant to the SPA, Kures issued to Columbia certain shares of the Kures’ capital stock, representing 5.0 % of Kures common stock on a fully diluted basis. Furthermore, the SPA provided that from time to time, Kures shall issue to Columbia additional shares of Kures’ common stock, at a per share price equal to the then fair market value of each such share, which price shall be deemed to have been paid in partial consideration for the execution, delivery and performance by Columbia of the License Agreement, such that the common stock held by Columbia shall equal to 5.0 % of the common stock on a fully diluted basis, at all times up to and through the achievement of certain funding threshold. In April 2022, Kures issued shares of Series A-2 Preferred Stock to certain investors upon the achievement of Series A-2 milestone events. Accordingly, the Company issued certain anti-dilution common stock to Columbia worth $ 0.3 million. The Company expensed the cost incurred for acquiring license as acquired in-process research and development expense at inception. Since, the additional anti-dilution shares were issued as partial consideration towards the same license arrangement, the $ 0.4 million cost of such additional share was also expensed as acquired in-process research and development expens e during the year ended December 31, 2022. During the years ended December 31, 2023 and 2022 , Kures made no material payments in connection with the Columbia agreement. Dalriada License Agreement In December 2021, Invyxis, Inc., or Invyxis, entered into an exclusive services and license agreement (the “Dalriada License Agreement”) with Dalriada Drug Discovery Inc. (“Dalriada”). Under the Dalriada License Agreement, Dalriada is to exclusively collaborate with Invyxis to develop products, services and processes with the specific purpose of generating products consisting of new chemical entities. Invyxis will pay Dalriada up to $ 12.8 million in service fees for research and support services. In May 2023, the Company executed an amendment to Dalriada License Agreement, which reduced the amount Invyxis will pay Dalriada in service fees to $ 7.4 million. In addition, Invyxis will pay Dalriada development milestone payments and low single digit royalty payments based on net product sales. The Company has the right, but not the obligation, to settle future royalty payments based on net product sales with the our common shares. Invyxis, our wholly-owned subsidiary, and Dalriada will determine the equity settlement based on a price per share determined by both parties. In December 2022, the Company executed an amendment to the Dalriada License Agreement, which reduced the upfront deposit from $ 1.1 million to $ 0.5 million. As such, the remaining $ 0.6 million was applied against research and development expense incurred. The Company will expense the remaining deposit as the services are performed as a component of research and development expense in the consolidated statements of operations. During the year ended December 31, 2023 and 2022 , the Company recorded $ 2.0 million and $ 2.8 million, respectively as research and development expense. During the years ended December 31, 2023 and 2022 , Invyxis made no other service fee payments to Dalriada.

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2023
Related Party Transactions [Abstract]
Related Party Transactions	18. Related Party Transactions atai Formation In connection with the formation of atai in 2018, the Company entered into a series of transactions with its shareholders, Apeiron, Galaxy Group Investments LLC. (“Galaxy”) and HCS Beteiligungsgesellschaft mbH (“HCS”) whereby these shareholders contributed their investments in COMPASS, Innoplexus and Juvenescence to the Company in exchange for atai’s common stock of equivalent value. Apeiron is the family office of the Company’s founder who owns 19.7 % and 19.7 % of the outstanding common stock in the Company as of December 31, 2023 and 2022 , respectively. Galaxy is a NYC-based multi-strategy investment firm that owns 6.5 % and 6.5 % of the outstanding common stock in the Company as of December 31, 2023 and 2022, respectively. Directed Share Program In connection with atai's initial public offering, the underwriters reserved 27 % of the common shares for sale at the initial offering price to the Company's managing directors, supervisory directors and certain other parties. Apeiron participated in the program and purchased $ 10.5 million of common stock Consulting Agreement with Mr. Angermayer In January 2021, the Company entered into a consulting agreement, (the “Consulting Agreement”), with Mr. Angermayer, one of the Company’s co-founders and supervisory director. Apeiron is the family office and merchant banking business of Mr. Angermayer. Pursuant to the Consulting Agreement, Mr. Angermayer agreed to render services to the Company on business and financing strategies in exchange for 624,000 shares under the 2020 Incentive Plan upon achievement of certain performance targets. In January 2024, this agreement was terminated, as further described in the Subsequent Events footnote below. As a result of the Consulting Agreement, year ended December 31, 2023 and 2022 , the Company recorded $ 0.7 million and $ 0.7 million, respectively, of stock-based compensation included in general and administrative expense in its consolidated statements of operations. For the year ended December 31, 2023 and 2022 , the Company recorded $ 0.6 million and $ 0.6 million, respectively, of stock-based compensation included in general and administrative expense in its consolidated statements of operations related to Mr. Angermayer's service as Chairman of the supervisory board.

Defined Contribution Plan

Defined Contribution Plan	12 Months Ended
	Dec. 31, 2023
Retirement Benefits [Abstract]
Defined Contribution Plan	19. Defined Contribution Plan The Company has a defined contribution retirement savings plan under Section 401(k) of the Internal Revenue Code. This plan allows eligible employees to defer a portion of their annual compensation. Employees may make contributions by having the Company withhold a percentage of their salary up to the Internal Revenue Service annual limit. The Company recognized $ 0.5 million and $ 0.5 million of related compensation expense for the years ended December 31, 2023 and 2022.

Corporate Restructuring

Corporate Restructuring	12 Months Ended
	Dec. 31, 2023
Restructuring and Related Activities [Abstract]
Corporate Restructuring	20. Corporate Restructuring In February 2023, the Company restructured its workforce and eliminated approximately 30 % of its global workforce in order to more effectively allocate its research and development and other resources supporting the revised business and program priorities and to reduce operational costs. Restructuring expense related to the workforce reduction was incurred primarily during the year ended December 31, 2023 , resulting in $ 3.2 million of restructuring expense, which consisted of $ 3.0 million of cash expenditures for severance and other employee separation-related costs and $ 0.2 million of stock-based compensation expense. Of the restructuring expense, for the year ended December 31, 2023 , $ 1.8 million and $ 1.4 million were recorded in research and development expenses and general and administrative expenses, respectively, in the consolidated statement of operations. As of December 31, 2023 , all restructuring liabilities had been paid in full and the Company had $ 0.0 of restructuring liabilities included in accrued expenses on the Company's consolidated balance sheets.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2023
Subsequent Events [Abstract]
Subsequent Events	21. Subsequent Events Following the events took place subsequent to the year ended December 31, 2023: The Company entered into a subscription and shareholders’ agreement with Beckley Psytech Limited ("Beckley Psytech") pursuant to which the Company acquired a 35.5 % interest in the voting securities of BPL. This is based on a $ 50 m total investment, with a $ 40 m direct investment into Beckley Psytech and an additional $ 10 m in secondary share purchases from existing shareholders. Upon closing, atai received 1:1 warrant coverage at a 30 % premium on the primary issuances. atai will also have the right to appoint and hold 3 of the 9 seats in Beckley Psytech’s Board of Directors, and will hold a time-limited right of first refusal on a future sale of the company, asset sales or other transfer of commercial rights, as well as an indefinite right of first negotiation for BPL-003 and ELE-101. As of December 31, 2023, the Company had deposited $ 25 million with Beckley Psytech's legal counsel, which was paid to Beckley Psytech at closing. The Company identified redundancies among certain positions, which resulted in a reduction in force of approximately 10 % of the Company’s global workforce. The Company and IntelGenx entered into a third amended and restated loan agreement, pursuant to which, among other things, the Company made a $ 1.0 million additional term loan following the execution and has agreed to make an additional $ 1.0 million term loan to be disbursed upon the achievement of a pre-defined milestone. The Company and Mr. Angermayer entered into the Termination and New Consultancy Agreement (the “2024 Consultancy Agreement"). Pursuant to the 2024 Consultancy Agreement, the parties agreed to terminate the Consultancy Agreement (as defined above) between ATAI AG and Mr. Angermayer dated January 16, 2021 (the “Original Consultancy Agreement”) and enter into a new consultancy agreement between the Company and Mr. Angermayer to, among other things, extend the term of the Original Consultancy Agreement to January 5, 2028, increase the services to include various business objectives (including related to business and finance, communication and investor relations), and provide for the grant of an option to purchase 1,658,094 shares of the Company that vests over four years in part based on continued service and in part based on the Company's total shareholder return compared to the four-year total shareholder return of the companies comprising the XBI.

Basis of Presentation, Consol_2

Basis of Presentation, Consolidation and Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2023
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) and follow the requirements of the United States Securities and Exchange Commission ("SEC"), and in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for a fair statement of the Company's financial position, results of operations and comprehensive loss, and cash flows for the periods presented. Any reference in these notes to applicable accounting guidance is meant to refer to the authoritative U.S. GAAP included in the Accounting Standards Codification (“ASC”), and Accounting Standards Update (“ASU”) issued by the Financial Accounting Standards Board (“FASB”). Reclassifications Certain reclassifications were made to prior period amounts in the consolidated financial statements and accompanying notes to conform with current year presentation due to the increase in the balances of the Company's operating right-of-use asset, related lease liability, and debt facility related interest during the period. Consolidation The Company's consolidated financial statements include the accounts of atai and its subsidiaries. All intercompany balances and transactions have been eliminated in the consolidation. Since its inception, the Company has created wholly owned subsidiaries or made investments in certain controlled entities, including partially-owned subsidiaries for which it has majority voting interest under the VOE model or for which it is the primary beneficiary under the VIE model, which it refers to collectively as its consolidated entities. For consolidated entities that are less than wholly-owned, the third-party’s holding of equity interest is presented as noncontrolling interests in the Company's consolidated balance sheets and consolidated statements of stockholders' equity. The portion of net income (loss) attributable to the noncontrolling interests is presented as net income (loss) attributable to noncontrolling interests in the Company's consolidated statements of operations. Ownership interests in entities over which the Company has significant influence, but not a controlling financial interest, are accounted for as cost and equity method investments. If the company has not elected the fair value option, the Company then records gains (losses) from investments in equity method investees, net of tax, for its proportionate share of the underlying company’s net results until the investment balance is adjusted to zero. If the Company makes subsequent additional investments in that same company, it may record additional gains (losses) based on changes to its investment basis and also may record additional income (loss) in equity method investments. If the Company has elected the fair value option, the fair value of the investments will be recorded upon acquisition and any changes in fair value will be recorded as a component of other income (expense), net.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Significant estimates and assumptions made in the accompanying consolidated financial statements include, but are not limited to the fair value of securities carried at fair value, the fair value of other investments held at fair value, the fair value of convertible notes receivable, accruals for research and development costs, the fair value of contingent consideration liabilities, in-process research and development assets (“IPRD”), noncontrolling interests recognized in acquisitions, and the valuation of stock-based awards. The Company bases its estimates and assumptions on historical experience and on various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates.
Concentrations of Credit Risk	Concentrations of Credit Risk Financial instruments which potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents, short-term investments, and all no tes receivables. The Company’s cash is mainly held in financial institutions in the United States. Amounts on deposit may at times exceed federally insured limits. The credit risk associated with the Company’s investment in all notes receivables is monitored and assessed periodically. The Company does not believe that it is exposed to any significant credit risk related to these instruments.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all highly liquid investments purchased with original maturities of three months or less from the purchase date to be cash equivalents. As of December 31, 2023 and 2022, cash and cash equivalents consisted of cash on deposit and cash held in high-yield savings accounts and money market funds, and at times in excess of federally insured limits.
Investment Securities Portfolio	Investment Securities Portfolio The Company maintains an investment portfolio, which is comprised of money market funds, U.S. treasury securities, commercial paper, corporate notes/bonds, and U.S. government agencies securities. The Company classified securities in the investment portfolio as available-for-sale securities. Furthermore, the Company elected the fair value option for the available-for-sale securities in the investment portfolio. The decision to elect the fair value option, which is irrevocable once elected, is determined on an instrument-by-instrument basis and applied to an entire instrument. The net gains or losses, if any, on an investment for which the fair value option has been elected are recognized as a Change in fair value of assets and liabilities, net o n the consolidated statements of operations and the amortized cost of investments approximates their fair value. The Company's securities in the investment portfolio will mature within one year.
Property and Equipment	Property and Equipment Property and equipment, consisting primarily of furniture and fixtures and leasehold improvements, is r ecorded at cost, less accumulated depreciation. Maintenance and repairs that do not improve or extend the lives of the respective assets are expensed to operations as incurred. Upon disposal, retirement or sale, the related cost and accumulated depreciation is removed from the accounts and any resulting gain or loss is included in the results of operations. Depreciation of property and equipment is recorded using the straight-line method over the estimated useful lives of the related assets once the asset has been placed in service. The company estimates the useful life of furniture and fixtures to be 7 years. Leasehold improvements are amortized using the straight-line method over the estimated useful life or remaining lease term, whichever is shorter .
Operating lease right-of-use asset	Operating lease right-of-use asset At the inception of an arrangement, the Company determines if an arrangement is, or contains, a lease based on the unique facts and circumstances present in that arrangement. Lease classification, recognition, and measurement are then determined at the lease commencement date. For arrangements that contain a lease the Company (i) identifies lease and non-lease components, (ii) determines the consideration in the contract, (iii) determines whether the lease is an operating or financing lease; and (iv) recognizes lease right-of-use (ROU) assets and liabilities. Lease liabilities and their corresponding ROU assets are recorded based on the present value of lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable and as such, the Company uses its incremental borrowing rate based on the information available at the lease commencement date, which represents an internally developed rate that would be incurred to borrow, on a collateralized basis, over a similar term, an amount equal to the lease payments in a similar economic environment. Most leases include options to renew and, or, terminate the lease, which can impact the lease term. The exercise of these options is at the Company's discretion. The Company does not include any of these options within the expected lease term, as it is not reasonably certain it will exercise these options.
Variable Interest Entities and Voting Interest Entities	Variable Interest Entities and Voting Interest Entities The Company consolidates those entities in which it has a direct or indirect controlling financial interest based on either the variable interest model (the “VIE model”) or the voting interest model (the “VOE model”). VIEs are entities that, by design, either (i) lack sufficient equity to permit the entity to finance its activities without additional subordinated financial support from other parties; or (ii) have equity investors that do not have the ability to make significant decisions relating to the entity’s operations through voting rights, or do not have the obligation to absorb the expected losses, or do not have the right to receive the residual returns of the entity. The primary beneficiary of a VIE is required to consolidate the assets and liabilities of the VIE. The primary beneficiary is the party that has both (i) the power to direct the activities of the VIE that most significantly impact the VIE’s economic performance; and (ii) the obligation to absorb losses or the right to receive benefits from the VIE that could potentially be significant to the VIE through its interest in the VIE. To assess whether the Company has the power to direct the activities of a VIE that most significantly impact the VIE’s economic performance, the Company considers all the facts and circumstances, including its role in establishing the VIE and its ongoing rights and responsibilities. This assessment includes identifying the activities that most significantly impact the VIE’s economic performance and identifying which party, if any, has power over those activities. In general, the parties that make the most significant decisions affecting the VIE (management and representation on the board of directors) and have the right to unilaterally remove those decision-makers are deemed to have the power to direct the activities of a VIE. To assess whether the Company has the obligation to absorb losses of the VIE or the right to receive benefits from the VIE that could potentially be significant to the VIE, the Company considers all of its economic interests, which primarily include equity investments in preferred and common stock and notes receivable that are convertible into preferred stock, that are deemed to be variable interests in the VIE. This assessment requires the Company to apply judgment in determining whether these interests, in the aggregate, are considered potentially significant to the VIE. Factors considered in assessing the significance include: the design of the VIE, including its capitalization structure; subordination of interests; payment priority; relative share of interests held across various classes within the VIE’s capital structure; and the reasons why the interests are held by the Company. At the VIE’s inception, the Company determines whether it is the primary beneficiary and if the VIE should be consolidated based on the facts and circumstances. The Company then performs on-going reassessments of the VIE based on reconsideration events and reevaluates whether a change to the consolidation conclusion is required each reporting period. If the Company is not deemed to be the primary beneficiary in a VIE, the Company accounts for the investment or other variable interests in a VIE in accordance with the applicable GAAP. Upon the occurrence of certain events and on a regular basis, the Company evaluates whether it no longer has a controlling interest in its consolidated VIEs. If the Company determines it no longer has a controlling interest, the subsidiary is deconsolidated. The Company records a gain or loss on deconsolidation based on the difference on the deconsolidation date between (i) the aggregate of (a) the fair value of any consideration received, (b) the fair value of any retained noncontrolling investment in the former subsidiary and (c) the carrying amount of any noncontrolling interest in the subsidiary being deconsolidated, less (ii) the carrying amount of the former subsidiary’s assets and liabilities. Entities that do not qualify as a VIE are assessed for consolidation under the VOE model. Under the VOE model, the Company consolidates the entity if it determines that it, directly or indirectly, has greater than 50 % of the voting shares and that other equity holders do not have substantive voting, participating or liquidation rights.
Acquisitions	Acquisitions The Company evaluates each of its acquisitions under the accounting framework in Accounting Standards Codification (“ASC”) Topic 805, Business Combinations , to determine whether the transaction is a business combination or an asset acquisition. In determining whether an acquisition should be accounted for as a business combination or an asset acquisition, the Company first performs a screen test to determine whether substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or a group of similar identifiable assets. If this is the case, the acquired set is not deemed to be a business and is instead accounted for as an asset acquisition. If this is not the case, the Company then further evaluates whether the acquired set includes, at a minimum, an input and a substantive process that together significantly contribute to the ability to create outputs. If so, the Company concludes that the acquired set is a business. During the years ended December 31, 2023 and 2022, the Company did not have any acquisitions that were accounted for as business combinations. For asset acquisitions that involve the initial consolidation of a VIE that is not a business for which the Company is the primary beneficiary, the transactions are accounted for under ASC 810, Consolidation , and no goodwill is recognized. Rather, the Company recognizes the identifiable assets acquired (excluding goodwill), the liabilities assumed, and any noncontrolling interests as though the VIE was a business and subject to the guidance on recognition and measurement in a business combination under ASC 805, and recognizes a gain or loss for the difference between (a) the sum of the fair values of consideration paid (including any contingent consideration) and noncontrolling interests, (b) the fair value of the VIE’s identifiable assets and liabilities, and (c) the reported amounts of any previously held interests. Acquisition-related expenses incurred by the Company in asset acquisitions that involve the initial consolidation of a VIE that is not a business, are not included as a component of consideration transferred, but are accounted for as an expense in the period in which the costs are incurred. In an asset acquisition, including the initial consolidation of a VIE that is not a business, acquired in-process research and development (“IPR&D”) with no alternative future use is charged to operating expenses at the acquisition date.
Other Investments Held at Fair Value	Other Investments Held at Fair Value As permitted under Accounting Standards Codification 825, Financial Instruments, or ASC 825, the Company has elected the fair value option to account for its investment in IntelGenx, which otherwise would be subject to ASC 323. In accordance with ASC 825, the Company records this investment at fair value under the Other investments held at fair value in the Company's consolidated balance sheets and changes in fair value are recognized asChange in fair value of assets and liabilities, net, a component of other income (expense), net in the consolidated statements of operations. At the most recent remeasurement date, the Company evaluated its ability to continue to exercise significant influence over its investment and determined that it no longer had significant influence. The Company's COMPASS investment is accounted for at fair value under ASC 321 and recorded in Other investments held at fair value on the consolidated balance sheets and changes in fair value are recognized as Change in fair value of assets and liabilities, net, a component of other income (expense), net in the consolidated statements of operations.
Equity Method Investments	Equity Method Investments The Company utilizes the equity method to account for investments when it possesses the ability to exercise significant influence, but not control, over the operating and financial decisions of the investee. Generally, the ability to exercise significant influence is presumed when the investor possesses more than 20% of the voting interests of the investee. This presumption may be overcome based on specific facts and circumstances that demonstrate that the ability to exercise significant influence is not present. The Company applies the equity method to investments in common stock and to other investments in nonconsolidated entities that have risk and reward characteristics that are substantially similar to an investment in the investee’s common stock. In applying the equity method, the Company’s investments are initially recorded at cost in Other investments on the consolidated balance sheets. Upon recording an equity method investment, the Company evaluates whether there are basis differences between the carrying value and fair value of the Company’s proportionate share of the investee’s underlying net assets. Typically, the Company amortizes basis differences identified on a straight-line basis over the underlying assets’ estimated useful lives when calculating the attributable earnings or losses, excluding the basis differences attributable to IPR&D that had no alternative future use. To the extent a basis difference relates to IPR&D and the investee is not a business as defined in ASC 805, the Company immediately expenses such basis difference related to IPR&D. If the Company is unable to attribute all the basis difference to specific assets or liabilities of the investee, the residual excess of the cost of the investment over the proportional fair value of the investee’s assets and liabilities is recognized within the equity investment balance. The Company subsequently adjusts the carrying amount of the investment by the Company’s proportionate share of the net earnings or losses and other comprehensive income or loss of the investee based on the Company’s percentage of common stock or in-substance common stock ownership during the respective reporting period. The Company records its share of the results of equity method investees and any impairment related to equity method investments as earnings or losses from investments in equity method investees, net of tax in the consolidated statements of operations. In the event that net losses of the investee reduce the carrying amount to zero, additional net losses may be recorded if the Company has other investment or other outstanding loans and advances to the investee and would be determined based on the Company’s proportionate share of the respective class of securities. Currently the Company is not obligated to make additional capital contributions for its equity method investments, and therefore only records losses up to the amount of its total investment, inclusive of other investments in and loans to the investee, which are not accounted for as equity method investments. To the extent that the Company’s share of losses of the equity method investee on a cumulative basis exceeds its total investment amount, inclusive of its equity method investment, other investments, and loans, the Company will discontinue equity method loss recognition as the Company does not have guaranteed obligations of the investee nor has the Company otherwise committed to provide further financial support for the investee. The Company will resume recording its share of losses in future periods only after its share of the earnings of the equity method investee equals the Company’s share of losses not recognized during the suspended period. The Company evaluates additional equity method investments made after the suspension of loss recognition to determine whether such investments represent the funding of prior suspended losses of the equity method investee. Equity method investments are reviewed for indicators of other-than-temporary impairment at each reporting period. Equity method investments are written down to fair value if there is evidence of a loss in value that is other-than-temporary. Methodologies that the Company may use to estimate the fair value of its equity method investments include, but are not limited to, considering recent investee equity transactions, discounted cash flow analysis, recent operating results, comparable public company operating cash flow multiples and in certain situations, balance sheet liquidation values. If the fair value of the investment has declined below the carrying amount, management considers several factors when determining whether an other-than-temporary decline has occurred, such as the length of the time and the extent to which the estimated fair value or market value has been below the carrying value, the financial condition and the near-term prospects of the investee, the intent and ability of the Company to retain its investment in the investee for a period of time sufficient to allow for any anticipated recovery in market value and general market conditions. The estimation of fair value and whether an other-than-temporary impairment has occurred requires the application of significant judgment and future results may vary from current assumptions. If declines in the value of the equity method investments are determined to be other-than-temporary, a loss is recorded in earnings in the current period as a component of losses from investments in equity method investees, net of tax on the consolidated statements of operations. Evidence of a loss in value might include, but would not necessarily be limited to, absence of an ability to recover the carrying amount of the investment or inability of the investee to sustain an earnings capacity that would justify the carrying amount of the investment. This evaluation consists of several qualitative and quantitative factors including recent financial results and operating trends of the investee, implied values in recent transactions of investee securities, or other publicly available information that may affect the value of the Company’s investments. The Company presents income/losses from equity investments and any impairment related to equity method investments as Income(Losses) from investments in equity method investees, net of tax on the consolidated statement of operations.
Other Investments	Other Investments Other investments include ownership rights that either (i) do not provide the Company with control or significant influence, or (ii) do not have risk and reward characteristics that are substantially similar to an investment in the investee’s common stock. The Company records such investments under the measurement alternative method pursuant to ASC 321 as these investments do not have readily determinable fair values. Under the measurement alternative method, the Company records the investment at cost less impairment losses, if any, unless it identifies observable price changes in orderly transactions for the identical or a similar investment of the same issuer, in which case the Company will measure its investments at fair value as of the date that the observable transaction occurred. Such investments are presented as Other Investments on the consolidated balance sheets and any impairment recognized related to these investments are presented as Impairment of other investments, a component of other income(expense), net in the consolidated statements of operations. The Company performs a qualitative assessment at each reporting period considering impairment indicators to evaluate whether the investment is impaired. Impairment indicators that the Company considers include but are not limited to; i) a significant deterioration in the earnings performance, credit rating, asset quality, or business prospects of the investee, ii) a significant adverse change in the regulatory, economic, or technological environment of the investee, iii) a significant adverse change in the general market condition of either the geographical area or the industry in which the investee operates, iv) a bona fide offer to purchase, an offer by the investee to sell, or a completed auction process for the same or similar investment for an amount less than the carrying amount of that investment; v) factors that raise significant concerns about the investee’s ability to continue as a going concern, such as negative cash flows from operations, working capital deficiencies, or noncompliance with statutory capital requirements or debt covenants. If the qualitative assessment indicates that an investment is impaired, a loss is recorded equal to the difference between the fair value and carrying value of the investment.
Convertible Notes Receivable	Convertible Notes Receivable As permitted under ASC 825, Financial Instruments , or ASC 825, the Company has elected the fair value option to account for its IntelGenx convertible notes, which otherwise would be subject to ASC 320. In accordance with ASC 825, the Company records this investment at fair value under Convertible notes receivable - related party in the Company's consolidated balance sheets and changes in fair value are recognized as Change in fair value of assets and liabilities, net, a component of other income(expense), net in the consolidated statements of operations.
Notes Receivable	Notes Receivable The Company has certain notes receivable that are carried at cost, which includes the principal value of the note receivable, accrued interest and net of any payments received and expected credit losses. Management utilizes an undiscounted probability-of-default (“PD”) and loss-given-default (“LGD”) method for estimating credit losses on its assets pool, which is comprised of loans to other companies. Under the PD and LGD method, the expected credit loss percentage (or “loss rate”) is calculated as the probability of default (i.e., the probability the asset will default within the given time frame) multiplied by the loss given default (i.e., the percentage of the asset not expected to be collected because of default). Based on the terms of the notes receivable, certain notes receivable are classified as long term as their payments are due after twelve months from the balance sheet date.
Contingent Consideration Liability	Contingent Consideration Liability The Company may record contingent consideration as part of the cost of acquisitions. Contingent consideration is recognized at fair value as of the date of acquisition and accounted under Contingent consideration liability on the consolidated balance sheet. Contingent considerations are remeasured on a quarterly basis, as appropriate, using a discounted cash-flow valuation technique until fulfillment of the contingency. Changes in the fair value of the contingent consideration are recognized as Change in fair value of assets and liabilities, net , a component of other income (expense), net in the consolidated statements of operations.
Debt Issuance Costs and Debt Discount	Debt Issuance Costs and Debt Discount Debt issuance costs include incremental and direct costs incurred in relation to debt, such as legal fees, accounting fees, and other direct costs of the financing. Amounts paid to the lender are a reduction in the proceeds received by the Company and are generally considered a component of issuance discount, unless it is paid to compensate the lender for the services rendered or as a reimbursement of direct costs incurred by them in relation to the debt, in which case it would be akin to a debt issuance cost. Debt issuance costs related to a recognized debt liability are presented in the consolidated balance sheet as a direct deduction from the carrying amount of the debt liability rather than as an asset, consistent with the presentation of debt discounts, and are amortized to interest expense over the term of the related debt using the effective interest method.
Research and Development Costs	Research and Development Costs Research and development costs are expensed as incurred. Research and development consist of salaries, benefits and other personnel related costs including equity-based compensation expense, laboratory supplies, preclinical studies, clinical trials and related clinical manufacturing costs, costs related to manufacturing preparations, fees paid to other entities to conduct certain research and development activities on the Company’s behalf and allocated facility and other related costs. Nonrefundable advance payments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized as prepaid expenses until the related goods are delivered or services are performed. Preclinical and clinical study costs a re accrued over the service periods specified in the contracts and adjusted as necessary based upon an ongoing review of the level of effort and costs actually incurred. Payments for a product license prior to regulatory approval of the product and payments for milestones achieved prior to regulatory approval of the product are expensed in the period incurred as research and development expense.
Contingencies	Contingencies The Company may be, from time to time, a party to various disputes and claims arising from normal business activities. The Company continually assesses any litigation or other claims it may confront to determine if an unfavorable outcome would lead to a probable loss or reasonably possible loss which could be estimated. The Company will accrue for all contingencies at the earliest date at which the Company deems it probable that a liability has been incurred and the amount of such liability can be reasonably estimated. If the estimate of a probable loss is a range and no amount within the range is more likely than another, the Company will accrue the minimum of the range. In the cases where the Company believes that a reasonably possible loss exists, the Company will disclose the facts and circumstances of the litigation, including an estimable range, if possible.
Licenses of Intellectual Property	Licenses of Intellectual Property The Company may enter into collaboration and out-licensing arrangements for research and development, manufacturing, and commercialization activities with counterparties for the development and commercialization of its product candidates. The agreements may have units of account within the scope of ASC 606 where the counterparties meet the definition of a customer as well as units of account within the scope of ASC 808 where both parties are determined to be active participants exposed to significant risk and rewards. The arrangements may contain multiple components, which may include (i) licenses, or options to obtain licenses to the Company’s intellectual property or sale of the Company’s license, (ii) research and development activities, (iii) participation on joint steering committees, and (iv) the manufacturing of commercial, clinical or preclinical material. Payments pursuant to these arrangements may include non-refundable, upfront payments, milestone payments upon the achievement of significant development events, research and development reimbursements, sales milestones, and royalties on product sales. The amount of variable consideration is constrained until it is probable that the revenue is not at a significant risk of reversal in a future period. The contracts into which the Company enters generally do not include significant financing components. In determining the appropriate amount of revenue to be recognized as it fulfills its obligations under each of its collaboration and license agreements, the Company performs the following steps: (i) identification of the promised goods or services in the contract within the scope of ASC 606; (ii) determination of whether the promised goods or services are performance obligations including whether they are capable of being distinct and distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. As part of the accounting for these arrangements, the Company must use significant judgment to determine: a) the number of performance obligations based on the determination under step (ii) above; b) the transaction price under step (iii) above; c) the stand-alone selling price for each performance obligation identified in the contract for the allocation of transaction price in step (iv) above; and d) the measure of progress in step (v) above. The Company uses judgment to determine whether milestones or other variable consideration, except for sales-based milestones and royalties on license arrangements, should be included in the transaction price as described further below. If a license to the Company’s intellectual property is determined to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes revenue from consideration allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. In assessing whether a promise or performance obligation is distinct from the other elements, the Company considers factors such as the research, development, manufacturing and commercialization capabilities of the counterparties and the availability of its associated expertise in the general marketplace. In addition, the Company considers whether the counterparties can benefit from a promise for its intended purpose without the receipt of the remaining elements, whether the value of the promise is dependent on the unsatisfied promise, whether there are other vendors that could provide the remaining promise, and whether it is separately identifiable from the remaining promise. For licenses that are combined with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress as of each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. The measure of progress, and thereby periods over which revenue should be recognized, is subject to estimates by management and may change over the course of the arrangement. Such a change could have a material impact on the amount of revenue the Company records in future periods. Customer Options: If an arrangement is determined to contain customer options that allow the customer to acquire additional goods or services such as research and development services or manufacturing services, the goods and services underlying the customer options are not considered to be performance obligations at the inception of the arrangement unless a material right is provided to the customer. If the customer option does not represent a material right, the obligation to provide such goods and services is contingent on exercise of the option, and the associated consideration is not included in the transaction price. If a customer option is determined to include a significant and incremental discount and, therefore, represents a material right, the material right is recognized as a separate performance obligation at the outset of the arrangement. The Company allocates the transaction price to material rights based on the relative standalone selling price. Milestone Payments: At the inception of each arrangement that includes milestone payments, the Company evaluates whether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most-likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The Company evaluates factors such as the scientific, clinical, regulatory, commercial, and other risks that must be overcome to achieve the respective milestone in making this assessment. There is considerable judgment involved in determining whether it is probable that a significant revenue reversal would not occur. At the end of each subsequent reporting period, the Company reevaluates the probability of achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment. Royalties: For license arrangements that include sales-based royalties, including milestone payments based on a level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from any of its licensing arrangements.
Stock-Based Compensation	Stock-Based Compensation The Company accounts for all stock-based payment awards granted to employees, directors and non-employees as stock-based compensation expense based on their grant date fair value. The stock-based payment awards are measured at fair value on the date of the grant and that fair value is recognized as stock-based compensation expense in the Company’s consolidated statements of operations over the requisite service period of the respective award. The estimated fair value of awards that contain performance conditions is expensed when the Company concludes that it is probable that the performance condition will be achieved. The Company may grant awards with graded-vesting features. When such awards have only service vesting requirements, the Company elected to record stock-based compensation expense on a straight-line basis. Recognition of compensation cost relating to awards that vest on a “Liquidity Event” (as defined in the award) will be deferred until the consummation of such transaction. The Company measures the fair value of its stock options that only have service vesting requirements or performance-based options without market conditions using the Black-Scholes option pricing model. For performance-based awards with market conditions, the Company determines the fair value of the awards as of the grant date using a Monte Carlo simulation model. Certain assumptions need to be made with respect to utilizing the Black-Scholes option pricing model, including the expected life of the award, volatility of the underlying shares, the risk-free interest rate and the fair value of the Company’s common shares. Since the Company has limited option exercise history, it has generally elected to estimate the expected life of an award based upon the “simplified method” with the continued use of this method extended until such time the Company has sufficient exercise history. The risk-free interest rate is based on the rates paid on securities issued by the U.S. Treasury with a term approximating the expected life of the equity award. Because the Company did not have an extended trading history for its common shares, the expected volatility was estimated using weighted average measures of the Company's historical volatility and the historical volatility of a peer group of companies for a period equal to the expected life of the stock options. The Company’s peer group of publicly traded biopharmaceutical companies was chosen based on their similar size, stage in the life cycle or area of specialty. The Company has elected to recognize forfeitures of stock-based compensation awards as they occur. As part of the valuation of stock-based compensation under the Black-Scholes option pricing model, it is necessary for the Company to use the fair value of its common stock as a valuation input. Prior to the closing of the IPO, the fair value of the Company’s common stock was estimated on each grant date. The fair value of the Company's privately held subsidiaries' common stock was also estimated on each grant date. Given the absence of a public trading market, and in accordance with the American Institute of Certified Public Accountants’ Practice Guide, Valuation of Privately-Held-Company Equity Securities Issued as Compensation, the Company exercised reasonable judgment and considered numerous objective and subjective factors to determine its best estimate of the fair value of its common stock. The estimation of the fair value of the common stock considered factors including the following: the estimated present value of the Company’s future cash flows; the Company’s business, financial condition and results of operations; the Company’s forecasted operating performance; the illiquid nature of the Company’s common stock; industry information such as market size and growth; market capitalization of comparable companies and the estimated value of transactions such companies have engaged in; and macroeconomic conditions. After the closing of the IPO in June 2021, the Company’s board of directors determined the fair value of each share of common stock underlying stock-based awards based on the closing price of the Company’s common stock as reported by Nasdaq on the date of grant.
Noncontrolling Interests	Noncontrolling Interests The Company recognizes noncontrolling interests related to its consolidated VIEs in the consolidated balance sheets as a component of equity, separate from atai stockholders’ equity. Changes in the Company’s ownership interest in a consolidated VIE that do not result in a loss of control are accounted for as equity transactions. The noncontrolling interests related to its consolidated VIEs are initially recorded at fair value. Net losses in consolidated VIEs are attributed to noncontrolling interests considering the liquidation preferences of the different classes of equity held by the shareholders in the VIE and their respective interests in the net assets of the consolidated VIE in the event of liquidation, and their pro rata ownership. In addition, the Company evaluates the classification of noncontrolling interests based upon a review of the legal provisions governing the redemption of such interests as the obligation to redeem these shares are triggered by events that are within the control of the Company. The Company evaluates individual noncontrolling interests for the ability to recognize the noncontrolling interest as permanent equity on the consolidated balance sheets at the time such interests are issued and on a continual basis. Any noncontrolling interest that fails to qualify as permanent equity are considered redeemable noncontrolling interests and reclassified as temporary equity. The amount of net loss attributable to noncontrolling interests are included in consolidated net loss on the face of the consolidated statements of operations.
Income Taxes	Income Taxes Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and the respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is recorded when, after consideration of all positive and negative evidence, it is not more likely than not that the Company’s deferred tax assets will be realizable. If the Company determines that it would be able to realize its deferred tax assets in the future in excess of its net recorded amount, the Company would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit will more likely than not be realized. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. The Company recognizes interest and penalties related to the underpayment of income taxes as a component of the Provision for income taxes in its consolidated statements of operations.
Fair Value Measurements	Fair Value Measurements Assets and liabilities recorded at fair value on a recurring basis in the consolidated balance sheets are categorized based upon the level of judgment associated with the inputs used to measure their fair values. Fair value is defined as the exchange price that would be received for an asset or an exit price that would be paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The authoritative guidance on fair value measurements establishes a three-tier fair value hierarchy for disclosure of fair value measurements as follows: Level 1—Observable inputs such as unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date; Level 2—Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable for the asset or liability. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active; and Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. The carrying amount reflected in the accompanying consolidated balance sheets for cash and money market funds, funds held in trust, prepaid expenses and other current assets, accounts payable and accrued expenses approximate their fair values, due to their short-term nature. The COMPASS investment is a Level 1 asset as its quoted price can be found on the Nasdaq market. The carrying amounts of investment securities and IntelGenx common stock are determined according to Level 2 inputs in the fair value hierarchy above. The Company's investment in IntelGenx Warrants and Call Option Units, IntelGenx convertible notes receivable, and various contingent consideration liabilities are carried at fair value, determined according to Level 3 inputs in the fair value hierarchy described above.
Foreign Currency	Foreign Currency Assets and liabilities of foreign operations are translated using exchange rates in effect at the balance sheet date and their results of operations are translated using average exchange rates for the year. Investments accounted for under the equity method and stockholders’ equity are translated based on historical exchange rates. Certain transactions of the Company and its subsidiaries are denominated in currencies other than their functional currency. Adjustments resulting from the translation of the financial statements of the Company’s foreign functional currency subsidiaries into U.S. dollars are excluded from the determination of net loss and are accumulated in a separate component of shareholders’ equity. Foreign exchange transaction gains and losses are recognized as a component of other income(expense), net in the consolidated statements of operations.
Emerging Growth Company Status	Emerging Growth Company Status The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it (i) is no longer an emerging growth company or (ii) affirmatively and irrevocably opts out of the extended transition period provided in the JOBS Act. As a result, these consolidated financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.
Recently Adopted Accounting Pronouncements	Recently Adopted Accounting Pronouncements ASU 2016-13 Financial Instruments - Credit Losses In June 2016, the FASB issued ASU 2016-13, Financial Instruments — Credit Losses. This guidance requires immediate recognition of management’s estimates of current expected credit losses. Under the prior model, losses were recognized only when losses were deemed probable. The new model is applicable to most financial assets and certain other instruments that are not measured at fair value through net income. The Company utilizes an undiscounted probability-of-default (“PD”) and loss-given-default (“LGD”) method for estimating credit losses on its assets pool, which is comprised of loans to other companies. Under the PD and LGD method, the expected credit loss percentage (or “loss rate”) is calculated as the probability of default (i.e., the probability the asset will default within the given time frame) multiplied by the loss given default (i.e., the percentage of the asset not expected to be collected because of default). To implement the PD and LGD method, the Company utilizes readily observable market information from term-matched public debt to derive market implied current expected credit losses (“MICECL”) grouped by Standard & Poor’s (“S&P”) credit rating scale. The MICECL framework considers risk characteristics of assets pool based on publicly available or estimated S&P credit ratings to calculate an appropriate credit loss reserve for the pool or group of assets. ASU 2016-13 requires a cumulative effect adjustment to the statement of financial position as of the beginning of the first reporting period in which it is effective. On January 1, 2023, the Company adopted this guidance and applied a modified-retrospective transition approach through a cumulative-effect adjustment to retained earnings upon adoption. At transition, the new accounting guidance’s adoption resulted in an increase to accumulated deficit of $ 0.5 million, net of tax attributable to an increase in the allowance for credit losses related to its l ong term notes receivable - related parties. Further, the FASB issued ASU 2019-04, ASU 2019-05, ASU 2019-11, ASU 2020-03 and ASU 2022-02 to provide additional clarification and guidance on the credit losses standard. The Company adopted ASU 2019-04, ASU 2019-05, ASU 2019-11, ASU 2020-03 and ASU 2022-02 on January 1, 2023. The adoption of these standards did not have a material impact on the Company’s consolidated financial statements or disclosures.
Recently Issued Accounting Pronouncements Not Yet Adopted	Recently Issued Accounting Pronouncements Not Yet Adopted In November 2023, the Financial Accounting Standard Board ("FASB") issued new guidance designed to improve reportable segment disclosure requirements, primarily through enhanced disclosures about significant expenses per segment. The guidance is effective for all fiscal years beginning after December 15, 2023, and for interim periods beginning after December 15, 2024. The new standard must be adopted on a retrospective basis and early adoption is permitted. The Company is not early adopting the standard. We are currently evaluating this guidance to determine its impact on our consolidated financial statements. In December 2023, the FASB issued new guidance designed to improve income tax disclosure requirements, primarily through increased disaggregation disclosures within the effective tax rate reconciliation as well as enhanced disclosures on income taxes paid. The guidance is effective for all fiscal years beginning after December 15, 2024. The new standard can be adopted on a prospective basis with an option to be adopted retrospectively and early adoption is permitted. The Company is not early adopting the standard. We are currently evaluating this guidance to determine its impact on our consolidated financial statements.

Variable Interest Entities an_2

Variable Interest Entities and a Voting Interest Entity (Tables)	12 Months Ended
	Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Summary of Primary Beneficiary for VIEs Consolidated Under the VIE Model	As of December 31, 2023 and 2022, the Company has accounted for the following consolidated investments as VIEs, excluding the wholly owned subsidiaries: Consolidated Entities Relationship as of Relationship as of Date Ownership % Ownership % Perception Neuroscience Holdings, Inc. Controlled VIE Controlled VIE November 2018 59.2 % 58.9 % Kures, Inc. Controlled VIE Controlled VIE August 2019 64.5 % 64.5 % EntheogeniX Biosciences, Inc. Wholly Owned Subsidiary Controlled VIE November 2019 100.0 % 80.0 % DemeRx IB, Inc. Wholly Owned Subsidiary Controlled VIE December 2019 100.0 % 59.5 % Recognify Life Sciences, Inc. Controlled VIE Controlled VIE November 2020 51.9 % 51.9 % PsyProtix, Inc. Controlled VIE Controlled VIE February 2021 75.0 % 75.0 % Psyber, Inc. (1) - Controlled VIE February 2021 — 75.0 % InnarisBio, Inc. Wholly Owned Subsidiary Controlled VIE March 2021 100.0 % 82.0 % TryptageniX Inc. (1) — Controlled VIE December 2021 — 65.0 % (1) As discussed in Note 3, the Company deconsolidated Psyber, Inc. and TryptageniX, Inc. in October and December 2023, respectfully.
Summary of the Assets and Liabilities for all Consolidated VIEs	The following table presents the assets and liabilities (excluding intercompany balances that were eliminated in consolidation) for all VIEs as of December 31, 2023 (in thousands): Perception Kures EntheogeniX DemeRx IB Recognify PsyProtix InnarisBio Assets: Current assets: Cash $ 97 $ 257 $ 675 $ 528 $ 4,356 $ 35 $ 326 Accounts receivable 84 — — — — — — Prepaid expenses and other current assets 257 — 124 — 450 — 878 Total current assets 438 257 799 528 4,806 35 1,204 Long term notes receivable — — — — — 97 — Other assets — — — — — — 16 Total assets $ 438 $ 257 $ 799 $ 528 $ 4,806 $ 132 $ 1,220 Liabilities: Current liabilities: Accounts payable $ 31 $ 329 $ 59 $ 51 $ 1,926 $ — $ — Accrued liabilities 718 84 247 434 609 26 10 Other current liabilities 12 — — 2 1 — 1 Total current liabilities 761 413 306 487 2,536 26 11 Total liabilities $ 761 $ 413 $ 306 $ 487 $ 2,536 $ 26 $ 11 The following table presents the assets and liabilities (excluding intercompany balances that were eliminated in consolidation) for all consolidated VIEs as of December 31, 2022 (in thousands): Perception Kures EntheogeniX DemeRx IB Recognify PsyProtix Psyber InnarisBio TryptageniX Assets: Current assets: Cash $ 8,703 $ 220 $ 467 $ 12,251 $ 7,526 $ 1 $ 683 $ 719 $ 513 Accounts receivable 197 — — — — — — — — Prepaid expenses and other current assets 466 174 91 21 1,742 66 — 13 2,850 Total current assets 9,366 394 558 12,272 9,268 67 683 732 3,363 Long term notes receivable — — — 1,075 — 109 — — — Other assets — — — — — — 353 — — Total assets $ 9,366 $ 394 $ 558 $ 13,347 $ 9,268 $ 176 $ 1,036 $ 732 $ 3,363 Liabilities: Current liabilities: Accounts payable $ 661 $ 25 $ 124 $ 332 $ 381 $ 33 $ 10 $ 3 $ — Accrued liabilities 1,738 266 121 671 596 46 37 158 154 Other current liabilities 121 2 — 133 2 1 1 1 — Total current liabilities 2,520 293 245 1,136 979 80 48 162 154 Total liabilities $ 2,520 $ 293 $ 245 $ 1,136 $ 979 $ 80 $ 48 $ 162 $ 154
Schedule of Non Controlling Interest Recognized to Its Consolidated VIEs Roll Forward	The Company recognizes noncontrolling interests related to its consolidated VIEs and provides a rollforward of the noncontrolling interests balance, as follows (in thousands): Perception Kures Recognify Total Balance as of December 31, 2022 $ 1,731 $ 451 $ 2,844 $ 5,026 Issuance of noncontrolling interests — — — — Net loss attributable to noncontrolling interests - preferred ( 1,302 ) ( 84 ) ( 2,287 ) ( 3,673 ) Comprehensive income attributable to noncontrolling interests ( 1 ) 2 — 1 Balance as of December 31, 2023 $ 428 $ 369 $ 557 $ 1,354 Perception Kures Recognify Total Balance as of December 31, 2021 $ 5,232 $ — $ 3,819 $ 9,051 Issuance of noncontrolling interests — 957 — 957 Net income (loss) attributable to noncontrolling ( 3,551 ) ( 149 ) ( 975 ) ( 4,675 ) Net income (loss) attributable to noncontrolling — ( 357 ) — ( 357 ) Comprehensive loss attributable to noncontrolling 50 — — 50 Balance as of December 31, 2022 $ 1,731 $ 451 $ 2,844 $ 5,026

Equity Method Investments and_2

Equity Method Investments and Other Investments (Tables)	12 Months Ended
	Dec. 31, 2023
Equity Method Investments and Joint Ventures [Abstract]
Equity Method Investments	As o f December 31, 2023 and 2022, the Company accounted for the following investments in the investee’s common stock under the equity method (in thousands): As of December 31, 2023 As of December 31, 2022 Date First Common Stock Carrying Common Stock Carrying Investee Acquired Ownership % Value Ownership % Value Innoplexus A.G. August 2018 35.0 % $ — 35.0 % $ — COMPASS Pathways plc December 2018 15.4 % (1) — 22.4 % — GABA Therapeutics, Inc November 2020 3.6 % (2) — 7.5 % (2) — Total $ — $ — (1) The Company accounted for its investment in COMPASS Pathways plc ("COMPASS") under the equity method until August 18, 2023, the closing date of COMPASS's dilutive financing round described below in Other investments held at fair value. The Company is deemed to have significant influence over GABA Therapeutics, Inc ("GABA") through its total ownership interest in GABA, including the Company’s investment in GABA’s preferred stock, described below in Other investments. The Company’s total ownership interest, considering both preferred and common stock is 54.1% .
Investment	As of December 31, 2023 and 2022, the carrying values of Other investments, which consisted of investments in the investee’s preferred stock and common stock not in the scope of ASC 323 were as follows (in thousands): December 31, December 31, 2023 2022 GABA Therapeutics, Inc. $ 1,838 $ 5,387 DemeRx NB, Inc. — 1,024 Juvenescence Limited — 344 Total $ 1,838 $ 6,755
Schedule Of Equity Method Investment Summarized Balance Sheet	The following is a summary of financial data for investments accounted for under the equity method of accounting (in thousands): Balance Sheets December 31, 2023 GABA Current assets $ 1,720 Non-current assets — Total assets $ 1,720 Current liabilities $ 1,546 Non-current liabilities — Total liabilities $ 1,546 December 31, 2022 COMPASS (1) GABA Current assets $ 191,651 $ 3,933 Non-current assets 5,643 — Total assets $ 197,294 $ 3,933 Current liabilities $ 15,596 $ 1,542 Non-current liabilities 418 — Total liabilities $ 16,014 $ 1,542
Shedule Of Equity Method Investment Summarized Statement Of Operations	Statements of operations Nine Months Ended September 30, 2023 Year Ended December 31, 2023 COMPASS (1) GABA Revenue $ — $ — Loss from continuing operations $ ( 98,514 ) $ ( 3,593 ) Net loss $ 85,932 $ ( 3,593 ) Year Ended December 31, 2022 COMPASS (1) GABA Revenue $ — $ — Loss from continuing operations $ ( 110,403 ) $ ( 5,867 ) Net loss $ ( 91,505 ) $ ( 5,867 ) (1) As of August 18, 2023, the Company determined that it no longer had significant influence. At this remeasurement date, the Company qualified for and elected to account for its investment in COMPASS under the fair value option. Summarized financial information is as of and for the nine month period ending September 30, 2023 as this information is not readily available as of August 18, 2023 and the Company has no practical way to estimate otherwise.

Fair Value Measurement (Tables)

Fair Value Measurement (Tables)	12 Months Ended
	Dec. 31, 2023
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Summary of Fair Value Measurement on Recurring Basis	The following table presents information about the Company’s financial assets and liabilities that are measured at fair value on a recurring basis and indicates the fair value hierarchy of the valuation (in thousands): Fair Value Measurements as of As of December 31, 2023 Level 1 Level 2 Level 3 Total Assets: Cash equivalents: Cash & Money market funds $ 56 $ — $ — $ 56 Investment in securities at fair value: U.S. Treasuries — 67,119 — 67,119 Corporate Notes/Bonds — 5,007 — 5,007 U.S. Government Agencies — 37,097 — 37,097 Other investments held at fair value 83,701 — 6,124 89,825 Convertible notes receivable - related party — — 11,202 11,202 $ 83,757 $ 109,223 $ 17,326 $ 210,306 Liabilities: Contingent consideration liability - related parties $ — $ — $ 620 $ 620 Contingent consideration liability — — 1,637 1,637 2018 convertible promissory note conversion option — — 2,385 2,385 $ — $ — $ 4,643 $ 4,643 Fair Value Measurements as of December 31, 2022 Level 1 Level 2 Level 3 Total Assets: Cash equivalents: Cash & Money market funds $ 72,334 $ — $ — $ 72,334 Investment in securities at fair value: Commercial Paper — 5,958 — 5,958 Corporate Notes/Bonds — 17,719 — 17,719 U.S. Government Agencies — 58,819 — 58,819 $ 72,334 $ 82,496 $ — $ 154,830 Liabilities: Contingent consideration liability - related parties $ — $ — $ 953 $ 953 $ — $ — $ 953 $ 953
Summary of Fair Value Measurement Inputs and Valuation Techniques	The fair value of the Perception contingent consideration liability - related parties was calculated using the following significant unobservable inputs: December 31, 2023 December 31, 2022 Valuation Technique Significant Unobservable Inputs Input Range Input Range Discounted cash flow Milestone contingent consideration: Discount rate 13.5 % 13.1 % Probability of the milestone 28.0 % 10.0 % - 21.0 % Discounted cash flow Royalty contingent consideration: Discount rate for royalties 13.0 % - 14.2 % 20.0 % - 21.1 % Discount rate for royalties on milestones 13.0 % - 14.2 % 12.3 % - 13.4 % Probability of success rate 13.4 % - 28.0 % 10.1 % - 21.0 %
Summary of Fair Value Measurement on Recurring Basis, Unobservable Input Reconciliation	The following table provides a roll forward of the aggregate fair values of the Company’s financial instruments described above, for which fair value is determined using Level 3 inputs (in thousands): IntelGenx Convertible Notes Receivable IntelGenx Investments Held at Fair Value (1) Contingent (2) Contingent (3) 2018 Convertible Notes Call Option Balance as of December 31, 2022 $ — $ — $ 743 $ 210 $ — Initial fair value of instrument 10,800 5,787 — 1,329 1,668 Change in fair value, including interest ( 116 ) 105 ( 34 ) 98 717 Additional contribution 518 232 — — — Extinguishment of liability — — ( 89 ) — — Balance as of December 31, 2023 $ 11,202 $ 6,124 $ 620 $ 1,637 $ 2,385 (1) Includes, Initial Warrants, Additional Unit Awards, 2023 Initial Warrants, 2023 Subsequent Warrants, and Call Option Units (2) Includes Perception milestone based contingent consideration liability and InnarisBio milestone and royalty based contingent consideration liability (3) Includes contingent consideration liability related to DemeRx IB Stock Purchase and contingent consideration liability related to the TryptageniX research and development milestone success fee payments and royalties payments Contingent Warrant Liability Balance as of December 31, 2021 $ 2,483 $ 336 Change in fair value ( 1,480 ) ( 336 ) Extinguishment of liability ( 50 ) — Balance as of December 31, 2022 $ 953 $ —
DemeRx IB, Inc. [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Summary of Fair Value Measurement Inputs and Valuation Techniques	The fair value of the DemeRx contingent consideration liability - related parties was calculated using the following significant unobservable inputs: December 31, 2023 Valuation Technique Significant Unobservable Inputs Input Range Discounted cash flow Milestone contingent consideration: Discount rate 13.9 % Probability of the milestone 20 % - 25 %

Prepaid Expenses and Other Cu_2

Prepaid Expenses and Other Current Assets (Tables)	12 Months Ended
	Dec. 31, 2023
Prepaid Expense and Other Assets, Current [Abstract]
Summary of Prepaid Expenses and Other Current Assets	Prepaid expenses consist of the following (in thousands): December 31, December 31, Prepaid research and development related expenses $ 1,822 $ 4,626 Tax receivables 1,752 5,631 Prepaid insurance 1,410 2,034 Other 846 1,745 Total $ 5,830 $ 14,036

Accrued Liabilities (Tables)

Accrued Liabilities (Tables)	12 Months Ended
	Dec. 31, 2023
Accrued Liabilities, Current [Abstract]
Summary of Accrued Liabilities	Accrued liabilities consist of the following (in thousands): December 31, December 31, Accrued payroll $ 4,941 $ 5,260 Accrued accounting, legal, and other professional fees 5,468 3,566 Accrued external research and development expenses 3,031 5,550 Other liabilities 1,101 706 Taxes payable 715 2,224 Total $ 15,256 $ 17,306

ROU assets and lease liabilitie

ROU assets and lease liabilities (Tables)	12 Months Ended
	Dec. 31, 2023
Leases [Abstract]
Schedule Of Operating Leases Assets And Liabilities Lessee Table Text Block	ROU assets and lease liabilities related to the Company’s operating leases are as follows (in thousands): Balance Sheet Classification December 31, 2023 December 31, 2022 Right-of-use assets Operating lease right-of-use asset, net $ 1,223 $ 226 Current lease liabilities Current portion of lease liability 275 180 Non-current lease liabilities Non-current portion of lease liability 990 44

lease costs (Tables)

lease costs (Tables)	12 Months Ended
	Dec. 31, 2023
Leases [Abstract]
Components of expenses related to leases is recorded on a straight-line basis over the lease term	The following table summarizes lease costs by component for the year ended December 31, 2023 and 2022 (in thousands): Lease Cost Components Statement of Operations Classification December 31, 2023 December 31, 2022 Operating lease cost Operating expenses: General and administrative $ 663 $ 266 Short-term lease cost Operating expenses: General and administrative 338 434 Total lease cost $ 1,001 $ 700

Future minimum commitments unde

Future minimum commitments under all non-cancelable operating leases (Tables)	12 Months Ended
	Dec. 31, 2023
Leases [Abstract]
Schedule of future minimum commitments maturity operating leases	Future minimum commitments under all non-cancelable operating leases are as follows (in thousands): Year Ended 2024 $ 415 2025 370 2026 370 2027 370 2028 123 Total lease payments 1,648 Less: Imputed interest ( 383 ) Present value of lease liabilities $ 1,265

Supplemental cash flow informat

Supplemental cash flow information related to the Company's operating lease (Tables)	12 Months Ended
	Dec. 31, 2023
Leases [Abstract]
Schedule of supplemental cash flow information related to operating leases	Supplemental cash flow information related to the Company’s operating leases for the year ended December 31, 2023 and 2022 (in thousands): December 31, 2023 December 31, 2022 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 440 $ 267 Right-of-use assets obtained in exchange for new operating lease liabilities 1,377 487

Debt (Tables)

Debt (Tables)	12 Months Ended
	Dec. 31, 2023
Debt Disclosure [Abstract]
Schedule Of Outstanding debt obligations	Outstanding debt obligations are as follows (in thousands): December 31, 2023 December 31, 2022 Principal amount $ 15,000 $ 15,000 End of the term charge 1,042 1,042 Less: unamortized issuance discount ( 204 ) ( 274 ) Less: unamortized issuance costs ( 84 ) ( 113 ) Less: unamortized end of term charge ( 707 ) ( 952 ) Net carrying amount 15,047 14,702 Less: current maturities — — Long-term debt, net of current maturities and unamortized debt discount and issuance costs $ 15,047 $ 14,702

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	12 Months Ended
	Dec. 31, 2023
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Summary of Share-based Payment Arrangement, Option, Activity	The following is a summary of stock option activity from December 31, 2022 to December 31, 2023: Number of Weighted- Weighted- Aggregate Outstanding as of December 31, 2022 34,880,603 $ 5.98 5.71 $ 10,647 Granted 10,425,028 (1) 1.29 — — Exercised ( 74,562 ) 2.44 — — Cancelled or forfeited ( 6,164,615 ) 5.77 — — Outstanding as of December 31, 2023 39,066,454 (2) $ 4.62 5.56 $ 6,294 Options exercisable as of December 31, 2023 22,314,503 $ 5.40 3.67 $ 4,410 (1) Includes (a) 9,835,328 stock options that will vest over a four-year service period (b) 452,700 stock options that will vest over a one-year service period and (c) 137,000 stock options that will vest over a two-year service period . (2) Includes 16,751,951 outstanding unvested stock options; (a) 15,138,297 that will continue to vest over a one to four-year service period, (b) 992,654 that will continue to vest over a three to four-year service period and upon the satisfaction of specified performance-based vesting conditions, (c) 137,000 stock options that will continue to vest over a two-year service period, (d) 100,000 stock options that will continue to vest over a two-year service period and upon the satisfaction of specified market-based conditions tied to price of the Company's publicly traded shares, and (e) 384,000 stock options that will vest on the one-year anniversary of the date of grant.
Summary of Employee Stock Ownership Plan (ESOP) Disclosures	The following is a summary of stock option activity from December 31, 2022 to December 31, 2023: Number of Weighted- Weighted- Aggregate Outstanding as of December 31, 2022 6,921,829 $ 6.64 13.01 $ — Granted — — — — Exercised — — — — Cancelled or forfeited — — — — Outstanding as of December 31, 2023 6,921,829 $ 6.64 12.01 $ — Options exercisable as of December 31, 2023 6,754,232 $ 6.64 12.01 $ —
Summary of restricted stock unit activity	The following is a summary of restricted stock unit activity from December 31, 2022 to December 31, 2023: Restricted Stock Units Weighted Average Grant Date Fair Value Unvested at January 1, 2023 — $ — Granted 3,251,815 1.18 Vested — — Forfeited 306,880 1.18 Unvested at December 31, 2023 2,944,935 $ 1.18
Share-based Payment Arrangement, Expensed and Capitalized, Amount	The following table summarizes the total stock-based compensation expense by function for the year ended December 31, 2023, which includes expense related to stock options and restricted stock awards (in thousands): Year Ended December 31, 2023 atai atai Other Subsidiaries Equity Plan Total Research and development $ 12,262 $ — $ 426 $ 12,688 General and administrative 17,203 3,052 39 20,294 Total share based compensation expense $ 29,465 $ 3,052 $ 465 $ 32,982 The following table summarizes the total stock-based compensation expense by function for the year ended December 31, 2022, which includes expense related to stock options and restricted stock awards (in thousands): Year Ended December 31, 2022 atai atai Other Subsidiaries Equity Plan Total Research and development $ 15,797 $ — $ 527 $ 16,324 General and administrative 21,333 4,551 167 26,051 Total share based compensation expense $ 37,130 $ 4,551 $ 694 $ 42,375
Two Thousand And Twenty Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions	The Company estimates the fair values of stock options using the Black-Scholes option-pricing model on the date of grant. For the years ended December 31, 2023 and 2022, the assumptions used in the Black-Scholes option pricing model were as follows: Years Ended December 31, 2023 2022 Weighted average expected term in years 6.23 5.89 Weighted average expected stock price volatility 85.7 % 71.7 % Risk-free interest rate 3.50 % - 4.18 % 1.46 % - 4.31 % Expected dividend yield 0 % 0 %

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2023
Income Tax Disclosure [Abstract]
Schedule of Income before Income Tax, German and Overseas	The component of German and overseas income (loss) from continuing operations before income taxes is as follows (in thousands): Years Ended 2023 2022 Germany $ 19,916 $ ( 55,845 ) International ( 59,201 ) ( 79,337 ) Total loss before income taxes and loss from equity method investments $ ( 39,286 ) $ ( 135,182 )
Schedule of Components of Income Tax Provision (Benefit)	The tax provision (benefits) for income taxes consists of the following (in thousands): Years Ended December 31, 2023 2022 Current income tax provision: Germany $ — $ — International 1,016 1,155 Total current income tax provision: $ 1,016 $ 1,155 Deferred income tax provision: Germany $ — $ — International — 5,074 Total deferred income tax provision: — 5,074 Total income tax provision: $ 1,016 $ 6,229
Schedule of Effective Income Tax Rate Reconciliation	A reconciliation of the statutory income tax rate to the Company’s effective income tax rate for continuing operations is as follows (in thousands): Years Ended 2023 2022 Loss before income taxes: Germany $ 19,916 $ ( 55,845 ) International ( 59,201 ) ( 79,337 ) Total loss before income taxes: ( 39,286 ) ( 135,182 ) German statutory rate 30.18 % 30.18 % Expected income tax benefit ( 11,856 ) ( 40,791 ) US state income taxes, net of US federal tax benefit $ ( 3,662 ) $ ( 6,509 ) International tax rate differential 5,188 7,276 Effect of Australian R&D tax credit incentives 582 ( 338 ) Effect of taxes not provided on outside basis differences in investments regarding: fair value adjustments — ( 109 ) Effect of consolidation and deconsolidation of subsidiaries 3,250 ( 1,394 ) Effect of share-based compensation expense 975 216 Effect of non-deductible US compensation expense under IRC Section 162(m) 1,368 411 Expenses not deductible for tax purposes 600 ( 324 ) Effect of statutory to US GAAP accounting adjustments — 98 Return to Provision and deferred tax adjustments 10,188 758 Uncertain Tax Positions 96 — Change in German and international valuation allowance ( 5,713 ) 46,935 Total income tax expense $ 1,016 $ 6,229 Effective income tax rate: - 2.59 % - 4.61 %
Schedule of Components of Deferred Tax Assets and Deferred Tax Liabilities	Significant components of deferred tax assets and deferred tax liabilities consisted of the following (in thousands): As of 2023 2022 Deferred tax assets: German tax loss carryforward $ 49,014 $ 45,560 International tax loss carryforward 16,270 10,585 Share compensation 35,062 31,078 Capitalized research and experimentation expenses 19,312 11,975 Operating lease right-of-use liability 13 - Other deductible timing differences 1,127 1,864 Total deferred tax assets, gross 120,798 101,062 Valuation allowance ( 89,968 ) ( 95,678 ) Total deferred tax assets, net $ 30,830 $ 5,384 Deferred tax liabilities: Fixed and intangible assets $ ( 930 ) $ ( 908 ) Unrealized foreign exchange ( 4,904 ) ( 4,472 ) Outside basis differences in equity and other investments ( 2 ) ( 4 ) Investments ( 24,982 ) — Operating lease right-of-use asset ( 12 ) — Total deferred tax liabilities ( 30,830 ) ( 5,384 ) Total deferred tax asset $ — $ —
Schedule of Gross Tax Loss Carryforward for Tax Return Purpose	The Company’s gross tax loss carryforward for tax return purposes are as follows (in thousands): Year Ended 2023 2022 Germany tax losses $ 162,436 $ 150,991 International tax losses 56,691 41,908 Total $ 219,127 $ 192,899
Schedule of Unrecognized Tax Benefits	As of December 31, 2023 and 2022, the Company the Company notes the following unrecognized tax benefits. Year Ended 2023 2022 Balance at beginning of period $ — $ — Increases—prior year tax positions — — Decreases—prior year tax positions — — Increases—current year tax positions 369 — Balance at end of period $ 369 $ —

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	12 Months Ended
	Dec. 31, 2023
Earnings Per Share [Abstract]
Schedule of Basis and Diluted Net Loss Per Share Attributable to ATAI Stockholders	Basic and diluted net loss per share attributable to atai stockholders were calculated as follows (in thousands, except share and per share data): Years Ended December 31, 2023 2022 Numerator: Net loss $ ( 43,895 ) $ ( 157,417 ) Net loss attributable to noncontrolling ( 3,671 ) ( 5,032 ) Net loss attributable to ATAI Life Sciences $ ( 40,224 ) $ ( 152,385 ) Denominator: Weighted average common shares outstanding 158,833,785 155,719,585 Net loss per share attributable to ATAI Life $ ( 0.25 ) $ ( 0.98 )
Schedule of Computation of Diluted net Income (Loss) Per Share Attributable to Common Shareholders	Potentially dilutive securities to the Company’s common shares: As of December 31, 2023 2022 Options to purchase common stock 39,066,454 34,880,604 HSOP options to purchase common stock 6,921,829 6,921,829 2018 convertible promissory notes - related parties 2,367,200 6,201,824 2018 convertible promissory notes 3,818,704 — Unvested restricted stock units 2,944,935 — 55,119,122 48,004,257

Nature of Business - Additional

Nature of Business - Additional Information (Detail) $ / shares in Units, $ in Thousands		2 Months Ended
	Jun. 22, 2021 USD ($)	Dec. 31, 2020 USD ($)	Dec. 31, 2023 USD ($) $ / shares	Dec. 31, 2023 € / shares	Dec. 31, 2022 USD ($) $ / shares	Dec. 31, 2022 € / shares	Dec. 31, 2020 € / shares	Dec. 31, 2020 $ / shares	Jan. 03, 2020 $ / shares
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Common Stock, Par or Stated Value Per Share | (per share)			$ 0.12	€ 0.10	$ 0.12	€ 0.10			$ 0.0001
Sale of stock issue price per share | (per share)							€ 4.69	$ 5.56
Proceeds from initial public offering		$ 77,200
Cash and cash equivalents			$ 45,034		$ 190,613
Short-term notes payable			109,200
Accumulated deficit			$ (550,938)		$ (510,188)
IPO [Member]
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Underwriting discount	$ 18,100

Basis of Presentation, Consol_3

Basis of Presentation, Consolidation and Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Jan. 01, 2023	Dec. 31, 2022	Jan. 01, 2022
Accounting Policies [Line Items]
Property, plant, and equipment, useful life, term, description	Leasehold Improvements [Member]
Variable interest entity, qualitative or quantitative information, ownership percentage	10%
Operating lease right-of-use asset, net	$ 1,223		$ 226	$ 200
Current operating lease liability	$ 275		$ 180	$ 100
Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]	Operating lease right-of-use asset, net		Operating lease right-of-use asset, net	Operating lease right-of-use asset, net
Long-term operating lease liability	$ 990		$ 44	$ 100
Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]	Long-term operating lease liability		Long-term operating lease liability
Cumulative Effect, Period of Adoption, Adjustment [Member]
Accounting Policies [Line Items]
Accumulated deficit net of tax		$ 500
Furniture and Fixtures [Member]
Accounting Policies [Line Items]
Property and equipment, useful life	7 years
Minimum [Member] | VOE Model [Member]
Accounting Policies [Line Items]
Variable interest entity, qualitative or quantitative information, ownership percentage	50%

Dispositions - Additional Infor

Dispositions - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Business Combinations [Line Items]
Ownership %	10%
Recognized gain	$ 86,185	$ 9,605
Psyber, Inc. [Member]
Business Combinations [Line Items]
Recognized gain	300
Neuronasal, Inc. [Member]
Business Combinations [Line Items]
Impairment Of Loan Receivable		900
Recognized gain		$ 1,500
TryptageniX, Inc [Member]
Business Combinations [Line Items]
Recognized gain	$ 400

Variable Interest Entities an_3

Variable Interest Entities and a Voting Interest Entity - Additional information (Detail) - USD ($) $ in Thousands	1 Months Ended		3 Months Ended	9 Months Ended	12 Months Ended
	Oct. 31, 2023	Sep. 30, 2023	Mar. 31, 2023	Sep. 30, 2022	Dec. 31, 2023	Dec. 31, 2022	Nov. 30, 2023
Variable Interest Entity [Line Items]
Variable interest entity, qualitative or quantitative information, ownership percentage					10%
Net loss attributable to redeemable noncontrolling interests					$ (3,671)	$ (5,032)
Variable Interest Entity, Reporting Entity Involvement, Maximum Loss Exposure, Amount					6,100	6,800
Variable Interest Entity, Nonconsolidated, Comparison of Carrying Amount of Assets and Liabilities to Maximum Loss Exposure					100	$ 7,200	$ 200
Purchase of common stock		$ 500	$ 1,000	$ 2,200
Convertible Notes Receivable [Member]
Variable Interest Entity [Line Items]
Variable Interest Entity, Reporting Entity Involvement, Maximum Loss Exposure, Amount					$ 11,200
GABA Options [Member]
Variable Interest Entity [Line Items]
Equity method investment, ownership percentage		100%
DemeRx IB, Inc [Member] | Stock Purchase Agreement [Member]
Variable Interest Entity [Line Items]
Stock Purchase Consideration, Upfront Cash Payment	$ 8,000
Equity method investment, ownership percentage	100%
Fair value of the contingent milestone and royalty liabilities	$ 1,300
InnarisBio, Inc [Member] | Assignment, Termination and Release Agreement (ATRA) [Member]
Variable Interest Entity [Line Items]
Equity method investment, ownership percentage	100%
Intellectual Property, Fair Value	$ 100
Extinguishment of Contingent Commitment Liability	$ 100
PsyProtix, Inc. [Member]
Variable Interest Entity [Line Items]
Variable interest entity, qualitative or quantitative information, ownership percentage					75%	75%

Variable Interest Entities an_4

Variable Interest Entities and a Voting Interest Entity - Summary of Primary Beneficiary for VIEs Consolidated Under the VIE Model (Detail)		12 Months Ended
		Dec. 31, 2023	Dec. 31, 2022
Variable Interest Entity [Line Items]
Ownership %		10%
Perception Neuroscience Holdings, Inc. [Member]
Variable Interest Entity [Line Items]
Relationship		Controlled VIE	Controlled VIE
Date Control Obtained		November 2018
Ownership %		59.20%	58.90%
Kures, Inc. [Member]
Variable Interest Entity [Line Items]
Relationship		Controlled VIE	Controlled VIE
Date Control Obtained		August 2019
Ownership %		64.50%	64.50%
EntheogeniX Biosciences, Inc. [Member]
Variable Interest Entity [Line Items]
Relationship		Wholly Owned Subsidiary	Controlled VIE
Date Control Obtained		November 2019
Ownership %		100%	80%
DemeRx IB, Inc. [Member]
Variable Interest Entity [Line Items]
Relationship		Wholly Owned Subsidiary	Controlled VIE
Date Control Obtained		December 2019
Ownership %		100%	59.50%
Recognify Life Sciences, Inc. [Member]
Variable Interest Entity [Line Items]
Relationship		Controlled VIE	Controlled VIE
Date Control Obtained		November 2020
Ownership %		51.90%	51.90%
PsyProtix, Inc. [Member]
Variable Interest Entity [Line Items]
Relationship		Controlled VIE	Controlled VIE
Date Control Obtained		February 2021
Ownership %		75%	75%
Psyber, Inc. [Member]
Variable Interest Entity [Line Items]
Relationship	[1]	-	Controlled VIE
Date Control Obtained	[1]	February 2021
Ownership %	[1]	0%	75%
InnarisBio, Inc. [Member]
Variable Interest Entity [Line Items]
Relationship		Wholly Owned Subsidiary	Controlled VIE
Date Control Obtained		March 2021
Ownership %		100%	82%
TryptageniX Inc. [Member]
Variable Interest Entity [Line Items]
Relationship	[1]	—	Controlled VIE
Date Control Obtained	[1]	December 2021
Ownership %	[1]	0%	65%
[1] As discussed in Note 3, the Company deconsolidated Psyber, Inc. and TryptageniX, Inc. in October and December 2023, respectfully.

Variable Interest Entities an_5

Variable Interest Entities and a Voting Interest Entity - Summary of the Assets and Liabilities for all Consolidated VIEs (Detail) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Prepaid expenses and other current assets	$ 5,830	$ 14,036
Total current assets	185,592	287,145
Long term notes receivable - related parties, net	97	7,262
Other assets	2,720	3,125
Total assets	293,478	305,441
Current liabilities:
Accounts payable	4,589	2,399
Accrued liabilities	15,256	17,306
Other current liabilities	0	12
Total current liabilities	20,120	19,897
Total liabilities	49,162	39,675
Perception [Member]
Current assets:
Cash	97	8,703
Accounts receivable	84	197
Prepaid expenses and other current assets	257	466
Total current assets	438	9,366
Long term notes receivable - related parties, net	0	0
Other assets	0	0
Total assets	438	9,366
Current liabilities:
Accounts payable	31	661
Accrued liabilities	718	1,738
Other current liabilities	12	121
Total current liabilities	761	2,520
Total liabilities	761	2,520
Kures [Member]
Current assets:
Cash	257	220
Accounts receivable	0	0
Prepaid expenses and other current assets	0	174
Total current assets	257	394
Long term notes receivable - related parties, net	0	0
Other assets	0	0
Total assets	257	394
Current liabilities:
Accounts payable	329	25
Accrued liabilities	84	266
Other current liabilities	0	2
Total current liabilities	413	293
Total liabilities	413	293
EntheogeniX [Member]
Current assets:
Cash	675	467
Accounts receivable	0	0
Prepaid expenses and other current assets	124	91
Total current assets	799	558
Long term notes receivable - related parties, net	0	0
Other assets	0	0
Total assets	799	558
Current liabilities:
Accounts payable	59	124
Accrued liabilities	247	121
Other current liabilities	0	0
Total current liabilities	306	245
Total liabilities	306	245
DemeRx IB [Member]
Current assets:
Cash	528	12,251
Accounts receivable	0	0
Prepaid expenses and other current assets	0	21
Total current assets	528	12,272
Long term notes receivable - related parties, net	0	1,075
Other assets	0	0
Total assets	528	13,347
Current liabilities:
Accounts payable	51	332
Accrued liabilities	434	671
Other current liabilities	2	133
Total current liabilities	487	1,136
Total liabilities	487	1,136
Recognify [Member]
Current assets:
Cash	4,356	7,526
Accounts receivable	0	0
Prepaid expenses and other current assets	450	1,742
Total current assets	4,806	9,268
Long term notes receivable - related parties, net	0	0
Other assets	0	0
Total assets	4,806	9,268
Current liabilities:
Accounts payable	1,926	381
Accrued liabilities	609	596
Other current liabilities	1	2
Total current liabilities	2,536	979
Total liabilities	2,536	979
PsyProtix [Member]
Current assets:
Cash	35	1
Accounts receivable	0	0
Prepaid expenses and other current assets	0	66
Total current assets	35	67
Long term notes receivable - related parties, net	97	109
Other assets	0	0
Total assets	132	176
Current liabilities:
Accounts payable	0	33
Accrued liabilities	26	46
Other current liabilities	0	1
Total current liabilities	26	80
Total liabilities	26	80
Psyber [Member]
Current assets:
Cash		683
Accounts receivable		0
Prepaid expenses and other current assets		0
Total current assets		683
Long term notes receivable - related parties, net		0
Other assets		353
Total assets		1,036
Current liabilities:
Accounts payable		10
Accrued liabilities		37
Other current liabilities		1
Total current liabilities		48
Total liabilities		48
InnarisBio [Member]
Current assets:
Cash	326	719
Accounts receivable	0	0
Prepaid expenses and other current assets	878	13
Total current assets	1,204	732
Long term notes receivable - related parties, net	0	0
Other assets	16	0
Total assets	1,220	732
Current liabilities:
Accounts payable	0	3
Accrued liabilities	10	158
Other current liabilities	1	1
Total current liabilities	11	162
Total liabilities	$ 11	162
TryptageniX Inc. [Member]
Current assets:
Cash		513
Accounts receivable		0
Prepaid expenses and other current assets		2,850
Total current assets		3,363
Long term notes receivable - related parties, net		0
Other assets		0
Total assets		3,363
Current liabilities:
Accounts payable		0
Accrued liabilities		154
Other current liabilities		0
Total current liabilities		154
Total liabilities		$ 154

Variable Interest Entities an_6

Variable Interest Entities and a Voting Interest Entity - Schedule of Non Controlling Interest Recognized to Its Consolidated VIEs Roll Forward (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Noncontrolling Interest [Line Items]
Opening balance	$ 5,026	$ 9,051
Issuance of noncontrolling interests	0	957
Net income (loss) attributable to noncontrolling interests—common		(357)
Net income (loss) attributable to noncontrolling interests - preferred	(3,673)	(4,675)
Comprehensive income (loss) attributable to noncontrolling interests	1	50
Closing balance	1,354	5,026
Perception [Member]
Noncontrolling Interest [Line Items]
Opening balance	1,731	5,232
Issuance of noncontrolling interests	0	0
Net income (loss) attributable to noncontrolling interests—common		0
Net income (loss) attributable to noncontrolling interests - preferred	(1,302)	(3,551)
Comprehensive income (loss) attributable to noncontrolling interests	(1)	50
Closing balance	428	1,731
Recognify [Member]
Noncontrolling Interest [Line Items]
Opening balance	2,844	3,819
Issuance of noncontrolling interests	0	0
Net income (loss) attributable to noncontrolling interests—common		0
Net income (loss) attributable to noncontrolling interests - preferred	(2,287)	(975)
Comprehensive income (loss) attributable to noncontrolling interests	0	0
Closing balance	557	2,844
Kures [Member]
Noncontrolling Interest [Line Items]
Opening balance	451	0
Issuance of noncontrolling interests	0	957
Net income (loss) attributable to noncontrolling interests—common		(357)
Net income (loss) attributable to noncontrolling interests - preferred	(84)	(149)
Comprehensive income (loss) attributable to noncontrolling interests	2	0
Closing balance	$ 369	$ 451

Equity Method Investments and_3

Equity Method Investments and Other Investments - Summary of Equity Method Investments (Detail) - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2023		Aug. 31, 2023	Dec. 31, 2022	Dec. 31, 2020
Schedule of Equity Method Investments [Line Items]
Equity method investments		$ 0			$ 0
Innoplexus AG [Member]
Schedule of Equity Method Investments [Line Items]
Equity Method Investment, Description of Principal Activities		August 2018
Equity method investments		$ 0			$ 0
Equity Method Investment, Ownership Percentage		35%			35%	35%
COMPASS Pathways Plc Two [Member]
Schedule of Equity Method Investments [Line Items]
Equity Method Investment, Description of Principal Activities		December 2018
Equity method investments		$ 0			$ 0
Equity Method Investment, Ownership Percentage		15.40%	[1]	15.40%	22.40%
GABA Therapeutics Inc [Member]
Schedule of Equity Method Investments [Line Items]
Equity Method Investment, Description of Principal Activities		November 2020
Equity method investments		$ 0			$ 0	$ 0
Equity Method Investment, Ownership Percentage	[2]	3.60%			7.50%
[1] The Company accounted for its investment in COMPASS Pathways plc ("COMPASS") under the equity method until August 18, 2023, the closing date of COMPASS's dilutive financing round described below in Other investments held at fair value. The Company is deemed to have significant influence over GABA Therapeutics, Inc ("GABA") through its total ownership interest in GABA, including the Company’s investment in GABA’s preferred stock, described below in Other investments. The Company’s total ownership interest, considering both preferred and common stock is 54.1%

Equity Method Investments and_4

Equity Method Investments and Other Investments - Summary of Equity Method Investments and Other Investments (Detail) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Investment [Line Items]
Other Long-term Investments	$ 1,838	$ 6,755
DemeRx NB Inc [Member]
Investment [Line Items]
Other Long-term Investments	0	1,024
Juvenescence Limited [Member]
Investment [Line Items]
Other Long-term Investments	0	344
GABA Therapeutics Inc [Member]
Investment [Line Items]
Other Long-term Investments	$ 1,838	$ 5,387

Equity Method Investments and_5

Equity Method Investments and Other Investments - Summary of financial data for investments (Detail) - USD ($) $ in Thousands		Dec. 31, 2023	Dec. 31, 2022
Shedule Of Equity Method Investment Summarized Balance Sheet [Line Items]
Current assets		$ 185,592	$ 287,145
Total assets		293,478	305,441
Current liabilities		20,120	19,897
Total liabilities		49,162	39,675
COMPASS [Member]
Shedule Of Equity Method Investment Summarized Balance Sheet [Line Items]
Current assets	[1]		191,651
Non-current assets	[1]		5,643
Total assets	[1]		197,294
Current liabilities	[1]		15,596
Non-current liabilities	[1]		418
Total liabilities	[1]		16,014
GABA [member]
Shedule Of Equity Method Investment Summarized Balance Sheet [Line Items]
Current assets		1,720	3,933
Non-current assets		0	0
Total assets		1,720	3,933
Current liabilities		1,546	1,542
Non-current liabilities		0	0
Total liabilities		$ 1,546	$ 1,542
[1] As of August 18, 2023, the Company determined that it no longer had significant influence. At this remeasurement date, the Company qualified for and elected to account for its investment in COMPASS under the fair value option. Summarized financial information is as of and for the nine month period ending September 30, 2023 as this information is not readily available as of August 18, 2023 and the Company has no practical way to estimate otherwise.

Equity Method Investments and_6

Equity Method Investments and Other Investments - Summary of Statements of operations (Detail) - USD ($) $ in Thousands		9 Months Ended	12 Months Ended
		Sep. 30, 2023	Dec. 31, 2023	Dec. 31, 2022
Shedule Of Equity Method Investment Summarized Statement Of Operations [Line Items]
Revenue			$ 314	$ 233
Net loss			(43,895)	(157,417)
COMPASS [Member]
Shedule Of Equity Method Investment Summarized Statement Of Operations [Line Items]
Revenue	[1]	$ 0		0
Loss from continuing operations	[1]	(98,514)		(110,403)
Net loss	[1]	$ 85,932		(91,505)
GABA [member]
Shedule Of Equity Method Investment Summarized Statement Of Operations [Line Items]
Revenue			0	0
Loss from continuing operations			(3,593)	(5,867)
Net loss			$ (3,593)	$ (5,867)
[1] As of August 18, 2023, the Company determined that it no longer had significant influence. At this remeasurement date, the Company qualified for and elected to account for its investment in COMPASS under the fair value option. Summarized financial information is as of and for the nine month period ending September 30, 2023 as this information is not readily available as of August 18, 2023 and the Company has no practical way to estimate otherwise.

Equity Method Investments and_7

Equity Method Investments and Other Investments - Additional information (Detail) - USD ($) $ / shares in Units, $ in Thousands

1 Months Ended

12 Months Ended

Nov. 30, 2023

Aug. 30, 2023

May 31, 2021

May 15, 2021

Apr. 13, 2021

Nov. 30, 2023

Oct. 31, 2023

Feb. 28, 2021

Aug. 31, 2019

Dec. 31, 2023

Dec. 31, 2022

Dec. 31, 2019

Aug. 31, 2023

Jun. 30, 2022

Dec. 31, 2021

Dec. 31, 2020

Cash and Cash Equivalents [Line Items]

Net income (loss)

$ (43,895)

$ (157,417)

Change in fair value of assets and liabilities, net

(5,500)

(300)

Impairment of other investments

(1,011)

0

Other Investments held at fair value

$ 200

$ 200

100

7,200

Equity method investment, Investee shares sold

9,600

Other income (expense)

3,671

5,032

Research & development expense

$ 2,000

2,800

Equity method investment, Shares transaction date

Dec. 31, 2026

Secured debt

$ 2,400

2,400

Equity method investments

0

0

Losses from investments in equity method investees, net of tax

(3,593)

(16,006)

COMPASS Pathways Plc [Member]

Cash and Cash Equivalents [Line Items]

Net income (loss)

$ 10,100

Market value, ownership

83,700

Change in fair value of assets and liabilities, net

$ (81,900)

GABA INC [Member]

Cash and Cash Equivalents [Line Items]

Business Acquisition, Percentage of Voting Interests

50%

Percentage of voting interest acquired

50%

Common Stock [Member]

Cash and Cash Equivalents [Line Items]

Shares, Outstanding

166,026,396

165,935,914

160,677,001

Warrant [Member]

Cash and Cash Equivalents [Line Items]

Other Investments held at fair value

$ 700

Call Option [Member]

Cash and Cash Equivalents [Line Items]

Change in fair value of assets and liabilities, net

(100)

Other Investments held at fair value

5,100

5,100

$ 5,200

Convertible debenture units

7,401

Call Option [Member] | Convertible Notes Receivable [Member]

Cash and Cash Equivalents [Line Items]

Debt conversion price

$ 1,000

Call Option [Member] | Common Stock [Member] | 2021 Purchase Right [Member]

Cash and Cash Equivalents [Line Items]

Shares, Outstanding

100,000,000

Investment owned number of shares

100,000,000

Call Option [Member] | Common Stock [Member] | Maximum [Member] | 2021 Purchase Right [Member]

Cash and Cash Equivalents [Line Items]

Shares, Outstanding

130,000,000

Call Option [Member] | Common Stock [Member] | Minimum [Member]

Cash and Cash Equivalents [Line Items]

Shares, Outstanding

100,000,000

Call Option [Member] | Common Stock [Member] | Minimum [Member] | 2021 Purchase Right [Member]

Cash and Cash Equivalents [Line Items]

Shares, Outstanding

100,000,000

Call Option [Member] | Warrant [Member]

Cash and Cash Equivalents [Line Items]

Initial warrants

5,405

Innoplexus AG [Member]

Cash and Cash Equivalents [Line Items]

Equity method investment, ownership percentage

35%

35%

35%

Equity method investments

$ 0

$ 0

Innoplexus AG [Member] | Innoplexus SPA [Member]

Cash and Cash Equivalents [Line Items]

Equity method investment, Investee shares sold

$ 2,400

Equity method investment, Proceeds

$ 22,300

COMPASS Pathways Plc Two [Member]

Cash and Cash Equivalents [Line Items]

Equity method investment, ownership percentage

15.40%

[1]

22.40%

15.40%

Equity method investments

$ 0

$ 0

GABA Therapeutics Inc [Member]

Cash and Cash Equivalents [Line Items]

Equity method investment, ownership percentage

[2]

3.60%

7.50%

Equity method investments

$ 0

$ 0

$ 0

Losses from investments in equity method investees, net of tax

3,600

5,900

GABA Therapeutics Inc [Member] | Additional Shares [Member]

Cash and Cash Equivalents [Line Items]

Payments to acquire investments

2,000

GABA Therapeutics Inc [Member] | Amended GABA PSPA | Preferred Stock [Member] | Series A Preferred Stock [Member]

Cash and Cash Equivalents [Line Items]

Equity method investment, ownership percentage

20%

Payments to acquire investments

$ 600

$ 5,500

GABA Therapeutics Inc [Member] | Amended GABA PSPA | Common Stock [Member] | Series A Preferred Stock [Member]

Cash and Cash Equivalents [Line Items]

Equity method investments

900

Payments to acquire investments

600

$ 5,000

$ 5,000

10,000

GABA Therapeutics Inc [Member] | Amended GABA PSPA | Additional Shares [Member] | Series A Preferred Stock [Member]

Cash and Cash Equivalents [Line Items]

Equity method investments

1,500

GABA Therapeutics Inc [Member] | Omnibus Amendment Agreement [Member]

Cash and Cash Equivalents [Line Items]

Payments to acquire investments

1,800

DemeRx NB Options [Member]

Cash and Cash Equivalents [Line Items]

Impairment of other investments

$ (1,000)

DemeRx NB Options [Member] | Series A Preferred Stock [Member]

Cash and Cash Equivalents [Line Items]

Equity method investment, ownership percentage

20%

Payments to acquire investments

$ 1,000

Juvenescence Limited [Member]

Cash and Cash Equivalents [Line Items]

Other income (expense)

100

IntelGenx [Member]

Cash and Cash Equivalents [Line Items]

Change in fair value of assets and liabilities, net

0

0

Deferred purchase credit

$ 5,100

Investment measured at fair value as per fair value option

$ 12,300

IntelGenx [Member] | Securities Purchase Agreement [Member]

Cash and Cash Equivalents [Line Items]

Business Acquisition, Percentage of Voting Interests

25%

Percentage of voting interest acquired

25%

Number of years determining units purchase

3 years

Percentage of premium to market price

20%

Percentage of the volume weighted average price of the common share

20%

IntelGenx [Member] | Convertible Debenture [Member]

Cash and Cash Equivalents [Line Items]

Investment measured at fair value as per fair value option

800

800

IntelGenx [Member] | Convertible Debenture [Member] | 2023 Subsequent Notes [Member]

Cash and Cash Equivalents [Line Items]

Investment measured at fair value as per fair value option

600

600

IntelGenx [Member] | Common Stock [Member]

Cash and Cash Equivalents [Line Items]

Investment measured at fair value as per fair value option

$ 3,000

IntelGenx [Member] | Warrant [Member]

Cash and Cash Equivalents [Line Items]

Common shares

$ 12,300

Investment measured at fair value as per fair value option

1,200

IntelGenx [Member] | Warrant [Member] | Securities Purchase Agreement [Member]

Cash and Cash Equivalents [Line Items]

Business acquisition, Share price

$ 0.35

Number of years determining units purchase

3 years

IntelGenx [Member] | Warrant [Member] | Convertible Debenture [Member] | 2023 Subsequent Warrants [Member]

Cash and Cash Equivalents [Line Items]

Investment measured at fair value as per fair value option

200

$ 200

IntelGenx [Member] | Unit [Member]

Cash and Cash Equivalents [Line Items]

Investment measured at fair value as per fair value option

$ 8,200

IntelGenx [Member] | Subscription Agreement [Member] | 2023 Warrant [Member]

Cash and Cash Equivalents [Line Items]

Equity method investment, Shares transaction date

Aug. 31, 2026

IntelGenx [Member] | Subscription Agreement [Member] | Convertible Notes Receivable [Member]

Cash and Cash Equivalents [Line Items]

Interes rate

12%

Debt conversion price

$ 0.185

Investment measured at fair value as per fair value option

$ 1,000

IntelGenx [Member] | Subscription Agreement [Member] | Convertible Debenture [Member]

Cash and Cash Equivalents [Line Items]

Debt conversion price

$ 1,000

Secured debt

$ 2,200

Convertible debenture units

2,220

IntelGenx [Member] | Subscription Agreement [Member] | Warrant [Member]

Cash and Cash Equivalents [Line Items]

Initial warrants

5,405

IntelGenx [Member] | Subscription Agreement [Member] | Warrant [Member] | 2023 Warrant [Member]

Cash and Cash Equivalents [Line Items]

Initial warrants

5,405

Exercise price, warrants

$ 0.26

IntelGenx [Member] | Subscription Agreement [Member] | Unit [Member] | Convertible Debenture [Member]

Cash and Cash Equivalents [Line Items]

Conversion of units, debentures, Value

$ 750,000

$ 750,000

Convertible debenture units

750

IntelGenx [Member] | Call Option [Member] | Convertible Notes Receivable [Member]

Cash and Cash Equivalents [Line Items]

Investment measured at fair value as per fair value option

$ 500

IntelGenx [Member] | Call Option [Member] | Convertible Debenture [Member]

Cash and Cash Equivalents [Line Items]

Investment measured at fair value as per fair value option

2,200

IntelGenx [Member] | Call Option [Member] | Warrant [Member] | Convertible Debenture [Member] | 2023 Warrant [Member]

Cash and Cash Equivalents [Line Items]

Investment measured at fair value as per fair value option

700

IntelGenx [Member] | Strategic Development Agreement [Member]

Cash and Cash Equivalents [Line Items]

Credit received

2,500

Research & development expense

$ 700

$ 500

Percentage of the funds to be used for research and development purpose

20%

[1] The Company accounted for its investment in COMPASS Pathways plc ("COMPASS") under the equity method until August 18, 2023, the closing date of COMPASS's dilutive financing round described below in Other investments held at fair value. The Company is deemed to have significant influence over GABA Therapeutics, Inc ("GABA") through its total ownership interest in GABA, including the Company’s investment in GABA’s preferred stock, described below in Other investments. The Company’s total ownership interest, considering both preferred and common stock is 54.1%

Equity Method Investments and_8

Equity Method Investments and Other Investments - Securities Purchase Agreement - Additional information (Detail) - USD ($) $ / shares in Units, $ in Millions		12 Months Ended
	May 31, 2021	Dec. 31, 2023	Dec. 31, 2022
Cash and Cash Equivalents [Line Items]
Fair value option gain loss		$ 5.5	$ 0.3
IntelGenx [Member]
Cash and Cash Equivalents [Line Items]
Investment measured at fair value as per fair value option		12.3
Fair value option gain loss		$ 0	$ 0
IntelGenx [Member] | Securities Purchase Agreement [Member]
Cash and Cash Equivalents [Line Items]
Number of years determining units purchase		3 years
Percentage of the volume weighted average price of the common share		20%
Percentage of premium to market price		20%
Percentage of voting interest acquired		25%
IntelGenx [Member] | Tranche 1 | Securities Purchase Agreement [Member]
Cash and Cash Equivalents [Line Items]
Number of share purchased during period		74,600,000
Business acquisition, Share price		$ 0.331
Number of months determining unit price		12 months
IntelGenx [Member] | Tranche 2 | Securities Purchase Agreement [Member]
Cash and Cash Equivalents [Line Items]
Number of share purchased during period		74,600,000
Business acquisition, Share price		$ 0.5
Number of months determining unit price		12 months
IntelGenx [Member] | Tranche 3 | Securities Purchase Agreement [Member]
Cash and Cash Equivalents [Line Items]
Number of share purchased during period		44,000,000
Business acquisition, Share price		$ 0.75
Number of months determining unit price		12 months
IntelGenx [Member] | Warrant [Member]
Cash and Cash Equivalents [Line Items]
Common shares	$ 12.3
Investment measured at fair value as per fair value option		$ 1.2
IntelGenx [Member] | Warrant [Member] | Securities Purchase Agreement [Member]
Cash and Cash Equivalents [Line Items]
Number of years determining units purchase	3 years
Business acquisition, Share price	$ 0.35
IntelGenx [Member] | Common Stock [Member]
Cash and Cash Equivalents [Line Items]
Investment measured at fair value as per fair value option		3
IntelGenx [Member] | Unit [Member]
Cash and Cash Equivalents [Line Items]
Investment measured at fair value as per fair value option		$ 8.2

Notes Receivable - Additional I

Notes Receivable - Additional Information (Detail)

1 Months Ended

12 Months Ended

Nov. 30, 2023 USD ($)

Aug. 30, 2023 USD ($) shares

Sep. 14, 2021 USD ($)

Jan. 03, 2020 USD ($) $ / shares

Nov. 30, 2023 USD ($)

Dec. 31, 2023 USD ($)

Dec. 31, 2022 USD ($)

Dec. 31, 2021

Dec. 31, 2023 € / shares

Dec. 31, 2023 USD ($) $ / shares shares

Sep. 30, 2023 USD ($)

Aug. 31, 2023

Jan. 01, 2023 USD ($)

Dec. 31, 2022 € / shares

Dec. 31, 2022 USD ($) $ / shares

Mar. 08, 2021 USD ($)

Notes Receivable [Line Items]

Equity method investment, Shares transaction date

Dec. 31, 2026

Change in fair value of assets and liabilities, net

$ (5,500,000)

$ (300,000)

Loans and lease receivable, Outstanding

$ 0

$ 1,100,000

Interest expense

2,656,000

923,000

Other Investments held at fair value

$ 200,000

$ 200,000

100,000

7,200,000

Convertible promissory notes issued

15,000,000

$ 15,000,000

Secured debt

2,400,000

2,400,000

Short-term notes payable

$ 109,200,000

Debt Instrument, face amount inclusive other payments

$ 1,000,000

Issuance of common stock shares par value | (per share)

$ 0.0001

€ 0.10

$ 0.12

€ 0.10

$ 0.12

IntelGenx [Member]

Notes Receivable [Line Items]

Change in fair value of assets and liabilities, net

(300,000)

Investment measured at fair value as per fair value option

800,000

800,000

IntelGenx Corp [Member]

Notes Receivable [Line Items]

Investment measured at fair value as per fair value option

$ 2,200,000

Subscription Agreement [Member] | IntelGenx [Member]

Notes Receivable [Line Items]

Other Investments held at fair value

500,000

Common Stock [Member] | IntelGenx Corp [Member]

Notes Receivable [Line Items]

Investment measured at fair value as per fair value option

500,000

Warrant [Member]

Notes Receivable [Line Items]

Other Investments held at fair value

700,000

Warrant [Member] | IntelGenx Corp [Member]

Notes Receivable [Line Items]

Investment measured at fair value as per fair value option

$ 700,000

Convertible Debenture [Member] | IntelGenx [Member]

Notes Receivable [Line Items]

Investment measured at fair value as per fair value option

600,000

600,000

Convertible Debenture [Member] | Subscription Agreement [Member] | IntelGenx Corp [Member]

Notes Receivable [Line Items]

Common share purchase warrants | shares

5,405

Investment measured at fair value as per fair value option

$ 1,000

Convertible debenture units | shares

2,220

Secured debt

$ 2,200,000

Convertible Debenture [Member] | Unit [Member] | Subscription Agreement [Member] | IntelGenx [Member]

Notes Receivable [Line Items]

Conversion of units, debentures, Value

750,000

Convertible Debenture [Member] | Warrant [Member] | IntelGenx [Member]

Notes Receivable [Line Items]

Investment measured at fair value as per fair value option

200,000

200,000

2023 Initial Notes [Member] | IntelGenx [Member]

Notes Receivable [Line Items]

Change in fair value of assets and liabilities, net

$ (300,000)

2023 Initial Notes [Member] | Subscription Agreement [Member] | IntelGenx [Member]

Notes Receivable [Line Items]

Other Investments held at fair value

$ 800,000

March Term Loan Receivable [Member] | IntelGenx Corp [Member]

Notes Receivable [Line Items]

Receivable, Face amount

$ 2,000,000

Aggregate principal amount

2,000,000

Loans receivable, Fixed interest rate

8%

2023 Term Loan Note [Member] | IntelGenx Corp [Member]

Notes Receivable [Line Items]

Receivable, Face amount

500,000

Aggregate principal amount

500,000

Loans receivable, Fixed interest rate

14%

Interest income

$ 500,000

Additional Term Loan Receivable [Member] | IntelGenx Corp [Member]

Notes Receivable [Line Items]

Receivable, Face amount

500,000

Aggregate principal amount

$ 500,000

Additional Term Loan Receivable [Member] | Amended and Restated Loan Agreement [Member] | IntelGenx Corp [Member]

Notes Receivable [Line Items]

Receivable, Face amount

$ 3,000,000

Aggregate principal amount

3,000,000

Term Loan Receivable [Member]

Notes Receivable [Line Items]

Accumulated deficit net of tax

$ 400,000

Term Loan Receivable [Member] | IntelGenx Corp [Member]

Notes Receivable [Line Items]

Receivable, Face amount

8,500,000

8,500,000

8,500,000

$ 5,500,000

Proceeds from changes in fair value

100,000

300,000

Aggregate principal amount

8,500,000

8,500,000

8,500,000

5,500,000

Long-Term Debt, Fair Value

9,300,000

9,300,000

$ 8,600,000

6,100,000

Interest income

$ 600,000

$ 400,000

Conversion Price

$ 0.185

Accrued interest

1,200,000

1,200,000

$ 600,000

Allowance for credit losses

400,000

400,000

Notes Receivable, Fair Value Disclosure

$ 9,200,000

$ 9,200,000

Term Loan Receivable [Member] | Amended and Restated Loan Agreement [Member]

Notes Receivable [Line Items]

Loan agreement

6,000,000

Term Loan Receivable [Member] | Amended and Restated Loan Agreement [Member] | IntelGenx Corp [Member]

Notes Receivable [Line Items]

Receivable, Face amount

6,000,000

Aggregate principal amount

$ 6,000,000

Term Loan Receivable [Member] | Minimum [Member] | Amended and Restated Loan Agreement [Member] | IntelGenx Corp [Member]

Notes Receivable [Line Items]

Term loan maturity date

Jan. 05, 2024

Term Loan Receivable [Member] | Maximum [Member] | Amended and Restated Loan Agreement [Member] | IntelGenx Corp [Member]

Notes Receivable [Line Items]

Term loan maturity date

Jan. 05, 2025

Loans Receivable [Member]

Notes Receivable [Line Items]

Receivables, Maturity description

In September 2021, the Company entered into an amended and restated loan agreement which, among other things, increased the principal amount of loans available to IntelGenx by $6.0 million, for a total of up to $8.5 million. The additional $6.0 million loan amount was funded via two separate $3.0 million tranches. The first $3.0 million tranche was funded in January 2022

Promissory Note Agreement [Member]

Notes Receivable [Line Items]

Debt Instrument, face amount inclusive other payments

$ 1,000,000

DemeRx Note [Member]

Notes Receivable [Line Items]

Receivables, Maturity terms

5 years

Fair Value Measurement - Summar

Fair Value Measurement - Summary of Fair Value Measurement on Recurring Basis (Detail) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Liabilities:
Contingent consideration liability	$ 1,637	$ 0
Fair Value, Recurring [Member]
Cash equivalents:
Cash & Money market funds	56	72,334
Other investment held at fair value	89,825
Assets fair value	210,306	154,830
Liabilities:
Contingent consideration liability—related parties	620	953
Contingent consideration liability	1,637
2018 convertible promissory note conversion option	2,385
Liability fair value	4,643	953
Fair Value, Recurring [Member] | U.S. Treasuries [Member]
Cash equivalents:
Fair value of debt securities	67,119
Fair Value, Recurring [Member] | Commercial Paper [Member]
Cash equivalents:
Fair value of debt securities		5,958
Fair Value, Recurring [Member] | Corporate Notes/Bonds [Member]
Cash equivalents:
Fair value of debt securities	5,007	17,719
Fair Value, Recurring [Member] | US Government Agencies [Member]
Cash equivalents:
Fair value of debt securities	37,097	58,819
Fair Value, Recurring [Member] | Convertible Notes Receivable - Related Party [Member]
Cash equivalents:
Other investment held at fair value	11,202
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Cash equivalents:
Cash & Money market funds	56	72,334
Other investment held at fair value	83,701
Assets fair value	83,757	72,334
Liabilities:
Contingent consideration liability—related parties	0	0
Contingent consideration liability	0
2018 convertible promissory note conversion option	0
Liability fair value	0	0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | U.S. Treasuries [Member]
Cash equivalents:
Fair value of debt securities	0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | Commercial Paper [Member]
Cash equivalents:
Fair value of debt securities		0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | Corporate Notes/Bonds [Member]
Cash equivalents:
Fair value of debt securities	0	0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | US Government Agencies [Member]
Cash equivalents:
Fair value of debt securities	0	0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | Convertible Notes Receivable - Related Party [Member]
Cash equivalents:
Other investment held at fair value	0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Cash equivalents:
Cash & Money market funds	0	0
Other investment held at fair value	0
Assets fair value	109,223	82,496
Liabilities:
Contingent consideration liability—related parties	0	0
Contingent consideration liability	0
2018 convertible promissory note conversion option	0
Liability fair value	0	0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | U.S. Treasuries [Member]
Cash equivalents:
Fair value of debt securities	67,119
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | Commercial Paper [Member]
Cash equivalents:
Fair value of debt securities		5,958
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | Corporate Notes/Bonds [Member]
Cash equivalents:
Fair value of debt securities	5,007	17,719
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | US Government Agencies [Member]
Cash equivalents:
Fair value of debt securities	37,097	58,819
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | Convertible Notes Receivable - Related Party [Member]
Cash equivalents:
Other investment held at fair value	0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Cash equivalents:
Cash & Money market funds	0	0
Other investment held at fair value	6,124
Assets fair value	17,326	0
Liabilities:
Contingent consideration liability—related parties	620	953
Contingent consideration liability	1,637
2018 convertible promissory note conversion option	2,385
Liability fair value	4,643	953
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member] | U.S. Treasuries [Member]
Cash equivalents:
Fair value of debt securities	0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member] | Commercial Paper [Member]
Cash equivalents:
Fair value of debt securities		0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member] | Corporate Notes/Bonds [Member]
Cash equivalents:
Fair value of debt securities	0	0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member] | US Government Agencies [Member]
Cash equivalents:
Fair value of debt securities	0	$ 0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member] | Convertible Notes Receivable - Related Party [Member]
Cash equivalents:
Other investment held at fair value	$ 11,202

Fair Value Measurement - Summ_2

Fair Value Measurement - Summary of Fair Value Measurement Inputs and Valuation Techniques (Detail) - Contingent Consideration Liability - Related Parties [Member]	Dec. 31, 2023	Dec. 31, 2022
Measurement Input, Discount Rate [Member] | Valuation Technique, Discounted Cash Flow [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Contingent Consideration, Liability, Measurement Input	0.135	0.131
Measurement Input, Discount Rate [Member] | Valuation Technique, Discounted Cash Flow [Member] | DemeRx [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Contingent Consideration, Liability, Measurement Input	0.139
Measurement Input, Probability of the Milestone [Member] | Valuation Technique, Discounted Cash Flow [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Contingent Consideration, Liability, Measurement Input	0.28
Measurement Input, Probability of the Milestone [Member] | Valuation Technique, Discounted Cash Flow [Member] | Minimum [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Contingent Consideration, Liability, Measurement Input		0.10
Measurement Input, Probability of the Milestone [Member] | Valuation Technique, Discounted Cash Flow [Member] | Minimum [Member] | DemeRx [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Contingent Consideration, Liability, Measurement Input	0.20
Measurement Input, Probability of the Milestone [Member] | Valuation Technique, Discounted Cash Flow [Member] | Maximum [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Contingent Consideration, Liability, Measurement Input		0.21
Measurement Input, Probability of the Milestone [Member] | Valuation Technique, Discounted Cash Flow [Member] | Maximum [Member] | DemeRx [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Contingent Consideration, Liability, Measurement Input	0.25
Measurement Input, Discount Rate for Royalties [Member] | Valuation Technique, Discounted Cash Flow with SBM [Member] | Minimum [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Contingent Consideration, Liability, Measurement Input	0.13	0.20
Measurement Input, Discount Rate for Royalties [Member] | Valuation Technique, Discounted Cash Flow with SBM [Member] | Maximum [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Contingent Consideration, Liability, Measurement Input	0.142	0.211
Measurement Input, Discount Rate for Royalties on Milestones [Member] | Valuation Technique, Discounted Cash Flow with SBM [Member] | Minimum [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Contingent Consideration, Liability, Measurement Input	0.13	0.123
Measurement Input, Discount Rate for Royalties on Milestones [Member] | Valuation Technique, Discounted Cash Flow with SBM [Member] | Maximum [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Contingent Consideration, Liability, Measurement Input	0.142	0.134
Measurement Input, Probability of Success Rate [Member] | Valuation Technique, Discounted Cash Flow with SBM [Member] | Minimum [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Contingent Consideration, Liability, Measurement Input	0.134	0.101
Measurement Input, Probability of Success Rate [Member] | Valuation Technique, Discounted Cash Flow with SBM [Member] | Maximum [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Contingent Consideration, Liability, Measurement Input	0.28	0.21

Fair Value Measurement - Summ_3

Fair Value Measurement - Summary of Fair Value Measurement on Recurring Basis, Unobservable Input Reconciliation (Detail) - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2023	Dec. 31, 2022
IntelGenx Convertible Notes Receivable [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning balance		$ 0
Initial fair value of instrument		10,800
Change in fair value		(116)
Additional contribution		518
Extinguishment of liability		0
Ending balance		11,202	$ 0
IntelGenx Investments Held at Fair Value [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning balance	[1]	0
Initial fair value of instrument	[1]	5,787
Change in fair value	[1]	105
Additional contribution	[1]	232
Extinguishment of liability	[1]	0
Ending balance	[1]	6,124	0
Contingent Consideration Liability - Related Parties [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning balance	[2]	743
Initial fair value of instrument	[2]	0
Change in fair value	[2]	(34)
Additional contribution	[2]	0
Extinguishment of liability	[2]	(89)
Ending balance	[2]	620	743
Contingent Consideration Liability [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning balance	[3]	210
Initial fair value of instrument	[3]	1,329
Change in fair value	[3]	98
Additional contribution	[3]	0
Extinguishment of liability	[3]	0
Ending balance	[3]	1,637	210
Contingent Consideration Liabilities - Related Parties [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning balance		953	2,483
Change in fair value			(1,480)
Extinguishment of liability			(50)
Ending balance			953
2018 Convertible Notes Call Option [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning balance		0
Initial fair value of instrument		1,668
Change in fair value		717
Additional contribution		0
Extinguishment of liability		0
Ending balance		2,385	0
Warrant Liability [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning balance		$ 0	336
Change in fair value			(336)
Extinguishment of liability			0
Ending balance			$ 0
[1] Includes, Initial Warrants, Additional Unit Awards, 2023 Initial Warrants, 2023 Subsequent Warrants, and Call Option Units Includes Perception milestone based contingent consideration liability and InnarisBio milestone and royalty based contingent consideration liability Includes contingent consideration liability related to DemeRx IB Stock Purchase and contingent consideration liability related to the TryptageniX research and development milestone success fee payments and royalties payments

Fair Value Measurement - Additi

Fair Value Measurement - Additional Information (Detail) - USD ($)	1 Months Ended	12 Months Ended
	Oct. 31, 2023	Dec. 31, 2023	Dec. 31, 2022
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Change in fair value of assets and liabilities, net		$ 5,500,000	$ 300,000
Fair value of common stock by applying discount for lack of marketability		5%	5%
Other investments held at fair value		$ 0	$ 0
Volatility		78.60%
ATAI LIFE SCIENCES N.V. [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Loss from change in fair value of the derivative liability		$ 700,000
Initial Warrants [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other investments held at fair value		700,000
2023 Subsequent Units [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other investments held at fair value		200,000
Call Option Units [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other investments held at fair value		5,200,000
DemeRx [Member] | Stock Purchase and Framework Agreement [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business combination, earn-out consideration	$ 8,000,000
Fair value of the contingent milestone and royalty liabilities		1,400,000
COMPASS Pathways Plc [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Change in fair value of assets and liabilities, net		$ 81,900,000
IntelGenx [Member] | Call Option Units [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Discount rate		45.90%
IntelGenx [Member] | 2023 Initial Notes [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Notes receivable, fair value disclosure		$ 1,700,000
Discount rate		45.90%
Volatility		100%
Share price		$ 0.13
IntelGenx [Member] | 2023 Subsequent Notes [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Notes receivable, fair value disclosure		$ 50,000
Discount rate		45.90%
Volatility		100%
Share price		$ 0.13
IntelGenx [Member] | IntelGenx Term Loan [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Discount rate		45.90%
Volatility		100%
Share price		$ 0.13
InnarisBio [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of the contingent milestone and royalty liabilities		$ 0	100,000
TryptageniX [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of the contingent milestone and royalty liabilities		$ 200,000	$ 200,000
Level 3 [Member] | Initial Warrants [Member] | Measurement Input, Value of Underlying [Member] | Neuronasal Inc [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant Liability, Measurement Input Including Discount for Lack of Marketability		0.13	0.13
Level 3 [Member] | Initial Warrants [Member] | Measurement Input, Price Volatility [Member] | Neuronasal Inc [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant Liability, Measurement Input Including Discount for Lack of Marketability		100	100
Level 3 [Member] | IntelGenx [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Long-term debt, fair value		$ 8,600,000
Level 3 [Member] | IntelGenx [Member] | Additional Warrants [Member] | Measurement Input, Value of Underlying [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Alternative Investment, Measurement Input Including Discount for Lack of Marketability		0.13	0.13
Level 3 [Member] | IntelGenx [Member] | Additional Warrants [Member] | Measurement Input, Price Volatility [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant Liability, Measurement Input Including Discount for Lack of Marketability		100	100
Royalty Liabilities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of the contingent milestone and royalty liabilities		$ 600,000	$ 600,000

Prepaid Expenses and Other Cu_3

Prepaid Expenses and Other Current Assets - Summary of Prepaid Expenses and Other Current Assets (Detail) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Prepaid Expense and Other Assets, Current [Abstract]
Prepaid research and development related expenses	$ 1,822	$ 4,626
Tax receivables	1,752	5,631
Prepaid insurance	1,410	2,034
Other	846	1,745
Total	$ 5,830	$ 14,036

Accrued Liabilities - Summary o

Accrued Liabilities - Summary of Accrued Liabilities (Detail) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Accrued Liabilities, Current [Abstract]
Accrued payroll	$ 4,941	$ 5,260
Accrued accounting, legal, and other professional fees	5,468	3,566
Accrued external research and development expenses	3,031	5,550
Other liabilities	1,101	706
Taxes payable	715	2,224
Total	$ 15,256	$ 17,306

Leases (Additional Information)

Leases (Additional Information) (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022	Jan. 01, 2022
Leases [Abstract]
Operating lease right-of-use asset, net	$ 1,223	$ 226	$ 200
Current operating lease liability	$ 275	$ 180	$ 100
Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]	Operating lease right-of-use asset, net	Operating lease right-of-use asset, net	Operating lease right-of-use asset, net
Long-term operating lease liability	$ 990	$ 44	$ 100
Operating Lease, Weighted Average Discount Rate, Percent	12.70%
Operating Lease, Weighted Average Remaining Lease Term	4 years 2 months 12 days

Leases - ROU assets and lease l

Leases - ROU assets and lease liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022	Jan. 01, 2022
Leases [Abstract]
Operating lease right-of-use asset, net	$ 1,223	$ 226	$ 200
Current operating lease liability	$ 275	$ 180	$ 100
Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]	Operating lease right-of-use asset, net	Operating lease right-of-use asset, net	Operating lease right-of-use asset, net
Long-term operating lease liability	$ 990	$ 44	$ 100
Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]	Long-term operating lease liability	Long-term operating lease liability

Leases - lease costs (Details)

Leases - lease costs (Details) - General and Administrative Expense [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Operating Leased Assets [Line Items]
Operating Lease, Cost	$ 663	$ 266
Short-Term Lease, Cost	338	434
Total lease cost	$ 1,001	$ 700

Leases - Future minimum commitm

Leases - Future minimum commitments under all non-cancelable operating leases (Details) $ in Thousands	Dec. 31, 2023 USD ($)
Leases [Abstract]
2024	$ 415
2025	370
2026	370
2027	370
2028	123
Operating Leases, Future Minimum Payments Receivable, Total	1,648
Less: Imputed interest	(383)
Present value of lease liabilities	$ 1,265

Leases - Supplemental cash flow

Leases - Supplemental cash flow information related to the Company's operating leases (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Leases [Abstract]
Operating cash flows from operating leases	$ 440	$ 267
Right-of-use assets obtained in exchange for new operating lease liabilities	$ 1,377	$ 487

Debt - Summary of Convertible P

Debt - Summary of Convertible Promissory Notes (Detail) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Debt Instrument [Line Items]
Unamortized discount and deferred issuance costs	$ (84)	$ (113)

Debt - Additional Information (

Debt - Additional Information (Detail) € / shares in Units, $ / shares in Units, € in Thousands, $ in Thousands

1 Months Ended

12 Months Ended

Jul. 31, 2022 USD ($)

Jul. 31, 2022 EUR (€) € / shares

Nov. 30, 2023 CommonStock $ / shares

Aug. 31, 2022 USD ($)

Nov. 30, 2020 shares

Dec. 31, 2023 USD ($)

Dec. 31, 2022 USD ($) shares

Dec. 31, 2021 USD ($)

Dec. 31, 2021 EUR (€) € / shares

Nov. 30, 2023 EUR (€)

Aug. 31, 2023 USD ($)

May 26, 2023 USD ($)

Oct. 31, 2020 $ / shares

Oct. 31, 2020 EUR (€)

Oct. 31, 2018 USD ($)

Oct. 31, 2018 EUR (€)

Debt Instrument [Line Items]

Convertible promissory notes issued

$ 15,000

$ 15,000

Convertible promissory notes, outstanding

15,047

14,702

Number of debt convertible into common shares | CommonStock

16

Amortization of debt discount

$ 371

131

Maturity Date

Aug. 01, 2026

Proceeds from Divestiture of Businesses, Net of Cash Divested

$ 175,000

Prime Rate Percent

4.55%

Accrued interest payable, percent

8.55%

General and administrative expense

$ 63,582

70,350

Borrowing amount percentage

33%

Hercules Loan Agreement

Debt Instrument [Line Items]

Convertible promissory notes, outstanding

16,200

14,900

Interest expense

$ 400

$ 100

Principal Amount

$ 175,000

Loan agreement description

In addition, the financial covenant under the Loan Agreement requires that beginning on the later of (i) July 1, 2023 and (ii) the date on which the aggregate outstanding amount borrowed under the 2022 Term Loan Facility is equal to or greater than $40.0 million, the Company shall maintain Qualified Cash in an amount no less than the sum of (1) 33% of the outstanding amount under the 2022 Term Loan Facility, and (2) the amount of the Borrowers’ and Subsidiary Guarantors’ accounts payable that have not been paid within 180 days from the invoice date of the relevant account payable, subject to certain exceptions; provided, that the financial covenant shall not apply on any day that the Company's market capitalization is at least $550.0 million measured on a consecutive 10-business day period immediately prior to such date of measurement and tested on a daily basis.

Line Of Credit

$ 40,000

$ 30,000

Market capitalization daily basis

$ 550,000

550,000

Term charge percentage

6.95%

Hercules Loan Agreement | Prepayment occurs on or prior to the first anniversary[Member]

Debt Instrument [Line Items]

Prepayment principal amount percentage

2%

Hercules Loan Agreement | Prepayment Occurs After The First Anniversary And On Or Prior To The Second Anniversary [Member]

Debt Instrument [Line Items]

Prepayment principal amount percentage

1%

Hercules Loan Agreement | Prepayment occurs after the second anniversary [Member]

Debt Instrument [Line Items]

Prepayment principal amount percentage

0.50%

Common Stock [Member]

Debt Instrument [Line Items]

Stock issued during period, convertible share | shares

8,773,056

4,320,000

ATAI LIFE SCIENCES N.V. [Member]

Debt Instrument [Line Items]

Debt conversion price | $ / shares

$ 17

$ 17

Face value of convertible notes | €

€ 1

€ 1

Gain from change in fair value of the derivative liability

$ 700

Gain (loss) from change in fair value of the derivative liability

700

Two Thousand Eighteen Convertible Note Agreement [Member]

Debt Instrument [Line Items]

Convertible promissory notes issued

2,700

Debt conversion price | € / shares

€ 17

€ 17

Debt carrying value

200

$ 400

Long-Term Debt, Fair Value

$ 1,500

$ 13,100

Fair value of ordinary shares

$ 4,600

€ 4,600

€ 5,800

Two Thousand Eighteen Convertible Note Agreement [Member] | Maximum [Member]

Debt Instrument [Line Items]

Convertible promissory notes issued

$ 1,200

€ 1,000

Two Thousand Eighteen Convertible Note Agreement [Member] | Common Stock [Member]

Debt Instrument [Line Items]

Fair value of ordinary shares

$ 6,900

Line of Credit Agreements [Member] | Hercules Loan Agreement

Debt Instrument [Line Items]

Line Of Credit

40,000

Line of Credit Agreements [Member] | Hercules Loan Agreement | Tranche 1B

Debt Instrument [Line Items]

Term loan advance

10,000

Line of Credit Agreements [Member] | Hercules Loan Agreement | Tranche 1C

Debt Instrument [Line Items]

Term loan advance

15,000

Line of Credit Agreements [Member] | Hercules Loan Agreement | Tranche 2

Debt Instrument [Line Items]

Term loan advance

15,000

Line of Credit Agreements [Member] | Hercules Loan Agreement | Tranche One D

Debt Instrument [Line Items]

Term loan advance

$ 20,000

Debt - Schedule of Outstanding

Debt - Schedule of Outstanding Debt Obligations (Detail) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Debt Disclosure [Abstract]
Principal amount	$ 15,000	$ 15,000
End of the term charge	1,042	1,042
Less: unamortized issuance discount	(204)	(274)
Less: unamortized issuance costs	(84)	(113)
Less: unamortized end of term charge	(707)	(952)
Net carrying amount	15,047	14,702
Less: current maturities	0	0
Long-term Debt, Total	$ 15,047	$ 14,702

Debt- Summary of Grant Date Fai

Debt- Summary of Grant Date Fair Value (Details)	12 Months Ended
	Dec. 31, 2023
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Volatility	78.60%

Common Stock - Additional Infor

Common Stock - Additional Information (Detail) $ / shares in Units, $ in Millions		1 Months Ended			2 Months Ended	12 Months Ended
	Jun. 22, 2021 USD ($) $ / shares shares	Mar. 31, 2021 USD ($)	Jan. 31, 2021 USD ($) shares	Nov. 30, 2020 USD ($) $ / shares shares	Dec. 31, 2020 USD ($)	Dec. 31, 2023 shares	Dec. 31, 2022 shares	Mar. 31, 2021 € / shares shares	Mar. 31, 2021 $ / shares shares	Dec. 31, 2020 € / shares shares	Dec. 31, 2020 $ / shares shares
Class of Stock [Line Items]
Common stock, shares, issued | shares						166,026,396	165,935,914
Sale of stock issue price per share | (per share)										€ 4.69	$ 5.56
Issuance costs		$ 4.9
Common stock issuance price, cash		$ 152.2
Common Stock, Value, Outstanding				$ 32.2
Proceeds from issuance of IPO					$ 77.2
IPO [Member]
Class of Stock [Line Items]
Underwriting discount	$ 18.1
Common Stock [Member]
Class of Stock [Line Items]
Common stock, shares, issued | shares								13,419,360	13,419,360	14,933,344	14,933,344
Sale of stock issue price per share | (per share)				$ 5.56				€ 9.69	$ 11.71	€ 0.1
Stock issued during period, Shares | shares						0
Stock issued during period, convertible share | shares				8,773,056			4,320,000
Class A Common Shares [Member]
Class of Stock [Line Items]
Stock issued during period, Shares | shares	2,250,000
Class A Common Shares [Member] | IPO [Member]
Class of Stock [Line Items]
Sale of stock issue price per share | $ / shares	$ 15
Stock issued during period, Shares | shares	17,250,000
Proceeds from issuance of IPO	$ 231.6
Offering costs	$ 9
Apeiron [Member]
Class of Stock [Line Items]
Common stock, shares, issued | shares			2,133,328
Issuance costs					$ 5.2
Common stock issuance price, cash			$ 12.2

Stock-Based Compensation - Summ

Stock-Based Compensation - Summary of share based Payment Arrangement Option Activity (Detail) - Service And Performance Based Options [Member] - Two Thousand And Twenty Incentive Plan [Member] - USD ($) $ / shares in Units, $ in Thousands		12 Months Ended
		Dec. 31, 2023		Dec. 31, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of options, Beginning		34,880,603
Number of Options, Granted	[1]	10,425,028
Exercised		(74,562)
Number of options, Cancelled or forfeited		(6,164,615)
Number of options, End		39,066,454	[2]	34,880,603
Number of options, Options exercisable		22,314,503
Weighted-Average Exercise Price, Beginning		$ 5.98
Weighted-Average Exercise Price, Granted		1.29
Weighted-Average Exercise Price, Exercised		2.44
Weighted-Average Exercise Price, Cancelled or forfeited		5.77
Weighted-Average Exercise Price, Outstanding		4.62		$ 5.98
Weighted-Average Exercise Price, Options exercisable		$ 5.40
Weighted-Average Remaining Contractual Term (Years)		5 years 6 months 21 days		5 years 8 months 15 days
Weighted-Average Remaining Contractual Term (Years), Options exercisable		3 years 8 months 1 day
Aggregate Intrinsic Value, Outstanding		$ 6,294		$ 10,647
Aggregate Intrinsic Value, Options exercisable		$ 4,410
[1] Includes (a) 9,835,328 stock options that will vest over a four-year service period (b) 452,700 stock options that will vest over a one-year service period and (c) 137,000 stock options that will vest over a two-year service period Includes 16,751,951 outstanding unvested stock options; (a) 15,138,297 that will continue to vest over a one to four-year service period, (b) 992,654 that will continue to vest over a three to four-year service period and upon the satisfaction of specified performance-based vesting conditions, (c) 137,000 stock options that will continue to vest over a two-year service period, (d) 100,000 stock options that will continue to vest over a two-year service period and upon the satisfaction of specified market-based conditions tied to price of the Company's publicly traded shares, and (e) 384,000 stock options that will vest on the one-year anniversary of the date of grant.

Stock-Based Compensation - Su_2

Stock-Based Compensation - Summary of vested and non vested option outstanding (Parenthetical) (Details)	12 Months Ended
	Dec. 31, 2023 shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of options outstanding, including both vested and non-vested options.	16,751,951
Share based payment arrangement, Options expected to vest outstanding	100,000
One to four year service period [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of options outstanding, including both vested and non-vested options.	15,138,297
One Year Service Period[Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share based payment arrangement, Options expected to vest outstanding	384,000
Two Year Service Period [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share based payment arrangement, Options expected to vest outstanding	137,000
Three To Four Year Service Period [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of options outstanding, including both vested and non-vested options.	992,654
Twenty Twenty Incentive Plan [Member] | One to four year service period [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	9,835,328
Twenty Twenty Incentive Plan [Member] | One Year Service Period[Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	452,700
Twenty Twenty Incentive Plan [Member] | Two Year Service Period [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	137,000

Stock-Based Compensation - Sche

Stock-Based Compensation - Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions (Detail)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Weighted average expected stock price volatility	78.60%
Service And Performance Based Options [Member] | Two Thousand And Twenty Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Weighted average expected term in years	6 years 2 months 23 days	5 years 10 months 20 days
Weighted average expected stock price volatility	85.70%	71.70%
Risk-free interest rate, Minimum	3.50%	1.46%
Risk-free interest rate, Maximum	4.18%	4.31%
Expected dividend yield	0%	0%

Stock-Based Compensation - Su_3

Stock-Based Compensation - Summary of restricted stock unit activity (Details) - Restricted Stock Units (RSUs) [Member]	12 Months Ended
	Dec. 31, 2023 $ / shares shares
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Number of options,Beginning | shares	0
Number of Options, Granted | shares	3,251,815
Number of options,Vested | shares	0
Number of Options, Cancelled or forfeited | shares	306,880
Number of options,End | shares	2,944,935
Weighted Average Grant Date Fair Value, Begining of period | $ / shares	$ 0
Weighted Average Grant Date Fair Value, Granted | $ / shares	1.18
Weighted Average Grant Date Fair Value, Vested | $ / shares	0
Weighted Average Grant Date Fair Value, Forfeited | $ / shares	1.18
Weighted Average Grant Date Fair Value, Ending of period | $ / shares	$ 1.18

Stock-Based Compensation - Su_4

Stock-Based Compensation - Summary of Employee Stock Ownership Plan (ESOP) Disclosures (Detail) - HSOP Shares [Member] - HSOP Plan[Member] - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of options,Beginning	6,921,829
Number of Options, Granted	0
Issuance of shares upon exercise of stock options, Share	0
Number of Options, Cancelled or forfeited	0
Number of options,End	6,921,829	6,921,829
Number of Options,Options exercisable	6,754,232
Weighted- Average Exercise Price,Beginning	$ 6.64
Weighted- Average Exercise Price,Granted	0
Weighted-Average Exercise Price, Exercised	0
Weighted- Average Exercise Price, Cancelled or forfeited	0
Weighted- Average Exercise Price,End	6.64
Weighted- Average Exercise Price,Options exercisable	$ 6.64
Weighted- Average Remaining Contractual Term (Years)	12 years 3 days	13 years 3 days
Weighted- Average Remaining Contractual Term (Years),Options exercisable	12 years 3 days
Aggregate Intrinsic Value,Beginning	$ 0
Aggregate Intrinsic Value,End		$ 0

Stock-Based Compensation - Su_5

Stock-Based Compensation - Summary of Share-based Compensation Arrangements by Share-based Payment Award (Detail)	Dec. 31, 2023 shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of options, Options vested and expected to vest	100,000

Stock-Based Compensation - Addi

Stock-Based Compensation - Additional Information (Detail)		1 Months Ended		6 Months Ended	12 Months Ended
	Jan. 23, 2021 € / shares	Jan. 31, 2023 shares	Jan. 31, 2022 shares	Jun. 30, 2021	Dec. 31, 2023 USD ($) $ / shares shares	Dec. 31, 2023 USD ($) € / shares shares	Dec. 31, 2022 USD ($) $ / shares	Dec. 31, 2021
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share based payment arrangement, Options expected to vest outstanding					100,000	100,000
Number of options outstanding, including both vested and non-vested options.					16,751,951	16,751,951
Weighted average grant-date fair value of options granted  | $ / shares					$ 1.02		$ 3.17
Other Subsidiaries Equity Plan
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Unrecognized stock based compensation compensation | $					$ 200,000	$ 200,000
Unrecognized stock based compensation compensation, Expected period of recognition					7 months 6 days
Share based compensation expenses | $					$ 500,000		$ 700,000
Restricted Stock [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Unrecognized stock based compensation compensation | $					2,000	2,000
Share based compensation expenses | $					1,400,000
Fair value of restricted stock units vested | $					$ 0
Weighted average period					1 year 2 months 8 days
HSOP Plan[Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share based payment arrangements, Award vesting rights percentage				25%				12.50%
Unrecognized stock based compensation compensation | $					$ 100,000	$ 100,000
Unrecognized stock based compensation compensation, Expected period of recognition					1 month 6 days
Employee stock ownership plan, Number of shares available for future issuance					257,419	257,419
Employee stock ownership plan, Weighted average purchase price of shares | € / shares						$ 0.06
Employee stock ownership plan, Employer loan guarantee | $					$ 500,000	$ 500,000
Percentage of per annum interest rate					2%
Share based payment arrangement, Shares issued in period					7,281,376
Share based compensation expenses | $					$ 3,100,000		4,500,000
HSOP Plan[Member] | Non Recourse Loan [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Employee stock ownership plan, Weighted average purchase price of shares | € / shares	€ 0.06
Percentage of compensation received	2%
Percentage of per annum interest rate					2%
HSOP Plan[Member] | HSOP Shares [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share based payment arrangements, Equity instruments other than options granted					0
Number of share options exercised during the current period					0
Two Thousand And Twenty Incentive Plan [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Shares reserved for future issuance					22,658,192	22,658,192
Unrecognized stock based compensation compensation | $					$ 34,500,000	$ 34,500,000
Unrecognized stock based compensation compensation, Expected period of recognition					1 year 11 months 1 day
Share based compensation expenses | $					$ 27,900,000		$ 37,100,000
Number of options outstanding					0	0
Two Thousand And Twenty One Incentive Award Plan [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Shares reserved for future issuance					55,035,590	55,035,590
Number of options outstanding					33,866,036	33,866,036
Common stock, for issuance to executive officers		8,296,796	8,033,850

Stock-Based Compensation - Su_6

Stock-Based Compensation - Summary of restricted stock awards (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Options and Restricted Stock Awards [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-Based Payment Arrangement, Expense	$ 32,982	$ 42,375
Atai ESOP [Member] | Options and Restricted Stock Awards [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-Based Payment Arrangement, Expense	29,465	37,130
Atai HSOP [Member] | Options and Restricted Stock Awards [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-Based Payment Arrangement, Expense	3,052	4,551
Other Subsidiaries Equity Plan
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-Based Payment Arrangement, Expense	500	700
Other Subsidiaries Equity Plan | Options and Restricted Stock Awards [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-Based Payment Arrangement, Expense	465	694
Research and Development Expense [Member] | Options and Restricted Stock Awards [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-Based Payment Arrangement, Expense	12,688	16,324
Research and Development Expense [Member] | Atai ESOP [Member] | Options and Restricted Stock Awards [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-Based Payment Arrangement, Expense	12,262	15,797
Research and Development Expense [Member] | Other Subsidiaries Equity Plan | Options and Restricted Stock Awards [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-Based Payment Arrangement, Expense	426	527
General and Administrative Expense [Member] | Options and Restricted Stock Awards [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-Based Payment Arrangement, Expense	20,294	26,051
General and Administrative Expense [Member] | Atai ESOP [Member] | Options and Restricted Stock Awards [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-Based Payment Arrangement, Expense	17,203	21,333
General and Administrative Expense [Member] | Atai HSOP [Member] | Options and Restricted Stock Awards [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-Based Payment Arrangement, Expense	3,052	4,551
General and Administrative Expense [Member] | Other Subsidiaries Equity Plan | Options and Restricted Stock Awards [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-Based Payment Arrangement, Expense	$ 39	$ 167

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Operating Loss Carryforwards [Line Items]
Valuation allowance	$ 89,968	$ 95,678
Unremitted earnings	0	0
Unrecognized tax benefits	$ 369	$ 0	$ 0
Maximum [Member]
Operating Loss Carryforwards [Line Items]
Utilization of tax losses	80%
Atai Therapeutics Pty Ltd [Member]
Operating Loss Carryforwards [Line Items]
Corporate income tax	30%
Germany | Weighted Average [Member]
Operating Loss Carryforwards [Line Items]
Corporate income tax	30.18%	30.18%
Corporate tax rate	15%	15%
Solidarity surcharge	0.83%	0.83%
Trade tax rate	14.35%	14.35%
US | Weighted Average [Member]
Operating Loss Carryforwards [Line Items]
Corporate income tax	21%	21%
Australia | Weighted Average [Member]
Operating Loss Carryforwards [Line Items]
Corporate income tax	25%	25%
United Kingdom | Weighted Average [Member]
Operating Loss Carryforwards [Line Items]
Corporate income tax	25%	19%
Singapore | Weighted Average [Member]
Operating Loss Carryforwards [Line Items]
Corporate income tax	17%

Income Taxes - Schedule of Inco

Income Taxes - Schedule of Income before Income Tax, German and Overseas (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Operating Loss Carryforwards [Line Items]
Germany	$ 19,916	$ (55,845)
International	(59,201)	(79,337)
Total loss before income taxes and loss from equity method investments	$ (39,286)	$ (135,182)

Income Taxes - Schedule of Comp

Income Taxes - Schedule of Components of Income Tax Provision (Benefit) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Current income tax provision:
Germany	$ 0	$ 0
International	1,016	1,155
Total current income tax provision:	1,016	1,155
Deferred income tax provision:
Germany	0	0
International	0	5,074
Total deferred income tax provision:	0	5,074
Total income tax provision:	$ 1,016	$ 6,229

Income Taxes - Schedule of Effe

Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Income (Loss), Including Portion Attributable to Noncontrolling Interest, before Tax [Abstract]
Loss before income taxes	$ (39,286)	$ (135,182)
German statutory rate	30.18%	30.18%
Expected income tax benefit	$ (11,856)	$ (40,791)
US state income taxes, net of US federal tax benefit	(3,662)	(6,509)
International tax rate differential	5,188	7,276
Effect of Australian R&D tax credit incentives	(582)	(338)
Effect of taxes not provided on outside basis differences in investments regarding: fair value adjustments	0	(109)
Effect of consolidation and deconsolidation of subsidiaries	3,250	(1,394)
Effect of share-based compensation expense	975	216
Effect of non-deductible US compensation expense under IRC Section 162(m)	1,368	411
Expenses not deductible for tax purposes	600	(324)
Effect of statutory to US GAAP accounting adjustments	0	98
Return to Provision and deferred tax adjustments	10,188	758
Change in German and international valuation allowance	(5,713)	46,935
Uncertain Tax Positions	96	0
Total income tax expense	$ 1,016	$ 6,229
Effective income tax rate:	(2.59%)	(4.61%)
Germany
Income (Loss), Including Portion Attributable to Noncontrolling Interest, before Tax [Abstract]
Loss before income taxes	$ 19,916	$ (55,845)
Overseas
Income (Loss), Including Portion Attributable to Noncontrolling Interest, before Tax [Abstract]
Loss before income taxes	$ (59,201)	$ (79,337)

Income Taxes - Summary of Compo

Income Taxes - Summary of Components of Deferred Tax Assets and Deferred Tax Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Deferred tax assets:
Share compensation	$ 35,062	$ 31,078
Capitalized research and experimentation expenses	19,312	11,975
Operating lease right-of-use liability	13	0
Other deductible timing differences	1,127	1,864
Total deferred tax assets, gross	120,798	101,062
Valuation allowance	(89,968)	(95,678)
Total deferred tax assets, net	30,830	5,384
Deferred tax liabilities:
Fixed and intangible assets	(930)	(908)
Unrealized foreign exchange	(4,904)	(4,472)
Outside basis differences in equity and other investments	(2)	(4)
Investments	(24,982)	0
Operating lease right-of-use asset	(12)	0
Total deferred tax liabilities	(30,830)	(5,384)
Total deferred tax asset	0	0
Germany
Deferred tax assets:
Operating loss carryforward	49,014	45,560
International
Deferred tax assets:
Operating loss carryforward	$ 16,270	$ 10,585

Income Taxes - Schedule of Gros

Income Taxes - Schedule of Gross Tax Loss Carryforward for Tax Return Purpose (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Tax Credit Carryforward [Line Items]
Germany tax losses	$ 162,436	$ 150,991
International tax losses	56,691	41,908
Total	$ 219,127	$ 192,899

Income Taxes - Schedule of Unre

Income Taxes - Schedule of Unrecognized Tax Benefits (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Balance at beginning of period	$ 0	$ 0
Increases-prior year tax positions	0	0
Decreases-prior year tax positions	0	0
Increases-current year tax positions	369	0
Balance at end of period	$ 369	$ 0

Net Loss Per Share - Summary of

Net Loss Per Share - Summary of Basic and Diluted Net Loss Per Share (Detail) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Numerator:
Net loss	$ (43,895)	$ (157,417)
Net loss attributable to noncontrolling interests	(3,671)	(5,032)
Net Income (Loss) Available to Common Stockholders, Basic, Total	(40,224)	(152,385)
Net loss per share attributable to ATAI Life Sciences N.V. shareholders - diluted	$ (40,224)	$ (152,385)
Denominator:
Weighted average common shares outstanding attributable to ATAI Life Sciences N.V.Stockholders basic	158,833,785	155,719,585
Weighted average common shares outstanding attributable to ATAI Life Sciences N.V. Stockholders diluted	158,833,785	155,719,585
Net loss per share attributable to ATAI Life Sciences N.V. shareholders basic	$ (0.25)	$ (0.98)
Net loss per share attributable to ATAI Life Sciences N.V. shareholders diluted	$ (0.25)	$ (0.98)

Net Loss Per Share - Schedule o

Net Loss Per Share - Schedule of Potentially dilutive securities to the Company's common shares (Detail) - shares	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	55,119,122	48,004,257
Options to purchase Common Stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	39,066,454	34,880,604
HSOP options to purchase common stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	6,921,829	6,921,829
2018 convertible promissory notes
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	3,818,704	0
2018 Convertible Promissory Notes - Related Parties (Note 11)
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	2,367,200	6,201,824
Restricted Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	2,944,935	0

Net Loss Per Share - Additional

Net Loss Per Share - Additional Information (Detail) - Common Stock [Member] - shares	1 Months Ended	12 Months Ended
	Nov. 30, 2020	Dec. 31, 2023	Dec. 31, 2022
Net Income (Loss) Per Share [Line Items]
Stock issued during period, convertible share	8,773,056		4,320,000
2018 Convertible Promissory Notes - Related Parties (Note 11)
Net Income (Loss) Per Share [Line Items]
Stock issued during period, convertible share		147,950	387,614
Common stock, Conversion basis		one-for-sixteen
2018 convertible promissory notes
Net Income (Loss) Per Share [Line Items]
Stock issued during period, convertible share		3,818,704

License Agreements - Additional

License Agreements - Additional Information (Detail) - USD ($) $ in Thousands			12 Months Ended
	Dec. 10, 2021	Aug. 31, 2017	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	Jun. 30, 2020	Feb. 29, 2020
License Agreements [Line Items]
Research & development expense			$ 2,000	$ 2,800
ATAI Kures Inc. [Member] | License Agreement Terms [Member]
License Agreements [Line Items]
Percentage of the common stock shares outstanding						5%
Research And Development Services [Member]
License Agreements [Line Items]
Research and development in process				400
Otsuka Agreement [Member] | Research And Development Services [Member]
License Agreements [Line Items]
Contract with customer liability, revenue recognized			300	200
Columbia Stock Purchase and License Agreement [Member]
License Agreements [Line Items]
Material Payment			0	0
Columbia Stock Purchase and License Agreement [Member] | ATAI Kures Inc. [Member]
License Agreements [Line Items]
Research and development in process				300
CHIBA License [Member]
License Agreements [Line Items]
Material Payment			0	0
Period of notice for termination of agremeent		90 days
Allergan License Agreement [Member]
License Agreements [Line Items]
Performance obligation							$ 500
Material Payment			0	0	$ 0
Dalriada License Agreement [Member]
License Agreements [Line Items]
Research and development in process				600
Service fees	$ 12,800
Upfront deposit				1,100
Upfront Deposit Decreases				500
Dalriada License Agreement [Member] | Service, Other [Member]
License Agreements [Line Items]
Service fees			0	$ 0	7,400
Clinical And Sale Milestones [Member] | CHIBA License [Member]
License Agreements [Line Items]
Milestone payment payable		$ 1,200
Clinical And Sale Milestones [Member] | CHIBA License [Member] | License Agreement Terms [Member]
License Agreements [Line Items]
Milestone payment payable		$ 1,000
Otsuka [Member] | Otsuka Agreement [Member]
License Agreements [Line Items]
Performance obligation					$ 20,000
Otsuka [Member] | Otsuka Agreement [Member] | Outset Of The Otsuka Agreement [Member]
License Agreements [Line Items]
Performance obligation			20,000
Otsuka [Member] | Commercial Milestones [Member] | Otsuka Agreement [Member]
License Agreements [Line Items]
Milestone payments, receivable			66,000
Otsuka [Member] | Development And Regulatory Milestones [Member] | Otsuka Agreement [Member]
License Agreements [Line Items]
Milestone payments, receivable			$ 35,000

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Detail) - USD ($) $ in Thousands	1 Months Ended	12 Months Ended
	Jan. 31, 2021	Dec. 31, 2023	Dec. 31, 2022
Related Party Transaction [Line Items]
Stock issued during period, Value		$ 24
Percentage of common stock reserved		27%
General and administrative expense		$ 63,582	$ 70,350
General and Administrative Expense [Member]
Related Party Transaction [Line Items]
stock-based compensation		700	$ 700
Common Stock [Member]
Related Party Transaction [Line Items]
Stock issued during period, Value		$ 0
Founder [Member] | Atai Formation [Member]
Related Party Transaction [Line Items]
Equity method investment, ownership percentage		19.70%	19.70%
Galaxy NYC Based Multi Strategy Investment Firm [Member] | Atai Formation [Member]
Related Party Transaction [Line Items]
Equity method investment, ownership percentage		6.50%	6.50%
Apeiron [Member] | Common Stock [Member]
Related Party Transaction [Line Items]
Stock issued during period, Value		$ 10,500
Mr Angermayer [Member] | Consulting Agreement [Member]
Related Party Transaction [Line Items]
General and administrative expense		$ 600	$ 600
Mr Angermayer [Member] | Consulting Agreement [Member] | Two Thousand And Twenty Incentive Plan [Member]
Related Party Transaction [Line Items]
Stock issued during period, share based payments	624,000

Defined Contribution Plan - Add

Defined Contribution Plan - Additional Information) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Retirement Benefits [Abstract]
Labor and related expense	$ 0.5	$ 0.5

Corporate Restructuring - Addit

Corporate Restructuring - Additional Information) (Details) - USD ($)		12 Months Ended
	Feb. 28, 2023	Dec. 31, 2023
Restructuring Cost and Reserve [Line Items]
Percentage Of Restructed Workforce	30%
Restructuring Costs, Total		$ 3,200,000
Restructuring Reserve		0
Deferred Compensation, Share-Based Payments [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Costs, Total		200,000
Employee Severance [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Costs, Total		3,000,000
General and Administrative Expense [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Costs, Total		1,400,000
Research and Development Expense [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Costs, Total		$ 1,800,000

Subsequent Events - Additional

Subsequent Events - Additional Information (Detail) $ in Thousands	12 Months Ended
	Dec. 31, 2023 USD ($) Seats	Jan. 31, 2024 shares	Dec. 31, 2022 USD ($)
Equity method investments	$ 0		$ 0
Variable interest entity, qualitative or quantitative information, ownership percentage	10%
Long-term debt, net	$ 15,047		$ 14,702
Beckley Psytech Limited [Member]
Equity method investment, ownership percentage	35.50%
Equity method investments	$ 50,000
Direct investment	40,000
Secondry investment	$ 10,000
Premium received on primary issuances	30%
Right to appoint number of seats in board of directors | Seats	3
Total number of seats in board of directors | Seats	9
Payments to acquire investments	$ 25,000
IntelGenx [Member]
Long-term debt, net	1,000
Term loan advance	$ 1,000
Consulting Agreement [Member] | Mr Angermayer [Member] | Subsequent Event [Member]
Grant of an option shares vested for continued service | shares		1,658,094